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Chapter 1 
Introduction: Protein Posttranslational Modification 
(Portions of the text in this chapter were reprinted or adapted from: Senevirathne, C., Green, K. 
D., and Pflum, M. K. H. (2009) Kinase-Catalyzed Biotinylation of Peptides, Proteins, and 
Lysates, In Current Protocols in Chemical Biology, John Wiley & Sons, Inc. and Suwal, S., 
Senevirathne, C., Garre, S., and Pflum, M. K. (2012) Structural analysis of ATP analogues 
compatible with kinase-catalyzed labeling, Bioconjugate chemistry 23, 2386-2391) 
Proteins undergo diverse modifications to regulate their functions and stability.
(1)
 Protein 
modifications can occur after translation, and are commonly called posttranslational 
modifications (PTMs). PTMs enhance the cellular diversity of roughly 30,000 human genes.  
More than 100 PTMs have been recognized to date. Fifteen out of 20 amino acid residues have 
been identified with various PTMs, which include acetylation, acylation, adenylation, ADP-
ribosylation, glycosylation, methylation, phosphopantetheinylation, phosphorylation, 
prenylation, sulfation, transglutamination, etc.
(2)
 These PTMs influence various cellular 
processes, functions and disease formation. With a major role in biological systems, 
characterizing PTMs is important to understanding cell biology and disease formation.  
1.1 Protein Phosphorylation 
 
Protein phosphorylation was identified more than 100 years ago;
(3)
 enzyme-mediated 
reversible phosphorylation was reported in 1954.
(4)
 Kinase-catalyzed protein phosphorylation is 
an important PTM occurring in cells.
(5)
 Phosphorylation is involved in a variety of biological 
processes including cell signaling, diseases, cancer, and immunosuppression.
(6)
 Proteins kinases 
are the enzymes that are responsible for protein phosphorylation, and protein phosphatases are 
the enzymes that are involved in dephosphorylation.
(5, 7)
  In phosphorylation, adenosine 5’-
triphosphate (ATP) acts as a universal phosphate donor and the protein kinase assists in the 
transfer of a phosphate group from the γ position of ATP.(8)  In eukaryote, phosphorylation 
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occurs on the hydroxyl group of serine, threonine, and tyrosine (Scheme 1.1).
(9)
 In addition, 
histidine, arginine, and lysine phosphorylation (N-phosphorylation)
(10)
 is possible in procaryote. 
When the neutral hydroxyl group is replaced with a negatively charged phosphate group, the 
activity of the protein may change, which influences cell biology.
(1)
 At any given time, 30% of 
proteins are phosphorylated at serine, threonine, and tyrosine.
(5)
  
 
Scheme 1.1: Reversible Protein Phosphorylation of Amino Acids Containing Hydroxyl Side 
Chains  
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1.2 Phosphorylation and Protein Functions 
Phosphorylation influences protein activity through a variety of mechanisms. Protein 
binding is enhanced upon phosphorylation. For example, p53 is a tumor suppressor 
transcriptional activator, which is stabilized after phosphorylation (Figure 1.1).
(11)
 There are 22 
phosphorylation sites identified on p53, which influence its stability.
(11, 12)
 Stress signals such as 
UV radiation, DNA damage, etc, activate various kinases to phosphorylate p53.
(13)
 This 
phosphorylation occurs sequentially, as phosphorylation of serine-15 leads to phosphorylation of 
additional sites.
(14, 15)
 Upon phosphorylation, p53 is stabilized and dissociated from its inhibitor 
MDM2,
(13)
 and binds to transcriptional activator p300.
(16)
 p53 binding to DNA enhances gene 
transcription to protect the cell from stress condition.
(17)
    
 
 
 
 
 
 
 
 
Figure 1.1: Stabilization of p53 with Phosphorylation. Stress signals stimulate several kinases 
to phosphorylate p53. Upon phosphorylation, p53 is stabilized, translocated to the nucleus, and 
bound to DNA, which activates transcription of different genes. 
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Another example of protein-protein interactions that are dependent on phosphorylation 
involves CREB (cyclic adenosine 3’, 5’-monophosphate responsive element binding) protein and 
CBP (CREB binding protein) (Figure 1.2).
(18, 19)
 Upon phosphorylation, the neutral serine-133 on 
CREB becomes a negatively charged phosphoserine, which alters its hydrogen bond donor 
ability  into a hydrogen bond acceptor. Once phosphorylated at serine-133, a hydrogen bond can 
form between CREB S-133 and Y-658 on CBP. Phosphorylation at S-133 is critical for 
interaction of two proteins, CREB and CBP.
(18)
 The transcriptional activity of CREB is greatly 
enhanced upon CBP binding.   
 
 
 
 
 
 
 
Figure 1.2: Phosphorylation of CREB Facilitates Interactions with CBP. Structure of CREB 
bound to CBP highlighting phosphoserine 133 (pS133) in red interacting with tyrosine 658 
(Y658) in green. 
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Kinase-catalyzed phosphorylation also influences cell growth, arrest and apoptosis, by 
mediating cell signaling cascades.
(20)
 For example, signaling pathways depend on 
phosphorylation to begin neuronal cell growth (Figure 1.3).
(21)
 Binding of neuronal growth factor 
(NGF) to TrkA leads to autophosphorylation of tyrosine on TrkA (Neurotrophic tyrosine kinase 
receptor type 1).
(21)
 The phosphotyrosine of TrkA then binds to Grb (Growth factor receptor-
bound protein), which binds to Sos (Son of sevenless). The Ras (protein kinase produced by the 
ras gene)/Raf (protein kinase produced by the raf gene)/MEK (Mitogen activated or extracellular 
signal regulated protein kinase) pathway is activated by Sos. Activation of the Ras/Raf/MEK 
pathway promotes phosphorylation of MAPK (Mitogen activated protein kinase).
(22)
 
Phosphorylated MARK leads to phosphorylation of ELK-1 (E-26 like protein 1) which then 
activates the transcriptional machinery for cell growth. MARK can also stimulate p21
CIP
, which 
is responsible for growth arrest. Additionally, the activity of RhoA (Ras homolog gene family, 
member A) can increase via activated Ras. Activated RhoA can stop growth arrest by inhibiting 
MARK activity toward p21
CIP
.
(21)
 Although only one example, this kinase signaling pathway 
demonstrates the fundamental role of phosphorylation in cell biology. The next section focuses 
on the involvement of phosphorylation in disease formation.   
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Figure 1.3: Signaling Cascade of Phosphorylation Dependent Cell Growth. NGF binding to 
TrkA leads to TrkA autophosphorylation. This phosphorylation results in interaction of the 
receptor with various kinases and activation of the Ras/Raf/Mek pathway. Phosphorylated 
MAPK initiates phosphorylation of ELK-1, which results in cell growth.   
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1.3 Protein Phosphorylation in Disease  
A number of kinases and phosphorylation pathways are associated with diseases. 
Aberrant phosphorylation levels and elevated kinase activities are responsible for disease 
formation, and are highlighted here. As one example, translocation of chromosome 9 and 22 
leads to fusion of the Abelson kinase (Abl) gene with the BCR (break point cluster) gene to 
produce the Bcr-Abl gene fusion.
(23)
 The Bcr-Abl protein product of this gene fusion has higher 
kinase activity than regular Abl kinase, which leads to formation of chronic myelogenous 
leukemia (CML).
(23-27)
 Gleevec, an Abl kinase inhibitor and an FDA approved drug, is used to 
treat CML.
(28)
 
Additionally, several other kinases are linked with cancer formation, such as casein 
kinase 2 (CK2),
(29)
 phosphoinositide 3-OH kinase (PI3K),
(30)
 cellular Src (c-Src),
(31)
 protein 
kinase B (PKB),
(32)
 and epithelial growth factor receptor (EGFR).
(33)
  Various other signaling 
pathways influenced by kinases are also linked to cancer, including PI3K/PKB, Ras-Raf-ERK, 
JAK-signal transducer and activator of transcription (STAT) pathways.
(34, 35)
 
1.4 Kinase inhibitors 
Protein phosphorylation and kinase enzymes play critical roles in disease formation. 
Hence many pharmaceutical drugs have developed to target kinases (Table 1.1 and Figure 1.4). 
A number of FDA approved kinase inhibitors are used to treat a wide range of diseases, 
including diabetes, rheumatoid arthritis, cancer, and immunosupression.
(6)
 However cancer is the 
most targeted disease. Rapamycin and Everolimus are two natural products that have the same 
core structure, and are used to treatment of immunosupression by targeting mTOR. 
Staurosporine is a natural product, used as a general kinase inhibitor used in laboratory research 
only. Fasudil inhibits ROCK and is used for the treatment of cerebral vasospasms. However, this 
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sulphonamide is approved only in Japan.  Iressa and tarceva both target EGFR kinase for 
treatment of cancer. Nexavar targets Raf-1 for cancer treatment. Axitinib and Sunitinib target 
multiple kinases such as VEGFR-1, 2, 3 and PDGFR.  Some approved drugs bind to more than 
one kinase, which may lead to unnecessary side effects.
(6)
 
The main drawback of kinase inhibitors is their non-specific binding to many kinases. 
Because of the highly conserved active sites of kinases, drugs do not generally differentiate 
between members of the kinase family.  Hence, it is extremely difficult to synthesize molecules 
that selectively inhibit a single kinase. Gleevec (Imatinib) which selectively inhibited tyrosine 
kinase Bcr-Abl was the first selective kinase inhibitor. Other examples of selective kinase 
inhibitors are DRB (5,6-Dichloro-1-β-D-ribofuranosyl benzimidazole) and H8 (N-[2-
(methylamino) ethyl]-5-isoquinolonesulfonamide), which selectively inhibit CK2 and PKA, 
respectively.  
Kinase inhibitors show diverse structural features, including riboses, glucoses, 
polyketides, sulfonamide, piperazines, and heterocyclic derivatives. With the interest of kinases 
as drug targets, understanding their function and structure has been useful.  
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Table 1.1: List of FDA Approved Kinase Inhibitors Found in Market 
(6, 36)
 
 
 
Inhibitor 
Kinase 
Targeted Disease Company Status 
Rapamycin m-TOR Immunosuppression Wyeth-Ayerst 
FDA approved 
(1999) 
Gleevec Bcr-Abl Cancer Novartis 
FDA approved 
(2001) 
Iressa  EGFR Cancer Astra-Zeneca 
FDA approved 
(2003) 
Tarceva  EGFR Cancer OSI Pharm. 
FDA approved 
(2004) 
Nexavar Raf-1 Cancer Bayer 
FDA approved 
(2005) 
Sunitinib  
VEGFR, 
PDGFR Cancer Pfizer 
FDA approved 
(2006) 
Crizotinib ALK, ROS-1 Cancer Pfizer 
FDA approved 
(2011) 
Vemurafenib BRAF Cancer Roche 
FDA approved 
(2011) 
Axitinib  
VEGFR, 
PDGFR Cancer Pfizer 
FDA approved 
(2012) 
Bosutinib Bcr-Abl, Src Cancer Pfizer 
FDA approved 
(2012) 
Fasudil ROCK Cerebral vasospasm 
Asahi Chem. 
Ind 
Japan approved 
(1995) 
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Figure 1.4: Structural Diversity of Kinase Inhibitors. Structure of some kinase inhibitors are 
shown here. Sturosporine, H8, and DRB are used only in laboratory research. All others are used 
in treatment of various diseases (see Table 1.1).   
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1.5 Protein Kinases: Family, Structure, and Enzymatic Mechanism 
Kinase enzymes catalyze protein phosphorylation. There are over 500 human kinases 
known.
(37)
 Protein kinases are classified into two different groups-the serine/threonine protein 
kinases (SPK) and tyrosine protein kinases (TPK).
(38)
 These classifications are based on each 
enzymes preferred amino acid substrate. There is a third class of kinases that phosphorylate both 
serine/threonine and tyrosine side chains, but they not well characterized. One kinase enzyme 
can act upon multiple protein substrates.
(39)
 Human kinases are divided into 7 major groups 
according to sequence similarities in their catalytic sites (Figure1.5).
(37)
   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Main Groups of Human Kinases. Human kinases are mainly divided into 7 major 
groups including; 
a
AGC: Containing PKA, PKG, PKC families; CAMK: Calcium/calmodulin-
dependent protein kinase; CK1: Casein kinase 1; CMGC: Containing CDK, MAPK, GSK3, 
CLK families; STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK: Tyrosine 
kinase; TKL: Tyrosine kinase-like. Other: other kinases not belong to above groups. 
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Scheme 1.2: Mechanism of Protein Phosphorylation Illustrated with a Serine Residue  
 
As mentioned in section 1.1, ATP acts as a phosphate donor and binds to the active site 
of kinases.
(8)
 The catalytic sites of protein kinases display very similar primary structures.
(40)
 
Generally there are nine conserved amino acids found in kinase catalytic sites,
(41)
 including G52, 
K72, Q91, D166, N171, D184, G186, Q208, and R280. Six of these residues stabilize the 
triphosphate and three of them interact with the adenine base portion. Within the kinase family, 
this core active site structure is conserved.
(38)
 The kinases consist of two domains, which contain 
α-helical and β-sheets. The linker portion between the α-helical and β-sheet domains generates 
the binding region for the ATP molecule.
(42)
 The α-helical domain contains the substrate binding 
site. The substrate binds to the active site of the kinase through interactions with specific amino 
acids in the substrate binding site (Figure 1.6).
(38)
 ATP binding to the active site occurs in such a 
way that adenine portion points inside the conserved site and its phosphates point away from the 
pocket. ATP binding brings the α-helical and β-sheet domains in close proximity to facilitate 
tight binding of ATP as well as binding of the protein substrate to the kinase.
(43)
 Hence, the 
protein kinase forms a ternary complex with its protein substrate and ATP cosubstrate in close 
proximity to achieve enzymatic phosphorylation.
(8)
 ATP cosubstrate binding is stabilized by two 
divalent metal ions,
 
either Mg
2+
 or Mn
2+
, which chelate with charged amino acid residues within 
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the catalytic site (Figure 1.6).
(38)
 D166 acts as a base during the kinase reaction by removing 
hydrogen from the hydroxyl group on the protein substrate, to making it nucleophilic.
(38)
  The 
interactions between the metal ion and oxygen atoms in the phosphoryl group hold the ATP 
appropriately for nucleophilic attack of the γ-phosphate by the substrate hydroxyl. This produces 
a phosphorylated substrate and ADP as a byproduct (Scheme 1.2).  
The enzymatic phosphorylation mechanism has two possibilities (Figure 1.7).
(44, 45)
 First, 
an associative mechanism was proposed,
(46)
 which is similar to an SN2 (bimolecular nucleophilic 
substitution) type mechanism. In the associative transition state, bonds between the nucleophilic 
oxygen of the substrate and the γ-phosphate of ATP are formed simultaneously with the ADP 
leaving group still connected (Figure 1.7 A). Interestingly, recent experimental evidence has 
been more consistent with a dissociative type transition state for phosphorylation,
(44,45,47)
 similar 
to SN1(unimolecular nucleophilic substitution) type reaction. In the dissociative transition state, 
the ADP leaving group departs in advance of nucleophilic oxygen attack on the electrophilic γ-
phosphate of ATP (Figure 1.7 B). Currently, the dissociative mechanism is considered the most 
appropriate for many kinases.
(44, 45, 47)
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Figure 1.6: Crystal Structure of PKA with Amino Acid Residues. (A) Crystal structure of 
PKA with peptide substrate inhibitor and Solvent expose ATP. (B) Kinase-catalyzed 
phosphorylation mechanism showing the major interaction of PKA enzyme with protein 
substrate, ATP and metal ions with side chains (GenBank ID 6755076, PDB 1ATP). 
 
 
 
A 
B 
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Figure 1.7: Proposed Associative vs Dissociative Phosphorylation Mechanism. (A) The 
leaving group and incoming nucleophile remain attached to the reactive center in an associative 
mechanism. (B) The leaving group departs in advance of nucleophile attack at the reactive center 
in a dissociative mechanism. 
 
The peptide or protein substrate must contain a consensus sequence that can be 
recognized by a specific kinase.
(38)
 Phosphorylation occurs when the consensus sequence of the 
substrate is recognized by the appropriate protein kinase, which directs phosphorylation of the 
serine, threonine, or tyrosine within the consensus sequence. Generally, the amino acids 
immediately surrounding the phosphorylated residue are critical for kinase recognition.  
Consensus sequences for many kinases are known and indicate that specific kinases can 
recognize basic, acidic, hydrophobic or proline residues to direct phosphorylation (Table 1.2). 
For example, Abl protein kinase is a tyrosine kinase with a hydrophobic consensus sequence of 
I/V/L-Y-X-X-P/F (X represents any amino acid).
(48)
 Casein Kinase II (CK2) is a serine/threonine 
kinase with an acidic consensus sequence of S/T-X-X-D/E.
(49)
 Another serine/threonine kinase, 
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c-AMP dependent protein kinase (PKA) prefers to phosphorylate peptides having a basic amino 
acid consensus site of R-R/K-X-S/T.
(50)
  
Table 1.2: Consensus Sequence of Selected Protein Kinases  
Kinase Consensus sequence
(51)
 
Abl I/V/L-Y-X-X-P/F 
AKT1  R-X-R-XX-S/T 
Aurora-A R/K/N-R-X-S/T-B 
CDK 1  S/T-P-X-R/K 
CHK 1 R-X-X-S/T 
CK2 S/T-X-X-D/E 
ERK 1 P-X-S/T-P 
GRK 5 D/En-S/T-X-X-X 
GSK 3 X-S/T-X-X-X-Sp 
PKA R-R-X-S/T-Y 
SRC E-E-I-Y-E/G-X-F 
 
 
1.6 Kinase cosubstrate promiscuity 
1.6.1: ATP-γS 
Many PTM enzymes show cosubstrate promiscuity.
(52-73)
 Indeed, kinases also show 
cosubstrate promiscuity with different ATP analogs. The first reported kinase cosubstrate analog 
was adenosine 5’-[γ-thio]-triphosphate (ATP-γS).(74, 75) ATP-γS is an analog of ATP where O is 
replaced by S at the γ-phosphate. ATP-γS acts as a cosubstrate for many kinases, making a 
thiophosphorylated product (Figure 1.8). The reactivity of thiol on phosphate is used for identify 
and purify of thiophosphorylated products. A similar phosphorylation mechanism to ATP occurs 
with ATP-γS, with hydroxyl attack on the γ-phosphate group producing a thiophosphorylated 
product and the byproduct ADP. However, kinetic analysis with ATP-γS showed low catalytic 
efficiency compared to ATP,
(76-79)
 known as the thio effect.  Despite the poorer catalytic 
efficiency, ATP-γS is widely used in the proteomic field,(76, 80-83) due to the stability of 
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thiophosphorylated proteins towards phosphatases,
(74, 84-86)
 which can lead to identification of 
low abundance proteins.   
 
 
 
 
Figure 1.8: Kinase-Catalyzed Phosphorylation with ATP-γS. Serine, threonine, or tyrosine 
hydroxyl groups on proteins attack the γ-thiophosphate group on ATP-γS to label proteins with a 
thiophosphoryl group.   
 
In addition to the ATP-γS analog, another class of ATP analogs was synthesized for 
selective phosphorylation with specific kinases (Figure 1.9).
(82, 83)
 In this case, the ATP analog is 
modified at both the γ-phosphate group and the adenine base. Kinases were mutated to 
selectively bind the base modified ATP analogs. This method was used for specific purification 
of substrates for MS analysis (more details discussed in chapter 4).
(87)
 This method was 
developed by Shokat and coworkers,
(82, 83)
 and was used to identify substrates for a specific 
kinases. The method has been applied to various engineered kinases to identify their substrates.      
As a significant extension of the ATP-γS analog, the Pflum lab was interested in adding 
large groups at the γ-phosphate ATP for kinase transfer. The crystal structures of many protein 
kinases have been reported, such as those for PKA,
 
CK2 and Abl
(88-90)
. Analyses of crystal 
structures of protein kinase active sites showed that the γ-phosphate of ATP is solvent-exposed 
(Figure 1.6). With this analysis, we hypothesized that other γ-phosphate modified ATP analogs 
should act as kinase cosubstrates. In fact, our group showed that several γ-phosphate modified 
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ATP analogs act as cosubstrates for kinase-catalyzed phosphorylation,
(91-93)
 as discussed bellow. 
These analogs can be used to understand and characterize cell signaling pathways leading to 
disease.  
 
 
 
 
 
Figure 1.9: Phosphorylation of modified ATP-γS with Mutant Kinase. Cell lysates were 
incubated with mutant kinases and modified N
6
-Benzyl-ATP-γS. Substrates for the mutant 
kinase were labeled as thiophosphorylated products. Thiophosphorylated products were purified 
and identified by MS analysis (more details discussed in chapter 4).  
1.6.2: ATP-biotin 
To initially validate the cosubstrate tolerance of kinase, we performed kinase-catalyzed 
biotinylation with an ATP-biotin analog, along with recombinant kinases and peptide substrates 
(Figure 1.10).
(91)
  Establishing that a kinase of interest is compatible with ATP-biotin was 
necessary before visualizing phosphoproteins from a complex cellular mixture. Commercially 
available ATP-biotin was incubated with three synthetic peptides containing either serine 
(LRRASLG), threonine (RRREEETEEE), or tyrosine (EAIYAAPFAKKK) and the 
corresponding kinase PKA, CK2, and Abl, respectively. Similar to biotinylation, 
phosphorylation was performed with ATP as a control reaction. To determine the success of the 
biotinylation reaction with the peptide substrates, a quantitative mass spectrometric (MS) 
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analysis method was performed. The relative conversion percentages were calculated, assuming 
reactions with ATP to be 100% complete (Table 1.3). This initial experiment provided evidence 
for the cosubstrate promiscuity of kinases.
(91, 94)
 
 
 
 
 
Figure 1.10: Kinase-Catalyzed Biotinylation. Peptides or proteins modified with a 
phosphorylbiotin group upon biotinylation with ATP-biotin in the presence of kinases. See Table 
1.3 for the structure of ATP-biotin. 
 
With the success of peptide labeling using ATP-biotin, the tolerance of kinases to ATP-
biotin was further tested with full length protein substrates. Kinase-catalyzed biotinylation was 
performed with ATP-biotin, CK2 and a full-length protein substrate (β-casein). Biotinylation of 
full-length protein substrates was analyzed using gel electrophoresis followed by visualizing the 
biotin tag using an SA-HRP (Streptavidin-horseradish peroxidase) conjugate. The biotinylation 
reaction was validated by observing biotin on the protein product after gel analysis.
(91)
 In 
addition to labeling known substrates of a specific kinase in vitro, the labeling of substrates in 
mammalian cell lysates provides a physiologically relevant means of monitoring kinase activity. 
We found that ATP-biotin collaborates with cellular kinases to biotinylate endogenous substrates 
in HeLa cell lysates. 
(91)
 The results suggest that kinase-catalyzed biotinylation is generally 
successful using mammalian cell lysates to probe endogenous cellular kinases and substrates.  
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Table 1.3: Kinase-catalyzed labeling with previously reported ATP analogs 
(91-93)
 
 
 
 
 
 
 
 
 
 
 
 
1.6.3: ATP-dansyl 
With the success of kinase-catalyzed biotinylation, we were interested in testing the 
compatibility of kinases with other γ-phosphate modified ATP analogs. To test additional analog 
compatibility, commercially available ATP-dansyl was employed (Figure 1.11).
(92)
 Like ATP-
biotin, ATP-dansyl was incubated with peptides in the presence of their corresponding kinase 
PKA, CK2 and Abl, respectively. Quantitative MS analysis was used to analyze the efficiency of 
dansylation compared to phosphorylation (Table 1.3). These data indicated that ATP-dansyl was 
also successfully used as a cosubstrate for kinase-catalyzed phosphorylation.
(92)
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Figure 1.11: Kinase-Catalyzed Dansylation. Peptides modified with a phosphoryldansyl group 
upon dansylation with ATP-dansyl in the presence of kinases. See Table 1.3 for structure of 
ATP-dansyl. 
 
With the success of the kinase-catalyzed dansylation of peptides, we further characterized 
the reaction by conducting kinetics measurements. Using an absorbance assay,
(95, 96)
 
measurements with PKA were taken in the presence of ATP vs. ATP-dansyl as cosubstrates. 
ATP-dansyl maintained a similar KM value of 23 μM, compared to 24 μM KM of ATP, indicating 
γ-phosphate modification did not alter the active site binding. In terms of kcat, ATP-dansyl had a 
9-fold reduced value compared to ATP, indicating that dansylation is slower than 
phosphorylation.
(92)
 These results indicate that kinases permissively accept ATP analogs 
containing different functional probes, opening the door for the use of multiple γ-phosphate 
modified ATP analogs in kinase-catalyzed phosphoprotein labeling reactions. 
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1.6.4: ATP-arylazide 
Kinase-catalyzed biotinylation and dansylation demonstrated the promiscuity of kinases 
towards the γ-phosphate modified ATP analogs. To increase the applicability of γ-phosphate 
modified ATP analogs as a biological tool, we created an ATP analog containing a 
photocrosslinking group attached at the phosphate (ATP-ArN3) to covalently link 
phosphoproteins to kinases in a phosphorylation-dependent manner (Figure 1.12).
(93)
 To 
understand the compatibility of this photocrosslinker, the kinase reaction was performed with 
synthetic peptides as describe earlier. As was observed with ATP-biotin and ATP-dansyl, ATP-
ArN3 served as a kinase cosubstrate with high conversion percentages (Table 1.3).
(93)
  
 
Figure 1.12: Kinase-Substrate Crosslinking with ATP-arylazide. Protein substrates are 
crosslinked with enzymes upon phosphorylation with ATP-arylazide under UV irradiation. See 
the Table 1.3 for structure of ATP-arylazide. 
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To test if the analog would promote crosslinking of the kinase to substrate, we used 
phosphorylation of casein by CK2 as a model system. SDS-PAGE and western blot analysis 
were used to identify the kinase-substrate complex. Upon UV irradiation, photocrosslinking with 
ATP-ArN3 resulted in the appearance of higher molecular weight species consistent with  
crosslinked complexes of kinase and substrate.
(93)
 In contrast, no higher molecular weight spots 
were observed with ATP under the same conditions. To assure that the higher molecular weight 
species was phosphorylation dependent, the phosphoramidate bond connecting the substrate and 
kinase was cleaved using acid treatment. As expected, the higher molecular weight species was 
reduced after TFA cleavage.
(93)
 In addition, an antibody specific to the catalytic subunit of CK2 
recognized the higher molecular weight species indicated the presence of CK2.
(93)
 All these 
observations support the formation of kinase substrate crosslinked products via kinase dependent 
phosphorylation with ATP-ArN3.
(93)
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Figure 1.13: Diversity of γ-Phosphate Modified ATP Analogs. Structures of ATP analogs 
containing various detection tags are shown here. Applications of all these individual compounds 
were discussed in the text.  
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1.6.5: ATP-BODIPY 
In addition to the ATP analogs studied in the Pflum lab, recently different types of γ-
phosphate modified ATP analogs were reported (Figure 1.13). ATP-BODIPY, γ-phosphate 
modified ATP, was used to label protein in an activity-dependent manner.
(97)
 In this specific 
case, histidine residues on histidine kinase were autophosporylated with extracellular signal. 
Then the aspartic acid of response regulator protein attacked phosphate group of histidine kinase. 
Hence the detection of phosphorylation event is important to understand the activity of histidine 
kinases. However the phosphoamidate bond on phosphor-histidine is much more labile with very 
short half-life.
(98)
 Therefore a fluorophore was attached to the ATP using a sulfur atom instead 
nitrogen (Figure 1.14),
(97)
 which formed a more stable intermediate. This ATP-BODIPY showed 
competitive binding with ATP, and was applied to measure the activity of histidine kinase 
catalyzed phosphorylation (Figure 1. 14).
(97)
    
 
Figure 1.14: Autophosphorylation of Histidine Kinase with ATP-BODIPY. Histidine kinase 
undergoes autophosphorylation with ATP-BODIPY (See Figure 1.13 for structure) to label the 
histidine residue with fluorescent modification upon stimulation, with subsequent transfer of the 
modification to the aspartic acid of response regulator.  
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1.6.6: ATP-ferrocene 
ATP-ferrocene was also successfully used in phosphorylation reactions to transfer the 
ferrocene-phosphate group to peptide or protein substrates (Figure 1.15).
(99)
 This modification 
was detected electrochemically and with anti-ferrocene antibodies. Additionally, γ-phosphate 
modified ATP analogs were shown to compete with ATP for kinase binding.This analog was 
used to monitor the activity of kinases and identification of kinase inhibitors.
(99)
   
 
Figure 1.15: Kinase-Catalyzed Phosphorylation by ATP-ferrocene. Peptides or proteins were 
labeled with ferrocene-phosphate modification upon phosphorylation with kinase and ATP-
ferrocene (See Figure 1.13 for structure). The ferrocene-phosphate modification can be identified 
by antiferrocene antibodies. 
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1.6.7: ATP-acyl-biotin 
Beyond substrate labeling, γ-phosphate modified ATP analogs were also used to label 
and identify kinases in complex mixtures.
(100, 101)
 This method is based on ATP binding to the 
active site of kinases. With few exceptions, protein kinases have two conserved lysine residues 
near the active site.
(37, 90, 102)
 One can be found in the ATP binding region, while the other is 
found near the C-terminus. In addition, co-crystal structures of kinases indicated that these lysine 
residues are close to the γ- and β-phosphates of ATP.(90) Hence this method was able to identify 
most protein kinases. Once ATP-acyl-biotin is bound to the kinase, the acyl-phosphate group is 
positioned towards a conserved lysine residue in the active site, allowing the amine on lysine to 
attack the acyl group to release ATP. The reaction forms a covalent bond between kinase and 
biotin tag through an amide bond (Figure 1.16).
(100, 101)
 Then the proteins were digested, purified 
with streptavidin beads, and identified by MS/MS analysis. This method was also used to 
identify kinase inhibitors.
(101)
       
 
Figure 1.16: Strategy of Kinase Labeling by ATP-Acyl-Biotin. The modified ATP analog 
binds to the kinase active site and a conserved lysine residue in the kinase attacks the acyl group, 
leading to labeling the kinase with biotin.  
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1.7 Significant and Highlight of the Projects 
During phosphorylation, the neutral hydroxyl group is replaced by a negatively charged 
phosphate group, which strongly influences protein activity within cells.
(20)
 Hence 
characterization of the phosphorylation events and phosphorylated amino acids is useful to study 
protein function in vivo. This posttranslational modification affects various processes in cell 
biology including, protein shape, function, activity, protein-protein interaction, and cell signaling 
cascades.
(1, 37, 103)
 With a significant role in biochemical functions, it is important to understand 
phosphorylation. Techniques to understand and monitor phosphorylation involve radiolabel with 
32
P,
(104)
 immobilizing metal affinity chromatography,
(105)
 covalent modifications of the 
phosphate,
(106)
 phosphate staining, such as with Pro-Q diamond stain,
(107)
 and visualization using 
specific antibodies.
(108)
 Besides these methods, the Pflum lab has developed the use of γ-
modified ATP analogues as tools for studying phosphorylation.
(91-93)
 These methods are 
discussed further in chapters 2 and 4. 
Based on kinase cosubstrate promiscuity, several kinase-catalyzed labeling methods have 
been reported. We aim here to characterize the kinase-catalyzed labeling as a biological tool in 
proteomic research. First, we explored the generality of kinase cosubstrate promiscuity by testing 
biotinylation with 26 kinases throughout the kinome phylogenetic tree. Using the ADP-Glo assay 
with peptide and protein substrates (Promega), all kinases maintained reasonable conversions 
with ATP-biotin, with most displaying only modestly reduced catalytic efficiencies (kcat/KM) 
compared to ATP (Chapter 2). To characterize the scope and limitations of the biotinylation 
reaction, we probed the sensitivity of biotinylated phosphoproteins to phosphatases. Our goal 
was to ultimately apply the biotinylation reaction to phosphoproteomics, making an 
understanding of phosphobiotin stability in lysates critical. We found that the modification is 
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resistant to both Ser/Thr and Tyr phosphatases (Chapter 3). These results argue that the stable 
biotin tag will facilitate identification of low abundance phosphoproteins. Given the generality of 
kinase-catalyzed biotinylation and stability to phosphatases, finally, we applied kinase-catalyzed 
biotinylation to phosphoprotein identification using MS analysis. We compared avidin 
purification to the widely used titanium oxide (TiO2) affinity chromatography. In addition, 
kinase-catalyzed biotinylation captured full-length phosphoproteins, which is not possible with 
TiO2 chromatography. The significant conclusion is that kinase-catalyzed biotinylation is well 
suited for low abundance phosphoprotein detection and complements existing methods to 
provide a more complete view of the phosphoproteome (Chapter 4).  
The enzymatic reactions with ATP-biotin, ATP-danzyl, ATP-ArN3, and other analogs 
established that kinases promiscuously accept γ-phosphate modified ATP analogs as 
cosubstrates. By studying both kinases and phosphatases, kinase-catalyzed labeling experiments 
will build a more detailed and complete picture of the complex cell signaling pathways 
governing disease. In total, the chemical tools established with different ATP analogs will 
provide innovative and unprecedented approaches to monitor the role of phosphorylation in 
biology. 
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Chapter 2 
The Generality of ATP-biotin as Kinase Cosubstrate 
(Portions of the text in this chapter were reprinted or adapted from: Senevirathne, C., Green, K. 
D., and Pflum, M. K. H. (2009) Kinase-Catalyzed Biotinylation of Peptides, Proteins, and 
Lysates, In Current Protocols in Chemical Biology, John Wiley & Sons, Inc. and Senevirathne, 
C., and Pflum, M. K. (2013) Biotinylated Phosphoproteins from Kinase-Catalyzed Biotinylation 
are Stable to Phosphatases: Implications for Phosphoproteomics, Chembiochem: a European 
journal of chemical biology 14, 381-387) 
In this chapter we focus on a systematic study of the labeling of substrates with ATP-
biotin in a kinase dependent manner. The Pflum lab recently discovered the utility of γ-modified 
ATP analogues as tools for studying phosphorylation.
(91-93)
 We found that kinases promiscuously 
accept γ-modified ATP analogs as cosubstrates (Chapter 1). Here we explore the generality of 
ATP-biotin with a variety of recombinant kinases, showing that 26 kinases accept ATP-biotin as 
cosubstrate and can be used for protein labeling. The kinetic data indicate that kinase-catalyzed 
biotinylation occurs with catalytic efficiency appropriate for phosphoproteomics application. A 
summary of phosphoprotein detection and identification methods is also discussed in this 
chapter.  
2.1 Current Methods Used to Identify Phosphopeptides and Phosphoproteins 
 
Historically, 2-D gel analysis has been used to detect phosphoproteins. In this method, 
proteins are separated by their isoelectric points (pI), followed by their molecular weight (Figure 
2.1). Differences in the pI and size of the proteins are seen between phosphorylated and 
unphosphorylated proteins.  Due to these differences, the shifted proteins can be isolated and 
characterized.
(109, 110)
 However, 2-D analysis is challenging with proteins that are highly acidic, 
basic, too large, too small, highly hydrophobic or additionally modified (other posttranslational 
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modification, e.g. sulfation), which can cause a non-phosphorylation dependent shift in pI and 
molecular weight. 
(111, 112)
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Theory of Two-Dimensional Gel Electrophoresis. Proteins are separated by 
isoelectric point followed by molecular weight. Treated protein sample (top) is compared to 
untreated sample (bottom). The shifted proteins in the treated sample (red circled) are digested 
and analyzed by MS/MS analysis. 
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Another classic method to identify protein phosphorylation involves radioactive labeling 
with 
32
P-labeled ATP with subsequent visualizing of the 
32
P labeled phosphoproteins by 
autoradiography.
(104, 113)
 With the in vivo method, radiolabelled inorganic phosphate (
32
Pi) is used 
to metabolically incorporate into ATP, which undergoes phosphorylation to label 
phosphoproteins.  ATP-γ32P is directly used with lysates to label phosphoproteins. The method is 
not efficient since the 
32
P labeled ATP competes with the natural ATP. In addition, large 
amounts of radioactive material are required, making the method hazardous. Hence, less 
hazardous ATP-γ35S has become popular with phosphoproteins labeling.(83)  
Phosphoprotein-specific detection using Pro-Q Diamond phosphoprotein stain 
(Invitrogen)
(107)
 and western blotting 
(108)
 are also used widely. Pro-Q is a fluorescent stain which 
detects phosphate groups at serine, threonine and tyrosine within SDS-polyacrylamide gels. 
Generally, Pro-Q stain is coupled with total protein detection using SYPRO Ruby stain for better 
quantification. Pro-Q Diamond phosphoproteins detection does not required any antibody or 
hazardous radioactive material. In additon, Pro-Q Diamond is compatible with MS analysis, 
which is an advantage of this phosphoproteins detection.
(114)
 Western blotting requires generation 
of specific antibody reagents for each phosphoprotein of interest, making it less appropriate for 
visualizing all phosphoproteins in a complex mixture.
(110, 115)
 For phosphoproteomics 
applications, antibodies recognizing a single phosphotyrosine amino acid have been used 
successfully, while the poor binding affinity of antibodies recognizing phosphoserine or 
phosphothreonine has limited their use.
(110, 115)
  
Mass spectrometric (MS) analysis is also widely used to identify protein 
phosphorylation.
(116-118)
 In MS analysis, a phosphorylated peptide within  80 Da greater mass 
would be expected, which facilitates its identification.
(119)
 MS analysis can be coupled with 
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different separation systems and mass analyzers to increase sensitivity and accuracy.
(120, 121)
 
Despite many improvements, MS has limitations. For example, the ion suppression of charged 
phosphates in MS analysis results in difficulty detecting phosphopeptides in complex 
mixtures.
(122)
 To minimize the influence of ion suppression, unphosphosphorylated peptides are 
often removed from the mixtures prior to MS analysis. As a result, multiple phosphopeptide 
purification methods have been developed to enhance phosphoproteomics analysis (see Chapter 
4 for more details). 
2.2 Kinase-Catalyzed Biotinylation 
While a variety of methods are available to visualize phosphoproteins in complex 
mixtures, each method has its strengths and weaknesses, making the development of alternate 
strategies of interest.  To provide an alternative, the Pflum lab has reported use of γ-modified 
ATP analogues as tools for studying phosphorylation.  In particular, we demonstrated that an 
ATP analogue with biotin attached to the γ-phosphate (ATP-biotin) acts as a cosubstrate for 
kinases and transfers biotin along with the phosphate group onto peptides and proteins (Figure 
2.2).
(91)
 The biotinylation reaction was successful with synthetic peptides and full-length protein 
substrates. Importantly, kinase-catalyzed biotinylation was successfully applied to cell lysates.  
The availability of a facile means of biotin-labeling phosphoproteins and phosphopeptides in 
complex mixtures using kinases as the catalyst represents a useful method to detect 
phosphoproteins.  In this chapter, we focus on the systematic study of the generality of ATP-
biotin with recombinant kinases.  
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Figure 2.2: Kinase-catalyzed biotinylation. (A) Chemical structure of ATP 1 and γ-modified 
ATP analogues ATP-biotin 2 are shown. (B) Peptides or proteins (3) undergo biotinylation with 
a kinase and ATP-biotin (2) to create biotinylated phosphopeptide (4), which can be subjected to 
avidin purification. The phosphoamidate bond is cleaved with acid to yield phosphopeptides or 
phosphoproteins (5). 
To characterize the generality of ATP-biotin for future applications, a diverse set of 
kinase substrate pairs were selected from the human kinome. There are over 500 human kinases 
are known up to date. These protein kinases are divided into different groups, families and 
subfamilies according to the sequence similarity (Figure 1.5).
(37, 102)
 Kinases are mainly 
categorized into seven groups and oriented as a kinome tree (Figure 2. 3),
(37)
 which represents 
the catalytic domain sequence similarity between kinases. Deviation of the sequence of two 
kinases is represented by the distance within the branches. Twenty-six kinases were selected to 
maximize kinome representation, as it is impossible to test all human kinases. Depending on the 
availability of kinase substrate pair, at least one kinase from each group was selected (Figure 2.3 
and Table 2.1). Twenty-six kinases were selected from different places on kinome tree to 
increase the diversity and kinase representation (Figure 2.3 and Table 2.1). Different ranges of 
substrates were selected including, peptides, poly-peptides, and proteins (Table 2.4). Hence 
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selected kinases and their substrates display the diversity of enzyme-substrate pairs and better 
human kinase illustration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Human Kinome Tree. Selected Kinase for labeling and kinetic analysis in the 
human kinome is highlighted in red. The figure is obtained from Manning et al. 2002, Sci, 298, 
5600. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).   
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Table 2.1: Selected Protein Kinase from Human Kinome Tree for Study with ATP-biotin 
Kinase Type Group
a
 
Abl Tyrosine TK 
AKT1  Serine/Threonine AGC 
ASK1 Serine/Threonine STE 
Aurora A Serine/Threonine Other 
CAMK4 Serine/Threonine CAMK 
CDK1  Serine/Threonine CMGC 
CHK1 Serine/Threonine CAMK 
CK1 Serine/Threonine CK1 
CK2 Serine/Threonine CMGC 
DAPK1 Serine/Threonine CAMK 
ERK1 Serine/Threonine CMGC 
FLT1 Tyrosine TK 
GRK5 Serine/Threonine AGC 
GSK3β Serine/Threonine CMGC 
HIPK1 Serine/Threonine CMGC 
JAK3 Tyrosine TK 
MARK1 Serine/Threonine CAMK 
MLK1 Serine/Threonine TKL 
MST1 Serine/Threonine STE 
NEK 2 Serine/Threonine Other 
PAK1 Serine/Threonine STE 
PKA Serine/Threonine AGC 
RSK1 Serine/Threonine AGC 
SRC Tyrosine TK 
TGFβR2  Serine/Threonine TKL 
TRKA Tyrosine TK 
a
AGC: Containing PKA, PKG, PKC families; CAMK: Calcium/calmodulin-dependent protein 
kinase; CK1: Casein kinase 1; CMGC: Containing CDK, MAPK, GSK3, CLK families; Other: 
other kinases; STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK: Tyrosine 
kinase; TKL: Tyrosine kinase-like.  
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In this chapter, we focus on the general use of ATP-biotin with variety of recombinant 
kinases. However, a systematic study of ATP-biotin with kinases has not reported yet. 
Phosphoprotein labeling and monitoring using promiscuous kinase-catalyzed biotinylation will 
advance the proteomic field.    
2.2.1 Synthesis of ATP-biotin 
Initially the Pflum lab used commercially available ATP-biotin for biotinylation studies 
(Chapter 1, section 1.7.2). To study the generality of kinase-catalyzed biotinylation, we 
synthesized ATP-biotin 2 (Scheme 2.1) using a similar strategy as previously published.
(93)
 
Commercially available biotin 6 was activated by TBTU, and then treated with 4, 7, 10-trioxa-1-
13-tridecanediamine 7 to yield biotin amine 8. Biotin amine 8 was then coupled with the 
disodium salt of ATP using EDCI in water while maintaining the pH between 5.6-5.8 to give 
ATP-biotin 2. Intermediate biotin amine 8 and the final ATP-biotin 2 were characterized by 
HRMS, 
1
H, 
13
C and 
31
P NMR (Figures A 2.1-2.9). The synthesized ATP-biotin analog has two 
extra methylene in linker compared to the commercially available ATP-biotin analogue used in 
previous work.
(91)
  
Scheme 2.1: Synthesis of ATP-biotin 
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2.2.2 Labeling of Peptides with ATP-biotin 
From previous studies, we have shown that three different recombinant kinases (PKA, 
CK2 and Abl) successfully utilized different γ-modified ATP analogs (ATP-biotin, ATP-danzyl, 
and ATP-arylazide).
(91-93)
 However no analog has been tested with additional kinases. With the 
ability to label and purify with avidin, the ATP-biotin analog was selected for systematic 
analysis with various kinases. Kinase-catalyzed biotinylation was studied with commercially 
available peptides containing either serine, threonine, or tyrosine along with 10 different 
recombinant kinases, AKT1, CAMK4, CHK1, FLT1, GSK3β, MARK1, MST1, PAK1, RSK1 
and SRC (Table 2.1). Biotinylated phosphopeptides were created by incubating ATP-biotin with 
AKT1 and AKT(PKB) substrate (CKRPRAASFAE), CAMK4 and Autocamtide 
(KKALRRQETVDAL-amide), CHK1 and CHKtide (KKKVSRSGLYRSPSMPENLNRPR), 
FLT1 and IGF1Rtide (KKKSPGEYVNIEFG), GSK3β and GSK3 peptide substrate 
(YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE), MARK1 and CHKtide 
(KKKVSRSGLYRSPSMPENLNRPR), MST1 and Axltide (KKSRGDYMTMQIG), PAK1 and 
PAKtide (RRRLSFAEPG), RSK1 and S6K substrate (KRRRLASLR), or SRC and SRC 
substrate (KVEKIGEGTYGVVYK-amide) in the manufacturer provide buffer (1X, Promega). 
As a control, the phosphorylation reaction with ATP was also performed. To unambiguously 
show that biotinylation is kinase-dependent, at the same time ATP-biotin was also incubated 
with peptide substrates without kinase. The reaction products were separated with 16% Tris-
tricine peptide gels (Biorad) and transferred to PVDF membrane. Peptides were visualized with 
coomassie stain, which indicated equal loading of peptides in each lane (Figure 2.4, top gels for 
each kinase). Biotinylated peptides were visualized with SA-Cy5 conjugate (Figure 2.4, bottom 
gels for each kinase). The results indicate that all ten kinases successfully transferred the 
phosphorylbiotin group to the peptide substrates (Figure 2.4, bottom gels, lane 3). As expected, 
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no biotin labeling was observed in the absence of kinases (Figure 2.4, bottom gels, lane 1) 
indicating that biotinylation occurred through a kinase-catalyzed pathway. These data 
demonstrate that ATP-biotin is compatible with several kinases and their corresponding peptide 
substrates.    
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 2.4: Labeling of Peptides using ATP-biotin. Peptides were subjected to kinase-
catalyzed biotinylation. The reactions were separated on 16% Tris-tricine gel and visualized by 
Coomassie Stain (top gel images for each kinase) and SA-Cy5 (bottom gel images for each 
kinase). Reaction contents are indicated above the lanes. Full gel images can be found in 
appendix Figure A 2.10. 
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2.2.3 Labeling of Proteins with ATP-biotin 
With successful peptide labeling with ATP-biotin and various kinases, our next goal was 
to label full-length proteins with additional kinases. Previously, Dr. Green used β-casein and 
CREB full-length protein substrate with CK2 and PKA enzymes in successful biotinylation 
reactions. In our systematic study of ATP-biotin with kinases, we used 16 additional kinases and 
their corresponding protein substrates. Phosphorylated proteins or biotinylated phosphoproteins 
were created by incubating ATP or ATP-biotin with Abl, ASK1, Aurora A, DAPK1, ERK1, 
HIPK1, MLK1, or TGFβR2 with Myelin basic protein (MBP), CDK1 with Histone H1 protein, 
CK1 with dephosphorylated Casein protein, CK2 and GRK5 with β-Casein protein, and JAK3, 
and TRKA with poly (Glu4, Tyr1) peptide substrate in the manufacturer provide buffer (1X, 
Promega). To verify that labeling is kinase-catalyzed, ATP-biotin was incubated with protein 
substrate only. Crude reaction mixtures were separated by 16% SDS-PAGE and transferred to a 
PVDF membrane. Proteins were visualized with Sypro Ruby Stain (Figure 2.5, top gels for each 
kinase) and biotinylated proteins with SA-Cy5 conjugate (Figure 2.5, bottom gels for each 
kinase).  
The results are shown in Figure 2.5 and Figure 3.5, and indicate that all the 16 kinases 
were compatible with ATP-biotin as a cosubstrate. Similar to the peptide labeling, protein 
labeling with ATP-biotin was observed in the presence of kinase (Figure 2.5, bottom gels, lane 
3). Incubating ATP-biotin with full-length proteins in the absence of kinases did not show biotin 
labeling with SA-Cy5 (Figure 2.5, bottom gels, lane 1), indicating no kinase-independent 
reaction between ATP-biotin and protein substrates, confirming that the labeling is kinase-
mediated. The conclusion of the labeling experiments is that kinases promiscuously accept ATP-
biotin as a cosubstrate. This study used peptides, poly-peptides, and proteins as cosubstrates with 
26 different kinase enzymes, which represent the human kinome. The data indicated that the all 
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the 26 kinases tested here were able to accommodate ATP-biotin in kinase-dependent 
phosphorylation and labeled their corresponding peptide, polypeptide, and protein substrates.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Labeling of Proteins using ATP-biotin. Proteins are subjected to kinase-catalyzed 
biotinylation with ATP-biotin and 16 recombinant kinases. The reactions are separated on 16% 
SDS-PAGE and visualized by Sypro Ruby Stain (top gels) and SA-Cy5 (bottom gels). Reaction 
contents are indicated above the lanes. Gel images for Abl, CK2, and PKA can be found in 
Figure 3.5. Full gel images can be found in appendix Figure A 2.11 and Figures A 3.4, 3.5, 3.6. 
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2.2.4 Quantification of Biotinylation-HPLC Analysis 
The results of the previous sections indicate that many kinases can utilize ATP-biotin and 
can be used to label peptides, poly-peptides, and proteins. Next we were interested in 
determining the efficiency of these biotinylation reactions compared to phosphorylation. In prior 
work, quantitative MS analysis was used to determine the efficiency of biotinylation with 
peptides and proteins.
(91-93)
 However this time we quantified the reaction using HPLC analysis 
with peptides and gel analysis with proteins (discussed in section 2.2.5). Phosphorylated peptides 
or biotinylated phosphopeptides were created by incubating ATP or ATP-biotin with Abl and 
Abl peptide substrate (EAIYAAPFAKKK), AKT1 and AKT(PKB) substrate 
(CKRPRAASFAE), CAMK4 and Autocamtide (KKALRRQETVDAL-amide), CK2 and CK2 
peptide (RRREEETEEE), FLT1 and IGF1Rtide (KKKSPGEYVNIEFG), GSK3β and GSK3 
substrate (YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE), PAK1 and PAKtide (RRRLSFAEPG), 
PKA and kemptide (LRRASLG), RSK1 and S6K substrate (KRRRLASLR), or SRC and SRC 
substrate (KVEKIGEGTYGVVYK-amide) in the manufacturer provide buffer (1X, Promega).  
After each kinase reaction, the crude mixtures were analyzed by HPLC (Figure 2.6 and 
Appendix A, section 2.4). As the HPLC buffer was acidic (~pH=2), the phosphoamidate bond 
was broken to yield a phosphopeptide after the biotinylation reaction. This bond cleavage is 
possible as the reaction mixture was heated to denature the kinase (95 °C, 1 min) and 
equilibrated with the acidic HPLC buffer prior to injection. However, without heat deactivation 
or acidic pre-equilibration, unreacted ATP-biotin was seen without loss of the phosphoamidate 
bond breaking (retention time 10.3 min, Figure A 2.49, top).On the other hand phosphoamidate 
bond cleavage was still observed with the peptides, yielding a phosphopeptide product (Figure A 
2.49, bottom). The biotin-amine, cleaved product was also observed (retention time 12.6 min, 
43 
 
Figure A 2.4 and 2.7). Cleavage of phosphoamidate bond on peptides is more facile and can be 
explained by mechanism through neighboring group participating (Figure A 2.50).  
HPLC analysis indicated that peptide substrates were efficiently phosphorylated with 
ATP (Figure 2.6). In the reaction with Abl, CAMK4, PAK1, and PKA phosphorylation was 
100% with all the three trials, indicating all the peptides were converted onto phosphopeptides. 
With other kinases tested, with peptide substrates showed phosphorylation conversion ranging 
from 26% to 94%. Specifically, 94(±6)% (AKT1), 91(±6)% (CK2), 35(±1)% (FLT1), 26(±2)% 
(GSK3β), 94(±6)% (RSK1), and 63(±5)% (SRC) conversion was observed. A similar trend in 
conversion efficiencies was observed with ATP-biotin. Kinase-mediated biotinylation indicated 
that the conversion was 85(±6)% with Abl, 49(±2)% with AKT1, 62(±3)% with CAMK4, 
46(±2)% with CK2, 30(±6)% with FLT1, 11(±2)% with GSK3β, 67(±1)% with PAK1, 61(±6)% 
with PKA, 74(±1)% with RSK1, and 59(±1)% with SRC. As some kinases do not show 100% 
conversion with phosphorylation, overall conversion efficiency of the biotinylation was 
calculated compared to ATP phosphorylation. This showed overall biotinylation efficiencies 
were 85(±6)% with Abl, 53(±2)% with AKT1, 62(±3)% with CAMK4, 51(±3)% with CK2, 
86(±13)% with FLT1, 42(±5)% with GSK3β, 67(±1)% with PAK1, 61(±6)% with PKA, 
79(±5)% with RSK1, and 94(±4)% with SRC. The data indicated that the percent conversion of 
biotinylation with peptide substrates ranged from 42% to 94% compared to ATP phosphorylation 
(Table 2.2). Thus, kinase-catalyzed biotinylation is occurring with comparable efficiency to the 
ATP phosphorylation.  
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Figure 2.6: Quantification of Biotinylation with Petides. (1) HPLC analysis of unmodified 
peptides (Abl peptide at ~13.8 min; AKT1 peptide at ~13.0 min; CAMK4 peptide at ~12.1 min; 
CK2 peptide at ~7.5 min; FLT1 peptide at ~15.8 min; GSK3β peptide at ~11.5 min; PAK1 
peptide at ~13.6 min; PKA peptide at ~10.9 min; RSK1 peptide at ~11.4 min; SRC peptide at 
~14.2 min). (2) HPLC analysis of ATP-phosphorylated peptides (Abl phosphopeptide at ~13.1 
min; AKT1 phosphopeptide at ~11.5 min; CAMK4 phosphopeptide at ~11.2 min; CK2 
phosphopeptide at ~7.1 min; FLT1 phosphopeptide at ~15.5 min; GSK3β phosphopeptide at 
~10.8 min; PAK1 phosphopeptide at ~13.3 min; PKA phosphopeptide at ~10.3 min; RSK1 
phosphopeptide at ~11.8 min; SRC phosphopeptide at ~13.1 min). (3) HPLC analysis of ATP-
biotin phosphopeptides (Abl phosphopeptide at ~13.0 min; AKT1 phosphopeptide at ~11.6 min; 
CAMK4 phosphopeptide at ~11.5 min; CK2 phosphopeptide at ~7.1 min; FLT1 phosphopeptide 
at ~15.5 min; GSK3β phosphopeptide at ~10.9 min; PAK1 phosphopeptide at ~13.3 min; PKA 
phosphopeptide at ~10.3 min; RSK1 phosphopeptide at ~11.8 min; SRC phosphopeptide at 
~13.0 min). The peaks at ~12.7 min with AKT1 and GSK3β are from biotin-amine due to 
phosphoamidate cleavage.  The complete HPLC traces are shown in section A 2.4, Figure A 
2.12- A 2.21. 
 
2.2.5 Quantification of Biotinylation-Gel Analysis 
To determine the efficiency of biotinylation with the remaining 16 kinases, gel analysis 
was performed. Phosphorylated proteins or biotinylated phosphoproteins were created by 
incubating ATP or ATP-biotin with ASK1 and MBP, Aurora A and MBP, CHK1 and MBP, 
CDK1 and Histone H1 protein, CK1 and dephosphorylated casein protein, DAPK1 and MBP, 
ERK1 and MBP, GRK5 and β-Casein protein, HIPK1 and MBP, JAK3 and poly (Glu4, Tyr1) 
peptide substrate, MARK1 and MBP, MLK1 and MBP, MST1 and MBP, NEK2 and MBP, 
TGFβR2 and MBP, or TRKA and poly (Glu4, Tyr1) peptide substrate in the manufacturer 
provide buffer (1X, Promega). As a control only full-length protein substrate was loaded to 
assess the initial phosphorylation state of the proteins. As phosphorylation produces 
phosphoproteins and biotinylation produces phosphorylbiotin products, direct quantification with 
Pro-Q was not appropriate here. However, the phosphoamidate bond can be easily cleaved under 
acidic conditions to yield phosphoproteins that are the same product obtained with the ATP 
reaction. After kinase reaction, ATP and ATP-biotin reaction products were treated with 50% 
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TFA to obtain phosphoproteins for direct comparison of biotin reactions. Crude reaction 
mixtures were separated by 16% SDS-PAGE. Total proteins were visualized with Sypro Ruby 
Stain (Figure 2.7, top gels) and phosphoproteins were observed with Pro-Q Diamond Stain 
(Figure 2.7, bottom gels). We used Pro-Q Diamond Stain for quantification of kinase conversion 
with ATP and ATP-biotin reactions. Sypro Ruby Stain provided evidence for equal protein 
loading for each lane.  
Myelin basic protein (MBP) displayed no or minimum phosphorylation before the kinase 
reaction, depending on the batch used in each particular reaction. The MBP that was used with 
AST1, Aurora A, DAPK1, ERK1, and HIPK1 was completely dephosphorylated (Figure 2.7, 
lane 1, bottom gels), whereas MBP used with CHK1, MARK1, MLK1, MST1, NEK2, and 
TGFβR2 displayed minimal initial phosphorylation on the proteins (Figure 2.7, lane 1, bottom 
gels). Poly-(Glu4, Tyr1) peptide substrate used with JAK3 and TRKA and β-casein used with 
GRK5 also showed minimum phosphorylation of purchased material (Figure 2.7, lane 1, bottom 
gels). Finally, purchased dephosphorylated casein protein used with CK1 does not indicate any 
phosphorylation before the kinase reaction. For the quantification, Pro-Q signal with untreated 
substrate was subtracted from the signal after the kinase-dependent phosphorylation or 
biotinylation.  
Pro-Q gel analysis indicated that kinase-catalyzed phosphorylation gave an intense signal 
on the gel (Figure 2.7, lane 2) compared to the untreated protein substrate only (Figure 2.7, lane 
1). Similarly, biotinylated proteins also gave high signal (Figure 2.7, lane 3) compared to the 
unreacted substrates (Figure 2.7, lane 1). For the quantification, ATP phosphorylation was 
assumed to be 100% conversion and biotinylation efficiency was calculated relative to ATP 
reaction. Reactions with Aurora A, ERK1, JAK3, NEK2, and TGFβR2 showed over 90% 
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conversion with biotinylation compared to phosphorylation. Other kinases also indicated good 
conversions with ATP-biotin, from 44% to 82%. The data from the quantitative analyses 
indicated that the biotinylation occurred to a reasonable extent compared to phosphorylation.  
To compare the HPLC and gel analysis methods, CAMK4 was tested with both peptide 
substrate and protein substrate. The percent conversion of biotinylation with CAMK4 was 62% 
with peptide (HPLC analysis, Figure 2.6) and 41% with protein (gel analysis, Figure A 2.22 gel 
C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                         
 
 
 
 
 
 
Figure 2.7: Quantification of Biotinylation with Proteins. Proteins were subjected to kinase-
catalyzed phosphorylation or biotinylation. Both phosphorylated and biotinylated samples were 
incubated with 50% TFA for 15 minutes. The reactions were separated by 16% SDS-PAGE and 
visualized by Sypro Ruby Stain (top) and Pro-Q Diamond Stain (bottom). Reaction contents are 
indicated above the lanes. Full gel images can be found in appendix Figure A 2.22. 
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Table 2.2: Efficiency of Kinase-Catalyzed Biotinylation with 26 Kinases  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kinase Method % Conversion 
ABL HPLC 85 ± 6 
AKT1 HPLC 53 ± 2 
ASK1 Gel 76 ± 6 
Aurora A Gel 96 ± 1 
CAMK4 HPLC (Gel) 62 ± 3 (41 ± 2) 
CDK1 Gel 77 ± 2 
CHK1 Gel 47 ± 4 
CK1 Gel 82 ± 9 
CK2 HPLC 51 ± 2 
DAPK1 Gel 63 ± 4 
ERK1 Gel 91 ± 6 
FLT1 HPLC 86 ± 13 
GRK5 Gel 53 ± 9 
GSK3β HPLC 42 ± 5 
HIPK1 Gel 44 ± 5 
JAK3 Gel 91 ± 3 
MARK1 Gel 65 ± 10 
MLK1 Gel 78 ± 6 
MST1 Gel 55 ± 2 
NEK2 Gel 94 ± 3 
PAK1 HPLC 67 ± 1 
PKA HPLC 61 ± 6 
RSK1 HPLC 79 ± 5 
SRC HPLC 94 ± 4 
TGFβR2 Gel 91 ± 5 
TRKA Gel 66 ± 12 
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2.3 ADP-Glo Assay-Theory and Control Reactions 
The efficiency of the biotinylation reaction was further characterized by a kinetic analysis 
using the ADP-Glo assay (Promega). The assay was performed as follows (Figure 2.8). The 
kinase reactions were performed at 30 °C for 30 minutes. Then an equal amount of ADP-Glo 
reagent was added to the mixture and incubated for 40 minutes at room temperature in the dark, 
which terminated the kinase reaction and degraded the unreacted ATP. Then an equal amount of 
kinase detection reagent (KDR) was added to the reaction mixture and allowed to react 60 
minutes at room temperature, which converted ADP into ATP. At the same time, the 
luciferase/luciferin reaction took place with the newly formed ATP. This luciferase/luciferin 
reaction produced a luminescence signal to measure the amount of formed ATP. Hence the 
signal corresponded to the amount of ADP produced in kinase reaction and the activity of the 
kinase reaction. Signal was determined with a micro plate luminescence reader (Tecan). 
Because the ATP-Glo assay was developed for ATP reactions, several control reactions 
were performed to characterize the ADP-Glo assay with ATP-biotin (Figure 2.9). First, 
experiments were done without performing a kinase reaction (Figure 2.9 A). Blank reactions not 
containing any ATP or ATP-biotin gave only background signal (Figure 2.9 A, lane 1). No 
significant signal was observed with ATP alone (Figure 2.9 A, lane 2) or ATP-biotin alone 
(Figure 2.9 A, lane 3), indicating that both were degraded by the ADP-Glo reagent. 
Luminescence signal was observed when ADP was treated with ADP-Glo reagent and kinase 
detection reagent itself (Figure 2.9 A, lane 4) or in the presence of ATP (Figure 2.9 A, lane 5) or 
ATP-biotin (Figure 2.9 A, lane 6). These ADP reactions indicate luminescence was produced 
with newly formed ATP from ADP.  
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Figure 2.8: Theory of ADP-Glo the Assay. Kinase reactions with ATP or ATP analog 
produced ADP as a byproduct. Addition of ADP-Glo reagent inhibited the kinase reaction and 
degraded remaining ATP or ATP analog. Kinase detection reagent converted ADP into ATP and 
this newly formed ATP was used in a luciferase reaction to produce light.  
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 Next, the same components were tested with kinase detection reagent only. When ATP 
(Figure 2.9 A, lane 7) or ADP (Figure 2.9 A, lane 8) was treated with only the kinase detection 
reagent, the signal intensity was the same as when ADP was treated with ADP-Glo reagent and 
KDR (Figure 2.9 A, compare lane 4 and 8). In contrast, the ATP-biotin reaction produced only 
back ground signal (Figure 2.9 A, lane 9). Also, addition of ATP-biotin to ATP or ADP did not 
significantly affect the luminescence signal (Figure 2.9 A, lane 10 and 11). As expected, a 
combination of the ATP and ADP almost doubled the signal compared to itself (Figure 2.9 A, 
compare lane 12 with lane 7 and 8). These reactions indicate that the ATP-biotin does not 
produced signal with KDR. 
Then we performed controls including the kinase reaction (Figure 2.9 B). After the kinase 
reaction, luminescence signal was observed in reactions containing ATP (Figure 2.9 B, lane 8) or 
ATP-biotin (Figure 2.9 B lane 9) as cosubstrates. However in the absence of kinase, ATP (Figure 
2.9 B, lane 6) or ATP-biotin (Figure 2.9 B, lane 7) did not show any significant signal with 
peptide substrate. Additionally, incubation of kinase with ATP (Figure 2.9 B, lane 4) or ATP-
biotin (Figure 2.9 B, lane 5) without peptide substrate did not give any luminescence. Similarly, 
kinase alone (Figure 2.9 B, lane 2) or peptide alone (Figure 2.9 B, lane 3) gave only background 
signal (Figure 2.9 B, lane 1).  These results indicated that ADP-Glo assay works with ATP-biotin 
similar to ATP, and ATP-biotin does not interfere with assay reagent and can be used for further 
analysis. 
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Figure 2.9: Control Experiments with ADP-Glo Assay. Several control experiments were 
carried out to validate the ADP-Glo assay with ATP-biotin. (A) ADP-Glo assay performed 
without a kinase reaction. Lanes 1-6 included both ADP-Glo reagent and kinase detection 
reagent. Lanes 7-12 used kinase detection reagent only. (B) ATP and ATP-biotin controls with 
kinase reaction. Lanes 1-9 included both ADP-Glo reagent and kinase detection reagent. Lane 8 
and 9 represent the kinase reaction with peptide substrate and, ATP and ATP-biotin respectively. 
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Next we were interested in finding the degraded product of ATP or ATP-biotin with the 
ADP-Glo reagent. Graduate student Maheeka Embogama performed the following control 
experiment.  If ATP-biotin was not degraded by the ADP-Glo reagent, would it could be used by 
luciferase to produce signal.  However, the above luminescence data indicated that ATP-biotin is 
either degraded or not used by ADP-Glo reagent (Figure 2.9 A, lane 3) and not used by 
luciferase/luciferin reaction to enhance the luminescence signal (Figure 2.9 A, lane 5,6, 9, 10 and 
11). To determine the fate of ATP-biotin in the ADP-Glo assay, HPLC analysis was performed 
with ATP vs.-7- ATP-biotin with the ADP-Glo reagent (Figure 2.10) and kinase detection 
reagent (Figure 2.11). The data indicate that ADP-Glo reagent converts ATP (Figure 2.10, tR=42. 
2 min) to an unidentified substance (Figure 2.10, tR=12.5 min), this reagent has no effect on ADP 
(Figure A 2.51, tR=38.2 min), AMP (Figure A 2.51, tR=32.6 min), adenosine (Figure A 2.51, 
tR=7.3 min), or adenine (Figure A 2.51, tR=6.9 min). Interestingly, ATP-biotin (Figure 2.10, 
tR=27.9 min) does not convert to any of these products indicating that the ATP-biotin is not a 
substrate for ADP-Glo reagent. As expected, reaction of ATP with kinase detection reagent 
produced AMP (Figure 2.11, tR=32.8 min), which is a byproduct in luciferase/luciferin reaction. 
Similarly, ATP-biotin also produced AMP (Figure 2.11, tR=32.8 min) with kinase detection 
reagent, indicating that the ATP-biotin is a substrate for luciferase. However, this conversion was 
around 60% compared to 100% with ATP, and luminescence produced by this hydrolysis did not 
show significant luminescence signal, from previous analysis (Figure 2.9 A, lane 9). To further 
clarify, ATP or ATP-biotin was incubated with kinase detection reagent and luminescence signal 
was measured every 2.5 minutes (Figure A 2.52) for a one hour period time. The data indicated 
that the amount of signal produced by ATP-biotin is 10-fold less compared to the signal 
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produced by ATP. These control reaction data indicate that ATP-biotin is compatible with the 
ADP-Glo assay for the kinetic analysis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Control Experiments with ADP-Glo Assay using HPLC. ATP (tR=42.2) min or 
ATP-biotin (tR=27.9 min) incubated with ADP-Glo reagent and separated with HPLC. ATP 
(tR=42.3 min) is degraded to an unidentified substance (tR=12.5 min) whereas ATP-biotin 
(tR=27.9 min) remained intact.  
ATP incubated with ADP-Glo reagent 
ATP-biotin only 
ATP only 
ATP-biotin incubated with ADP-Glo reagent 
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Figure 2.11: Control Experiments with ADP-Glo Assay using HPLC. ATP (tR=42.2) min or 
ATP-biotin (tR=27.9 min) incubated with kinase detection reagent and separated with HPLC. 
ATP (tR=42.3 min) was fully degraded to AMP (tR=32.8 min), whereas ATP-biotin (tR=28.1 
min) was only partially degraded to AMP (tR=32.8 min).  
 
 
ATP incubated with KDR 
ATP-biotin only 
ATP only 
ATP-biotin incubated with KDR 
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2.4 ADP-Glo Assay- Kinetic Analysis 
 The efficiency of the biotinylation reaction was further characterized using the ADP-Glo 
assay. Unlike the widely used enzyme-coupled assay, 
(95, 96)
 the ADP-Glo assay is an end point 
assay. Thus kinetic measurements were obtained by performing the reaction with different 
substrate concentrations (1, 3, 10, 30, and 100 µM) and time points (5, 10, 20, 30, and 40 min). 
We screened all 26 kinases and determined kinetic parameters such as KM, kcat and kcat/KM.  
 With the kinetic analysis, ATP-biotin displayed similar KM values compared to ATP for 
tested kinases, ranging from 0.6-fold to 2.9-fold increased values (Table 2.3). ATP-biotin 
showed a higher KM for 22 kinases and lower KM for 4 kinases (GRK5, NEK2, PAK and PKA), 
when compared to ATP. In addition, ATP-biotin showed only 2-fold higher KM for 4 enzymes 
(DAPK, GSK3β, HIPK and TGFβR2). This data suggested that the γ-phosphate modification 
does not affect significantly ATP analog kinase binding efficiency. 
 To assess the efficiency of phosphoamidate transfer using ATP-biotin, kcat values were 
compared to those of phosphate transfer. ATP-biotin showed similar kcat (1-1.5 fold reduced 
values) compared to ATP for 8 kinases. In contrast, the analog displayed reduced kcat relative to 
ATP (ranging from 2 to 53-fold) for the remaining 16 kinases. Significantly, ATP-biotin showed 
19-fold and 53-fold reduced kcat compared to ATP with ASK1 and GSK3β, respectively. 
Altogether, the reduced kcat demonstrated that unnatural phosphorylbiotin transfer with ATP-
biotin is slower than natural phosphate transfer with ATP. We also assessed the catalytic 
efficiencies (kcat/KM) for biotinylation and phosphorylation reactions. As expected, ATP-biotin 
showed lower catalytic efficiencies compared to ATP ranging from 1.1 to 135-fold reduced. 
These data indicated that ATP-biotin is an efficient substrate for some kinases and less efficient 
substrate for other kinases, compared to the natural ATP substrate. 
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 There is no direct correlation between catalytic efficiencies and the earlier percent 
conversion data. For example, kinases demonstrating low catalytic efficiencies, such as ASK1 
and GSK3β (Table 2.3) have reasonable ATP-biotin conversion under equilibrium condition 
(76% ASK1 and 42% GSK3β, Table 2.2). In addition, ATP-biotin showed similar catalytic 
efficiencies as ATP with NEK2 and PAK1 (Table 2.3), but 94% and 67% conversions, 
respectively. However, the remaining 22 kinases showed 2to7 fold reduced catalytic efficiencies 
for biotinylation compared to phosphorylation. These numbers are comparable to the catalytic 
efficiencies of ATP-γS, which is widely used compound for protein labeling.(81-83, 87) One report 
indicated that ATP-γS shows an 8-fold reduced kcat/KM compared to ATP. The data suggested 
that most kinases utilize ATP-biotin with good catalytic efficiencies and can be used for 
phosphoproteomics analysis. 
Table 2.3: Kinetic constant for Enzymes  
Kinase  
KM (µM) 
Ratio 
kcat (s
-1) 
Ratio 
kcat/KM (mM S)
-1 
Ratio 
ATP ATP-biotin ATP ATP-biotin ATP 
ATP-
biotin 
ABL 8.8 ± 1.6 12.0 ± 1.1 1.4 1.27 ± 0.06 0.27 ± 0.008 4.7 143.8 22.3 7 
AKT1 20.5 ± 2.1 23.7 ± 2.8 1.2 1.99 ± 0.01 0.39 ± 0.02 5 96.8 16.3 6 
ASK1 12.4 ± 2.3 16.0 ± 2.6 1.3 0.95 ± 0.05 0.05 ± 0.003 19 76.5 3.2 24 
Aurora 23.8 ± 1.3 36.4 ± 2.5 1.5 2.49 ± 0.05 1.53 ± 0.04 1.6 104.8 41.9 2.5 
CAMK4 13.1 ± 0.6 14.0 ± 2.5 1.1 0.37 ± 0.006 0.12 ± 0.006 3.1 28.5 8.6 3.3 
CDK1 19.5 ± 1.2 27.8 ± 3.0 1.4 6.90 ± 0.14 3.88 ± 0.16 1.8 354.7 139.6 2.5 
CHK1 15.0 ± 1.9 19.2 ± 2.8 1.3 1.60 ± 0.06 0.96 ± 0.05 1.7 104.8 49.7 2.1 
CK1 4.3 ± 0.9 7.3 ± 0.5 1.7 0.12 ± 0.006 0.10 ± 0.002 1.2 27.3 13.6 2.0 
CK2 5.8 ± 1.8 8.9 ± 1.9 1.5 1.36 ± 0.11 0.63 ± 0.04 2.1 233.8 71.2 3.3 
DAPK1 3.9 ± 0.9 11.5 ± 1.4 2.9 0.18 ± 0.01 0.17 ± 0.01 1.0 45.6 15.1 3.0 
ERK1 41.8 ± 3.0 47.1 ± 3.9 1.1 0.65 ± 0.02 0.22 ± 0.01 2.9 115.5 4.8 3.3 
FLT1 33.3 ± 2.5 36.6 ± 3.8 1.1 0.14 ± 0.004 0.06 ± 0.002 2.4 4.2 1.6 2.7 
GRK5 9.2 ± 1.6 9.1 ± 1.0 1.0 0.02 ± 0.001 0.01 ± 0.0002 2.6 1.9 0.8 2.4 
GSK3β 4.7 ± 0.6 11.4 ± 1.8 2.4 0.53 ± 0.02 0.01 ± 0.0004 53 113.6 0.8 135 
HIPK1 5.2 ± 0.4 14.6 ± 2.5 2.8 1.30 ± 0.03 1.06 ± 0.06 1.2 251.8 73.1 3.4 
JAK3 10.4 ± 1.3 15.4 ± 1.6 1.5 0.99 ± 0.04 0.89 ± 0.03 1.1 95.1 58.1 1.6 
MARK1 10.2 ± 0.7 12.7 ± 1.3 1.2 2.21 ± 0.04 1.32 ± 0.04 1.7 217.1 104.0 2.1 
MLK1 24.3 ± 3.0 27.7 ± 2.7 1.1 1.12 ± 0.05 0.28 ± 0.01 4.0 46.2 10.2 4.5 
MST1 17.2 ± 2.9 24.9 ± 3.7 1.4 0.37 ± 0.02 0.22 ± 0.01 1.7 21.6 8.7 2.5 
NEK2 25.0 ± 4.0 20.9 ± 2.9 0.8 0.58 ± 0.03 0.42 ± 0.02 1.4 23.3 20.0 1.2 
PAK1 23.3 ± 3.0 20.7 ± 2.3 0.9 0.04 ± 0.002 0.03 ± 0.001 1.3 1.8 1.6 1.1 
PKA 24.4 ± 1.5 15.0 ± 2.3 0.6 3.03 ± 0.07 0.41 ± 0.02 7 124.0 28.0 4.4 
RSK1 25.3 ± 1.9 35.8 ± 4.0 1.4 3.40 ± 0.10 1.90 ± 0.09 1.8 132.7 52.4 2.5 
SRC 15.3 ± 2.5 16.2 ± 1.8 1.1 0.83 ± 0.04 0.55 ± 0.02 1.5 54.4 33.8 1.6 
TGFβR2 1.4 ± 0.3 4.1 ± 0.9 2.9 0.03 ± 0.001 0.02 ± 0.001 1.2 20.0 5.9 3.4 
TRKA 28.6 ± 2.1 28.2 ± 2.0 1.0 1.12 ± 0.03 0.56 ± 0.02 2.0 41.9 19.8 2.1 
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2.5 Conclusion and Future Direction 
Analysis of ATP-biotin with 26 selected kinases indicated that peptide, poly-peptide, or 
protein substrates were labeled in a kinase-dependent manner (section 2.2.2 and 2.2.3). Previous 
work done by our group
(91-93)
 and others with different ATP analogs such as, ATP-γS,(81) ATP-
ferrocene
(99)
 and ATP-BODIPY
(97)
 also successfully labeled the corresponding substrates in 
invitro assay. Specially, ATP-γS is used for substrate labeling.(81-83, 87) Interestingly, 
commercially available ATP-biotin, which is two carbons shorter in the linker, was also used to 
label peptides and lysates with gel analysis.
(123)
  Additionally, the ATP-acyl-biotin derivative was 
used to identify over 200 kinases in ATP binding manner.
(100, 101)
 These data indicate the ability 
of ATP analogs to bind to a variety of kinases in complex mixture.     
In addition, the efficiency of biotinylation was measured with an end point assay (section 
2.2.4 and 2.2.5) and kinetic analyses (section 2.4). The end point analysis was performed using 
HPLC (for peptides) or gel electrophoresis (for poly-peptides and proteins), and indicated that 
conversion efficiencies ranged from 41% to 96%. This data suggest that under equilibrium 
conditions (higher concentration and longer reaction time) the kinases utilize ATP-biotin more 
efficiently to transfer the phosphorylbiotin group. The percent conversion of CAMK4 was tested 
with both HPLC (peptide, 62%) and gel (protein, 42%) methods, indicating that the efficiency of 
biotinylation with substrate and the method of analysis.   
As mentioned earlier ATP-γS is widely used for protein labeling and shows higher KM 
(10-fold) compared to ATP.
(76)
 Interestingly, opposite results were observed with kcat, indicating 
1.5-fold higher value and 18 to 137-fold lower numbers.
(76-79, 124)
 This variation can be due to the 
quality of enzymes, which depends on source and purification.
(95, 125)
 The kinetic constants of 
ATP-γS indicate that modification on γ-phosphate with electronically different and large atoms 
effects binding and catalytic mechanism.
(76-78, 124)
 The biotinylation reaction was characterized 
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using the ADP-Glo assay. ATP-biotin showed similar KM and decreased kcat compared to ATP. 
However the biotinylation displayed similar catalytic efficiency (kcat/KM) as thiophosphorylation. 
Biotinylation demonstrated a catalytic efficiency (kcat/KM) ranging from 1.1- to 135-fold reduced 
compared to natural phosphorylation, indicating that some kinases can utilize ATP-biotin nearly 
as well as ATP. Altogether, kinases accept ATP-biotin as a cosubstrate at a level useful for 
phosphoproteomic research. 
In the future, we will use ATP-biotin to test its generality with other kinase such as lipid 
kinase, sugar kinase, nucleotide kinase etc. We would also like to discover the labeling with 
kinase and to find correlation between kinase active site properties and binding of ATP analogs. 
Cell permeable version of ATP-biotin analog will help to understand the phosphorylation event 
within the cellular content. We also hope to use biotinylation to study kinase inhibitors and 
kinase substrate pairs. In addition, we will test other ATP analogs containing different 
functionalities.     
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2.6 Experimental 
2.6.1 Materials  
Biotin, triethylamine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDCI), 4, 7, 10-trioxa-1, 13-tridecanediamine, diisopropylethylamine (DIPEA), N, N-
dimethylformamide (DMF), and pyrrolidine were purchased from Acros. Adenosine 5’-
triphosphate (ATP), glycerol, sodium hydroxide (NaOH), potassium chloride (KCl), magnesium 
chloride (MgCl2), sodium chloride (NaCl), sodium dodecyl sulfate (SDS), glacial acetic acid, 
acetonitrile, and SA-Cy5 conjugate were purchased from Fisher. HPLC grade trifluoroacetic acid 
(TFA) and acetonitrile were obtained from VWR and EM Millipore, respectively. D2O and 
CD3OD were obtained from Cambridge Isotope Labs.  Ammonium bicarbonate, β-casein was 
bought from Sigma. PKA, CK2, Abl, enzymes, sodium fluoride, sodium orthovanadate and Abl 
peptide were purchased from New England Biolabs. All other kinases (AKT1, ASK1, Aurora A, 
CAMK4, CDK1, CHK1,CK1, DAPK1, ERK1, FLT1, GRK5, GSK3β, HIPK1, JAK3, MARK1, 
MLK1, MST1, NEK2, PAK1, RSK1, SRC, TGFβR2, and TRKA), AKT(PKB) substrate, 
Autocamtide,  CHKtide, IGF1Rtide, GSK3, Axltide, PAKtide, S6K substrate, SRC peptide 
substrate, Kemptide, CK2 peptide peptide, poly (Glu4, Tyr1) peptide substrate, Myelin Basic 
Protein (MBP), dephosphorylated Casein protein, Histone H1 protein and ADP-Glo assay were 
obtained from Promega. Triton X-100 was purchased from Fluka. Coomassie Briliant Blue was 
obtained from NuSep.  Immobilion P and P
sq
 PVDF membrane were purchased from Millipore. 
Sypro Ruby and Pro-Q diamond stain was obtained from Invitrogen. Ready Gel 16% Tris-tricine 
was purchased from Bio-Rad.  
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2.6.2 Instrumentation  
1
H NMR, 
13
C NMR and 
31
P NMR were recorded on a Varian Mercury (400 MHz) 
spectrometer. The peaks appearing at δ 4.78 and δ 5.12 in 1H NMR are due to D2O. The signals 
appearing at δ 1.58 and δ 3.52 in the 1H NMR and δ 8.2 and δ 46.4 in the 13C NMR are due to the 
triethylamine counter ion.  IR spectra were carried out in CHCl3 on FT/IR-460 plus (JASCO Co. 
Ltd.) spectrometer. High resolution mass spectra (HRMS) were obtained on LCT Premier XT 
(Waters). HP 8452A Diode array UV-Vis spectrophotometer was used to measure absorbance of 
ATP-biotin. The purified final product was lyophilized using VirTis BT 3.3 EL Benchtop 
lyophilizer. A SPD131 DDA ThermoSavant speed vac was used to evaporate solvents in vacuo. 
The luminescence values for the ADP-Glo assay were measured with a fluorimeter (GENios Plus 
Tecan). The SDS-PAGE apparatus was purchased from BioRad (Protean III) and a mini-gel 
setup was used. Western blotting was carried out using the Mini-Transblot Electrophoretic 
Transfer Cell apparatus from Bio-Rad. Peptides were analyzed using a Waters 1525 binary 
HPLC pump and Waters 2998 photodiode array detector. A reverse phase C-18 column (YMC 
America, INC 250×4.6 mm, 4µm, 8 nm) was used to separate peptide mixtures. After SOS – 
Page separation proteins were visualized using a Typhoon 9210 scanner (Amersham 
Biosciences). 
2.6.3 Synthesis of biotin-PEG amine (8) 
Biotin 6 (977.24 mg, 4 mmol) was dissolved in DMF (5 mL). TBTU (1.5412 g, 4.8 
mmol) and DIPEA (0.836 mL, 4.8 mmol) were added and the mixture was stirred at room 
temperature for 30 min. The mixture was added dropwise to a solution of 4, 7, 10-trioxa-1-13-
tridecanediamine 7 (2.2 mL, 10 mmol) in DCM (250 mL) at 4 ºC. After addition was complete, 
the reaction mixture was stirred overnight at room temperature. The reaction progress was 
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monitored by TLC (3:1:0.5 EtOH: DCM: NH4OH, Rf =0.60). The solvent was removed in vacuo. 
The product was purified by flash chromatography on silica gel with EtOH/DCM (1:1→3:1 v/v) 
to yield 82% of biotin-PEG-amine 8 as dark brown solid (1.463 g, 3.28 mmol). Figures A 2.1-
2.4; IR (CHCl3, cm
-1
): 724, 798, 847, 1129, 1184, 1434, 1658, 2939, 3052, 3206, 3457. 
1
H NMR 
(400 MHz, D2O): δ 1.19-1.27 (m, 2H), 1.36-1.65 (m, 8H), 2.08 (t, J=7.2 Hz, 2H), 2.56 (t, J=6.8 
Hz, 2H), 2.82 (dd, J=12.8 and 4.8 Hz, 2H), 3.09 (t, J=6.4 Hz, 2H), 3.12-3.18 (m, 1H), 3.40 (t, 
J=6.0 Hz, 2H), 3.43 (t, J=6.4 Hz, 2H), 3.51 (s, 8H), 4.25 (dd, J=8 and 4.4 Hz, 1H), 4.43 (dd, 
J=8.0 and 4.8 Hz, 1H). 
13
C NMR (100 MHz, D2O): δ 25.1, 27.6, 27.9 28.2, 30.7, 35.4, 36.2, 37.6, 
39.6, 55.3, 60.1, 61.9, 68.3, 68.8, 69.2, 69.3 69.5, 165.1, 176.5. HRMS (ESI): m/z calculated for 
C20H39N4O5S [M+H]
 +
 447.2641, observed 447.2633.   
2.6.4 Synthesis of ATP-biotin (2) 
Adenosine 5’- triphosphate disodium salt (27.5 mg, 0.05 mmol) was dissolved in water (5 
mL) and the pH of the solution was raised to 7.0 by adding 1M sodium hydroxide.  1-(3-
Dimethylaminpropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 383.42 mg, 2 mmol) dissolved 
in water (1 mL) was added to the reaction mixture. The pH of the solution was adjusted to 5.6 
with 1 M hydrochloric acid and a pH range between 5.6-5.8 was maintained throughout the 
reaction. Biotin-PEG-amine 8 (894.44 mg, 2 mmol) was added to the ATP solution and progress 
of the reaction was monitored by TLC (6:3:1 iPrOH: NH4OH: H2O Rf =0.69). The reaction was 
stirred for 4 hours and then treated with triethylamine (TEA) to reach pH 8.0. The product was 
purified on DEAE Sephadex-A25 anion exchange column. The column was run with flow rate of 
4 mL/min. A stepwise elution using 5%, 10%, 25%, 37.5%, 50%, 75% and 100% 
triethylammonium bicarbonate buffer (TEAB) was applied. The product eluted between 37.5-
50% TEAB. Purified product was lyophilized to yield 20% of ATP-biotin 2 as a white TEA salt 
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(10.2 mg, 0.01 mmol). Figures A 2.5-2.9; UV (MeOH): λ 259 nm. 1H NMR (400 MHz, D2O): δ 
1.68-2,16  (m, 8H), 2.57 (t, J=7.2 Hz, 2H), 3.24-3.46 (m, 6H), 3.58-3.64 (m, 4H), 3,84-4.01 (m, 
12H), 4.57-4.59 (m, 2H), 4.72-4.74 (m, 2H), 4.89-4.92 (m, 2H), 6.48 (t, J=6.0 Hz, 1H), 8.63 (s, 
1H), 8.92 (s, 1H). 
13
C NMR (100 MHz, D2O): δ 25.1, 26.4, 27.8, 28.0, 36.2, 37.5, 38.5, 39.6, 
42.1, 55.2, 60.1, 61.9, 65.1, 66.6, 68.2, 68.7, 69.2, 69.3, 69.4, 70.3, 74.2, 84.0, 86.6, 110.8, 118.5, 
140.0, 149.1, 152.3, 164.1, 176.6. 
31
P NMR (400 MHz, D2O): δ -0.06 (d, γ-P), -10.35 (d, α-P), -
21.78 (t, β-P). HRMS (ESI): m/z calculated for C30H51N9O17P3S [M-H]
- 
934.2337, observed 
934.2329. 
2.6.5 Storage of ATP-biotin (2) 
The quality of the ATP-biotin is very important for biotinylation reaction.  Like any 
triphosphate, ATP-biotin is prone to hydrolyze to ATP or ADP.  Degraded ATP will compete 
with ATP-biotin in the kinase reaction. Therefore, lyophilized product (section 2.6.4) of ATP-
biotin was dissolved in the storage buffer (Tris-base, 25 mM, pH 7.5) and stored at -80 °C as 
single use aliquots. In addition, it is critical that freeze thaw cycles be avoided with ATP-biotin.  
However, ATP-biotin will degrade over time and should be used within 3 months.   
2.6.6 Kinase-Catalyzed Phosphorylation and Biotinylation 
Phosphorylated or biotinylated peptides were created by incubating ATP or ATP-biotin 
(2 mM) with a kinase enzyme (Table 2.4) and its corresponding peptide substrate (0.25 mM) in 
the manufacturer provide buffer (1X). As a control, reactions were performed without kinases. 
The final volume of the reactions was 25 µL. The reaction mixtures were incubated at 30 ºC for 
2 hours without shaking. After reaction, the mixtures were heated at 95 ºC for 1 minute to 
denature the kinase activity. Crude sample was separated on a 16% Tris-tricine gel (section 
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2.6.7) and transferred to Immobilion P
SQ
 PVDF membrane, and visualized with Coomassie stain 
and SA-Cy5 conjugate as described in sections 2.6.11 and 2.6.10. For HPLC quantification, 
crude samples were pre-equilibrate in 50 µL HPLC buffer A (99.9% water with 0.1% 
trifluoroacetic acid) for 10-15 minutes and used directly for HPLC analysis, as described in 
section 2.6.9. 
Phosphorylated proteins or biotinylated phosphoproteins were generated as described 
above. In this case, after heat denaturation, the crude sample was separated by 16% SDS-PAGE 
and transferred to Immobilion P PVDF membrane, and visualized with Sypro Ruby Stain and 
SA-Cy5 conjugate as described in sections 2.6.10 and 2.6.12. For quantification experiments, 25 
μL of TFA (50% TFA final concentration) was added to both phosphorylated and biotinylated 
samples and incubated for 15 minutes to cleave the biotin tag. Then the samples were evaporated 
to dryness using a speed vac and subsequently neutralized with 1.5 M Tris-base (pH 12).  Then 
crude samples were used in SDS-PAGE separation, and gel imaging with Sypro Ruby Stain 
(section 2.6.12) and Pro-Q Diamond Stain (section 2.6.13). 
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Table 2.4: Enzymes and substrates used for labeling and quantification 
Kinase  
Kinase 
Concentration (nM) 
Substrate 
ABL 125 MBP, (EAIYAAPFAKKK)
a
 
AKT1 94 CKRPRAASFAE 
ASK1 133 Myelin Basic Protein 
Aurora A 112 Myelin Basic Protein 
CAMK4 101 KKALRRQETVDAL-amide 
CDK1 102 Histone-H1 
CHK1 98 KKKVSRSGLYRSPSMPENLNRPR, (MBP)
a
 
CK1 129 Casein Protein (dephospho) 
CK2 165 Casein Protein, (RRREEETEEE)
a
 
DAPK1 113 Myelin Basic Protein 
ERK1 182 Myelin Basic Protein 
FLT1 85 KKKSPGEYVNIEFG 
GRK5 70 Casein Protein 
GSK3β 110 YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE 
HIPK1 113 Myelin Basic Protein 
JAK3 125  Poly (4:1 Glu, Tyr) Peptides 
MARK1 64 KKKVSRSGLYRSPSMPENLNRPR, (MBP)
a
 
MLK1 104 Myelin Basic Protein 
MST1 96 KKSRGDYMTMQIG, (MBP)
a
 
NEK2 105 Myelin Basic Protein 
PAK1 88 RRRLSFAEPG 
PKA 150 MBP, (LRRASLG)
a
 
RSK1 74 KRRRLASLR 
SRC 96 KVEKIGEGTYGVVYK-amide 
TGFβR2 0.118 Myelin Basic Protein 
TRKA 0.121 Poly (4:1 Glu, Tyr) Peptides 
 
a= In some case different substrates were used in biotinylation and quantification experiments. 
Substrates in paranthesis were used for quantification experiments. Abl, CK2, PKA, and Abl 
substrates were purchased from New England Biolab. All other enzymes and substrates were 
purchased from Promega.   
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2.6.7 Tris-Tricine Gel Electrophoresis 
The tris-tricine gels were either purchased from Bio-Rad (cat no: 4563063) or prepared as 
follows. The tris-tricine gel was prepared in two layers, an upper “stacking” layer and a lower 
“separating” layer, as described in Nature Protocols.(126) A 16% separating layer was prepared 
consisting of a 10 mL of 3X Gel buffer (0.3% w/v SDS, 3 M Tris, brought to pH 8.45 with HCl), 
10 mL of 40% v/v 29:1 acrylamide:bisacrylamide, and 3 mL of glycerol, which was diluted to 30 
mL with distilled water. Polymerization was initiated by the addition of 100 µL of 10% 
ammonium persulfate, followed by 10µL of TEMED. After addition to the gel setup, distilled 
water was added on top of the separating layer to ensure a smooth edge and removed before 
adding the stacking layer. The upper stacking layer was composed of 4 mL of 3X gel buffer 
(0.3% w/v SDS, 3 M Tris, brought to pH 8.45 with HCl), and 1 mL of 40% v/v 29:1 
acrylamide:bisacrylamide, which was diluted to 12 mL by addion of distilled water. 
Polymerization was initiated by the addition of 90 µL of 10% ammonium persulfate followed by 
9 µL of TEMED, before loading on top of the separating layer. The gel running chamber was 
filled with a 1X Tris-Tricine-SDS running buffer, which was composed of 0.1% SDS, 100 mM 
Tris, and 100 mM tricine (at pH 8.3). A protein molecular weight marker (5 µL, Spectra 
Multicolor Low Range Protein Marker, Thermo Scientific) was used as a standard. The gel was 
run at a constant 100 V for 2 hours. 
2.6.8 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The polyacrylamide gel was prepared in two layers, an upper “stacking” layer and a 
lower “separating” layer (as described in Molecular Cloning, Appendix 8.40-8.45).(127) The 
lower layer contained approximately 4 mL of a 16% separating layer consisting of 1 mL of 4X 
Tris/SDS separating buffer (0.4% w/v SDS, 1.5 M Tris, brought to pH 8.8 with HCl), 1.6 mL of 
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40% w/v 37:1 acrylamide:bisacrylamide, 1.38 mL of distilled water, and 10% ammonium 
persulfate. Polymerization was initiated by the addition of 4 μL of TEMED. After addition to the 
gel setup, methanol was added on top of the separating layer to ensure a smooth edge and 
removed before adding the stacking layer. The upper stacking layer was composed of 0.5 mL of 
4X Tris/SDS stacking buffer (0.4% w/v SDS, 1.5 Tris, brought to pH 6.8 with HCl), 0.25 mL of 
40% w/v 37:1 acrylamide: bisacrylamide, 1.24 mL of distilled water, and 10 μL of 10% 
ammonium persulfate. Polymerization was initiated by the addition of 2 µL of TEMED. The gel 
running chamber was filled with a 1X SDS running buffer, which was composed of 0.1% SDS, 
0.025M Tris, and 0.25 M glycine (at pH 8.3). A protein molecular weight marker (5uL, EZ-RUN 
Pre-Stained Protein Marker, Fisher) was loaded onto the gel as a standard. The gel was run at a 
constant 200 V for 1 hour. 
2.6.9 HPLC Analysis 
For HPLC analysis, peptide reactions (25 µL) were incubated in Buffer A (50 µL; 99.9% 
water with 0.1% trifluoroacetic acid) for atleast 15 min at room temperature to pre-equilibrate. 
Reverse phase chromatographic separation of peptides was performed using a C18 column 
(YMC America INC; 250×4.6 mm, 4µm, 8 nm) and Waters 1525 binary HPLC pump. The 
elution gradient used started at 95% Buffer A in Buffer B (99.9% acetonitrile with 0.1% 
trifluoroacetic acid), and decreased to 70% Buffer A over 15 min.  The flow rate was 1 mL/min 
and the peptide absorbance was detected at 214 nm. The percentage of phosphopeptide was 
calculated by dividing the area under the phosphopeptide peak by the total area under both the 
phosphopeptide and unmodified peptide peaks.    
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2.6.10 Biotin Visualization 
Proteins separated by gel were transferred to a polyvinyldene fluoride (PVDF) membrane 
(Immobilon P or P
SQ
, Millipore). The membrane was pre-wet with methanol and proteins were 
transferred using the Mini-Transblot Electrophoretic Transfer Cell apparatus from BioRad, with 
CAPS/methanol buffer (0.01M CAPS [N-cyclohexyl-3-aminopropanesulfonic acid] at pH 10.5, 
and 10% methanol) used to fill the transfer chamber. The transfer was carried out at 90 V for 1 
hour. After the transfer was complete, the membrane was incubated overnight in a blocking 
solution of 5-10% (w/v) non-fat dry milk in PBST (0.1% Tween-20 in 1X PBS buffer: 137mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4). The membrane was washed with 
PBST and then incubated in a 1:500 dilution of SA-Cy5 for one hour (longer time incubation can 
lead to non-specific labeling). The membrane was rinsed with PBST for 5 minutes, thrice, to 
remove the excess antibody, and visualized using the Typhoon scanner at an excitation 
wavelength of 633 nm and an emission at 670 nm. 
2.6.11 Coomassie Stain   
The tris-tricine gel was fixed in 50 mL of fixing solution (50% methanol and 10% acetic 
acid in water) and incubated with gentle rocking at room temperature for 30 minutes. The used 
fix solution was removed and 50 mL of undiluted Coomassie Brilliant Blue stain (NuSep) was 
added. The gel was incubated in the staining solution at room temperature overnight, with gentle 
rocking. The gel was then transferred to another clean container containing 100 mL of the 
destaining solution (6% acetic acid), and incubated at room temperature for 10-12 hours. The 
coomassie stained gel was imaged using a commercial scanner (HP Scanjet G4010).  
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2.6.12 Sypro Ruby Stain 
The polyacrylamide gel was submerged in 50 mL of fixing solution (50% methanol and 
7% acetic acid in water) and incubated with gentle rocking at room temperature for 30 minutes. 
The used fix solution was removed and the process was repeated. The used fix solution was 
poured off and 50 mL of undiluted Sypro Ruby gel stain (Invitrogen) was added. In this and 
subsequent steps, the gel was protected from light by covering the container with aluminum foil. 
The gel was incubated in the staining solution at room temperature overnight, with gentle 
rocking. The gel was then transferred to another clean container containing a sufficient volume 
of the washing solution (10% methanol and 7% acetic acid in water), and incubated at room 
temperature for 30 minutes. The washing solution was discarded and the gel was rinsed with 
distilled H2O for 5 minutes to remove excess acid to prevent corrosive damage to the instrument 
used for visualization. The Sypro Ruby stained gel was imaged using the Typhoon scanner at an 
excitation wavelength of 450 nm and an emission of 610 nm. 
2.6.13 Pro-Q Staining  
The gel (independent gel from same crude reaction) was incubated in 50 mL of fixing 
solution (50% methanol and 10% acetic acid in water) overnight, and then the solution was 
discarded.  The gel was rinsed with distilled water for 30 minutes, three times. Then 50 mL of 
undiluted Pro-Q Diamond gel stain (Invitrogen) was added. In this and subsequent steps, the gel 
was protected from light by covering the container with aluminum foil. The gel was incubated in 
the staining solution at room temperature for 60-90 minutes, with gentle rocking. The gel was 
then transferred to another clean container containing 100 mL of the washing solution (20% 
acetonitrile, 50 mM sodium acetate pH 4), and incubated at room temperature for 90 minutes, 
three times. The washing solution was discarded and the gel was rinsed with distilled water for 5 
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minutes to wash off excess acid to prevent corrosive damage to the instrument used for 
visualization. The Pro-Q stained gel was imaged using the Typhoon scanner at an excitation 
wavelength of 532 nm and an emission of 555 nm. 
2.6.14 Gel Image Quantification 
Gel bands were quantified using ImageQuant 5.1 by drawing the same size rectangular 
shape around comparable bands. The background correction was calculated by substracting the 
untreated protein signal from kinase reaction signal. The percentage of phosphoproteins or 
biotinylated phosphoproteins observed after kinase reaction was calculated by dividing the 
protein signal with ATP-biotin treatment to the protein signal with ATP treatment. The 
percentages displayed in Figure 2.7 are average percentages and standard error of observed 
phosphoprotein or biotinylated phosphoprotein from three independent trials.  
2.6.15 Kinetics analysis 
Kinase kinetic analysis was performed using the ADP-Glo kinase assay (Promega). All 
kinase assays were performed in white, flat-bottom 96-well half-area micro plates (Corning). For 
kinase reactions, ATP or ATP-biotin (1, 3, 10, 30, and 100 µM final concentrations) were 
incubated with corresponding peptide (0.2 µg/μL final concentration) or protein (0.1 µg/μL final 
concentration) substrates and manufacture’s provided buffer (Table 2.5). The kinase reaction was 
initiated by adding protein kinase (manufacture’s recommended amount; see Table 2.5). The 
final volume of the reactions was 20 µL. The reaction mixtures were incubated at 30 °C for 5, 
10, 20, 30, and 40 minutes for each concentration. After the incubation period, an equal amount 
of ADP-Glo reagent (20 µL) was added to the mixture and incubated for 40 minutes at room 
temperature. Then, an equal amount of kinase detection reagent (40 µL) was added to the 
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reaction mixture and allowed to react 60 minutes at room temperature. Finally, luminescence 
signal was determined with a micro plate luminescence reader (GENios Plus Tecan). The 
concentration of ADP produced during the reaction was determined using a standard curve. Then 
the concentration of ADP produced in the reaction was plotted with the time. The initial rates of 
the reactions were obtained from the slope of the linear portion of the plots. The experimental 
results (rate vs concentration) were fitted by non-linear regression using Kaleidagraph 
(“Michaelis-Menten-Kinetic” model was used, V=Vmax*[S] / (KM + [S]), V=rate of the reaction 
and [S]= substrate concentration) to obtain the KM and Vmax, and Vmax was divided by the 
concentration of enzyme (Table 2.5) to obtain the kcat value. The fold change of the relevant 
kinetic constants were calculated by dividing the the kinetic constants with ATP-biotin reaction 
by the kinetic constants with the ATP reaction.  
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Table 2.5: Enzymes and substrates used for ADP-Glo assay 
Kinase  
Kinase 
Concentration 
(nM) 
Substrate 
Substrate 
Concentration 
µg/µL  
ABL 15.0 EAIYAAPFAKKK 0.2 
AKT1 5.9 CKRPRAASFAE 0.2 
ASK1 4.2 Myelin Basic Protein 0.1 
Aurora 1.4 Myelin Basic Protein 0.1 
CAMK4 1.3 KKALRRQETVDAL-amide 0.2 
CDK1 0.7 Histone-H1 0.1 
CHK1 3.1 KKKVSRSGLYRSPSMPENLNRPR 0.2 
CK1 16.1 Casein Protein (dephospho) 0.1 
CK2 10.0 RRREEETEEE 0.2 
DAPK 2.1 Myelin Basic Protein 0.1 
ERK1 4.6 Myelin Basic Protein 0.1 
FLT1 13.3 KKKSPGEYVNIEFG 0.2 
GRK5 10.0 Casein Protein 0.1 
GSK3 3.4 YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE 0.2 
HIPK 1.4 Myelin Basic Protein 0.1 
JAK3 1.6  Poly (4:1 Glu, Tyr) Peptides 0.1 
MARK1 0.4 KKKVSRSGLYRSPSMPENLNRPR 0.2 
MLK1 3.9 Myelin Basic Protein 0.1 
MST1 3.0 KKSRGDYMTMQIG 0.2 
NEK2 3.3 Myelin Basic Protein 0.1 
PAK1 10.5 RRRLSFAEPG 0.2 
PKA 12.0 LRRASLG 0.2 
RSK1 0.7 KRRRLASLR 0.2 
SRC 1.2 KVEKIGEGTYGVVYK-amide 0.2 
TGFβR2 18.4 Myelin Basic Protein 0.1 
TRKA 0.8 Poly (4:1 Glu, Tyr) Peptides 0.1 
 
Footnote: Figure 2.3 in this chapter were reprinted with permission from Cell Signaling 
Technology, Inc. (www.cellsignal.com). Request ID 315230. 
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Chapter 3 
Stability of Biotinylated Phosphoproteins from Kinase-Catalyzed Biotinylation 
(Portions of the text in this chapter were reprinted or adapted with permission from: 
Senevirathne, C., and Pflum, M. K. (2013) Biotinylated Phosphoproteins from Kinase-Catalyzed 
Biotinylation are Stable to Phosphatases: Implications for Phosphoproteomics, Chembiochem: a 
European journal of chemical biology 14, 381-387.) 
Previous data indicated that many recombinant kinases and cellular kinases accept ATP-
biotin as a cosubstrate. However the dynamics of the modified reaction were not characterized. 
Given that phosphorylation is a reversible process, we were interesting in testing the dynamics of 
biotinylation in a cellular contex. If the modification is sensitive to the phosphatases in lysates, 
biotinylation can be used to monitor dynamic of phosphorylation. Or if the modification is stable 
to phosphatases, the method would be great tool for identifying low abundance phosphoprotein 
in complex mixture. This chapter is focused on studying the phosphatase stability of the 
phosphorylbiotin group towards the use of kinase-catalyzed biotinylation for phosphoproteomics. 
 
3.1 Phosphatase Activity with Phosphoryl Biotin Tag  
Recently we reported use of γ-phosphate modified ATP analogs for studying 
phosphorylation.
(91-94)
 In particular, we demonstrated that an ATP analog with biotin attached to 
the γ-phosphate (ATP-biotin (2), Figure 3.1) acts as a cosubstrate for kinases and transfers a 
phosphorylbiotin group to peptides and proteins (Figure 3.1).
(94)
 With these successes, kinase-
catalyzed biotinylation has application towards characterizing the complete phosphoproteome.  
However, cellular experiments are complicated by the presence of protein phosphatases, which 
could alter the biotinylation state of the labeled phosphoproteins (Figure 3.1).  To assess the 
suitability of kinase-catalyzed biotinylation for phosphoproteomics applications, the sensitivity 
of the phosphorylbiotin tag to phosphatase activity must be characterized.  
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Figure 3.1: Protein Phosphorylation, Biotinylation and Dephosphorylation. Biotinylation 
with kinases and ATP-biotin gives biotinylated phosphopeptide products (5).  The sensitivity of 
biotinylated phosphopeptides to phosphatases is studied in this chapter.   
 
3.2 Protein Dephosphorylation: Phosphatases, Structure and Enzymatic Mechanism 
Many biological processes involve kinases and phosphatases, including cell signaling, 
and cancer formation, for examples.
(6, 128)
 In contrast to kinases (over 500), a fewer number of 
phosphatases (over 150) are known.  Phosphatases are divided into two major classes-
(7)
 
serine/threonine phosphatases
(129)
 and tyrosine phosphatases,
(130)
 which hydrolyze 
phosphoserine/threonine or phosphotyrosine, respectively. Unlike kinases, phosphatases have 
differing active sites and mechanisms depending on their substrate.
(10, 130-134)
 Serine/threonine 
phosphatases have an active site that utilizes catalytic metals (Mn, Fe, Zn) to bind the 
phosphate
(135-137)
 and activates water for phosphate ester hydrolysis (Figure 3.2 A).
(138)
 In 
contrast, tyrosine phosphatases hydrolyze the phosphate ester by employing a nucleophillic 
cysteine (Figure 3.2 B).
(130, 139, 140)
 To characterize the compatibility of the two active sites with 
phosphoryl biotin degradation, we tested two serine/threonine phosphatases (protein phosphatase 
1 (PP1) and calf intestinal phosphatase (CIP)) and one tyrosine phosphatase (T-cell protein 
tyrosine phosphatase (TCPTP)).  
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Figure 3.2: Mechanism of the Dephosphorylation by Protein Phosphatases. (A) Protein 
serine/threonine phosphatases employ two metal ions which activate a water molecule to attack 
the phosphate group during dephosphorylation. (B) Protein tyrosine phosphatases employ an 
amino acid cysteine to attack the phosphate group during dephosphorylation. 
 
3.3 Stability of Modifications on Phosphate towards Phosphatases 
Kinases utilize γ-thio-ATP (ATP-γS (6), Figure 3.3) to generate thiophosphorylated 
proteins.  Prior work revealed that the thiophosphoryl group is insensitive to phosphatases
(74, 86, 
141)
 and provided the foundation for use of ATP-γS and thiophosphorylation in 
phosphoproteomics applications.
(80, 81, 87, 124, 142)
 With this precedent, we examined whether the 
phosphorylbiotin modification is similarly insensitive to phosphatases. If the biotin tag is stable 
under cellular conditions, then kinase-catalyzed biotinylation would be an excellent tool to 
visualize and purify phosphorylated proteins in lysates, with the ability to monitor low 
abundance phosphoproteins. 
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Figure 3.3: Irreversible Kinase-Catalyzed Thiophosphorylation. (A) Chemical structure of 
ATP-γS (6). (B) Peptides or proteins (3) undergo thiophosphorylation with kinases and ATP-γS 
to give thiophosphopeptides or thiophosphoproteins products (7), which cannot be removed by 
phosphatases. The insensitivity of thiophosphopeptides and thiophosphoproteins to phosphatases 
is well documented.   
 
Here we test the susceptibility of the phosphorylbiotin tag of kinase-catalyzed 
biotinylation towards protein phosphatases.  We found that the phosphorylbiotin group on 
peptide and protein substrates was relatively insensitive to protein phosphatases. To understand 
how phosphatase stability would impact phosphoproteomics research applications, kinase-
catalyzed biotinylation of cell lysates was performed in the presence of kinase or phosphatase 
inhibitors.  We found that biotinylation with ATP-biotin was sensitive to inhibitors, although 
with variable effects compared to ATP phosphorylation.  The results suggest that kinase-
catalyzed biotinylation is well suited for phosphoproteomics studies, with particular utility 
towards monitoring low abundance phosphoproteins or characterizing the influence of inhibitor 
drugs on protein phosphorylation. 
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3.4 Phosphatase Activity with Biotinylated Phosphopeptides  
Two steps were employed to assess the phosphatase sensitivity of biotinylated 
phosphopeptides. First, biotinylphosphopeptides were prepared by incubating ATP-biotin with 
peptide/kinase pairs: PKA (Protein Kinase A) and serine-containing substrate (LRRASLG), CK2 
(Casein Kinase 2) and a threonine-containing substrate (RRREEETEEE), and Abl (Abl Protein 
Tyrosine Kinase) and a tyrosine-containing substrate (EAIYAAPFAKKK). After generating the 
biotinylphosphopeptides, the second step involved heat denaturation of the kinase, followed by 
incubation with PP1, CIP, or TCPTP.  As a control, identical experiments were carried out with 
ATP as a cosubstrate. All reactions were analyzed using high performance liquid 
chromatography (HPLC). In the presence of acidic HPLC Buffer A (0.1% TFA in water, pH ~2), 
the phosphoramidate bond of the biotinylphosphopeptide was cleaved to remove the biotin group 
and yield a phosphopeptide product (see chapter 2, section 2.2.4 for more information).
(143)
  
Therefore, ATP and ATP-biotin reactions produced HPLC traces containing identical 
unmodified (Figure 3.4 A) or phosphorylated peptide products (Figure 3.4 B and C).  
Under conditions where ATP control reactions demonstrated 90% to 100% kinase 
conversion to phosphopeptide products (Figure 3.4 B, top), the ATP-biotin reactions 
demonstrated 46-85% conversion (Figure 3.4 C, top). The efficiencies of the kinase reactions 
with ATP-biotin were comparable to the quantitative mass spectrometric analysis reported 
previously (56-80%),
(91)
 demonstrating the reliability of the HPLC analysis. After phosphatase 
treatment, ATP phosphorylated peptides were almost completely hydrolyzed; only 0-11% 
phosphopeptides remained by HPLC (Figure 3.4 B, bottom), indicating that the phosphatase 
maintains 89-100% activity.   
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Figure 3.4: HPLC analysis and quantification of phosphorylated and biotinylated peptides 
before and after phosphatase treatment (A) HPLC analysis of unmodified peptides (PKA 
peptide at ~8.3 min; CK2 peptide at ~7.5 min; Abl peptide at ~13.8 min). (B) HPLC analysis of 
ATP-phosphorylated peptides (top; PKA phosphopeptide at ~7.5 min; CK2 phosphopeptide at 
~7.1 min; Abl peptide at ~13.2 min) after phosphatase treatment (bottom).  (C) HPLC analysis of 
ATP-biotin phosphopeptides (top; PKA phosphopeptide at ~7.5 min; CK2 phosphopeptide at 
~7.1 min; Abl phosphopeptide at ~12.9 min) after phosphatase treatment (bottom).  The 
percentages in B and C represent the average percentage phosphopeptide observed from 3 
independent trials with standard error.  The complete HPLC traces are shown in Figure A 3.1, A 
3.2, and A 3.3. 
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In contrast, a significant amount of biotinylated phosphopeptide products were observed 
after phosphatase treatment; 34-49% phosphopeptides were still observed after phosphatase 
reaction (Figure 3.4 C, bottom).  Comparing the percentage of biotinylated product before and 
after phosphatase incubation (Figure 3.4 C, bottom versus top) revealed that 59% (PP1), 74% 
(CIP), and 58% (TCPTP) of the modification remained intact. Therefore, while phosphatases 
maintained 89-100% activity with phosphopeptide substrates, only 26-42% activity was seen 
against biotinylated phosphopeptides.  Of the three phosphatases tested, CIP was the least active 
(26%) with PP1 and TCPTP maintaining similar activities (41% and 42%).  These studies 
indicate that the phosphorylbiotin modification is less susceptible to phosphatase hydrolysis than 
a phosphate modification.  
3.5 Phosphatase Activity with Biotinylated Phosphoproteins 
Our next goal was to study the sensitivity of full-length biotinylated phosphoproteins to 
phosphatase activity.  While the kinase/phosphatase pairing was the same as with the peptides 
experiments, the full-length substrates used were myelin basic protein (MBP) with PKA and Abl 
and β-casein with CK2 (Figure 3.5). Similar to the peptide experiments, a two-step reaction 
series was employed with kinase reaction first, followed by phosphatase incubation.  In this case, 
the crude products were analyzed by gel methods.  
Control reactions with ATP demonstrated the sensitivity of phosphoproteins to 
degradation by phosphatases; only 6-7% of total phosphoproteins were observed by Pro-Q 
staining (Figure 3.5, lanes 2, 6, and 10, Pro-Q), indicating that phosphatases maintain 93-94% 
activity at removing phosphates. In contrast, a significant amount of biotinylated 
phosphoproteins was still detected after phosphatase treatment; 72-83% of total biotinylated 
phosphoproteins were observed (Figure 3.5, lanes 4, 8, and 12, SA-Cy5), indicating that the 
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phosphatases demonstrated only 17-28% activity at removing the biotin tag.  Consistent with the 
stability of the biotin tag to phosphatases, 37-66% biotinylated phosphoproteins were detected 
after phosphatase incubation using Pro-Q staining (Figure 3.5, lanes 4, 8, and 12, Pro-Q). 
Comparing the percentage of Pro-Q-visualized biotinylphosphoproteins after and before 
phosphatase incubation (Figure 3.5, lanes 4 vs 3, 8 vs 7, and 12 vs 11, Pro-Q) revealed that 85% 
(PP1), 66% (CIP), and 90% (TCPTP) of the modification remained intact.  The Pro-Q analysis 
indicated that phosphatases maintained 10-34% activity against biotinylated phosphopeptides.  
The differences in activity comparing biotin (17-28%) and phosphate (10-34%) detection (Figure 
3.5, SA-Cy5 versus Pro-Q) may be due to the presence of phosphorylation sites on the substrates 
prior to kinase reaction, which would skew the Pro-Q staining data. 
Figure 3.5: Gel analysis and quantification of phosphorylated and biotinylated proteins 
before and after phosphatase treatment. The contents of each reaction are indicated below 
each lane. Pro-Q staining visualizes phosphoproteins, SA-Cy5 staining detects biotin-labeled 
proteins, and Syproruby stains for total protein content. The percentages of phosphorylated (Pro-
Q) or biotinylated (SA-Cy5) proteins were calculated relative to lanes 1, 5, or 9 (Pro-Q, 100%) 
or lanes 3, 7, or 11 (SA-Cy5, 100%). The full gel images, along with additional control reactions, 
are shown in Figure A 3.4, A 3.5, and A 3.6 of appendix.    
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A comparison of the activity data suggests that full-length biotinylated proteins are less 
sensitive to phosphatases than biotinylated peptides (17-28% versus 26-42%). The protein data 
represents the aggregate reactivities of all phosphorylation sites in the protein to phosphatases.  
As a result, the data suggest that the majority of phosphorylation sites on full length proteins are 
less susceptible to phosphatase hydrolysis than in isolated peptides.  The steric bulk of full-
length proteins may prevent phosphatase binding and catalysis. The significant conclusion from 
the experiments is that the phosphorylbiotin group, particularly on full length proteins, shows 
significant stability to phosphatase degradation. 
3.6 Inhibitor Studies in Cell Lysates  
With an eye towards future phosphoproteomics applications, we were interested in 
probing how the phosphatase stability of the phosphorylbiotin tag would impact lysate labelling. 
Because cell lysates naturally contain phosphatases, typical phosphoproteomics experiments 
include phosphatase inhibitors in the cell lysates to stabilize phosphorylation.
(144, 145)
  With the 
stability of the phosphorylbiotin tag, we hypothesized that robust kinase-catalyzed labeling will 
occur in lysates without the need for phosphatase inhibitor treatment. In addition, we wondered 
how phosphatase inhibitors would impact kinase-catalyzed labeling. Given the interest in kinases 
and phosphatase inhibitors as drug targets,
(146-149)
 inhibitor experiments would also establish the 
utility of kinase-catalyzed labelling as a drug characterization tool.   
3.6.1 Phosphatase Inhibitors 
In contrast to kinase inhibitors (chapter 1.4), there are few inhibitors designed to target 
protein phosphatases (Figure 3.6). However, a handful of phosphatase inhibitors are used to 
treatment of diseases, such as diabetes, obesity and cancer.
(128, 150, 151) Sodium stibogluconate is 
the FDA approved phosphatase inhibitor used to treat for cutaneous leishmaniasis.
(148, 152)
 In 
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addition, suramin, phenylarsine oxide, aplidin, alendronate, vanadate, etidronate, and gallium 
nitrate are used as drugs.
(153)
 Interestingly, finding new phosphatase inhibitor drugs has become 
actively investigated recently.
(148, 150)
 However, it is challenging to find selective inhibitors due to 
similarities in the active sites of protein phosphatases and poor cell permeability of hydrophilic 
inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Structures of Common Phosphatase Inhibitors. Structures of widely used 
phosphatase inhibitor molecules are shown here including: Sodium stibogluconate, FDA 
approved drug; suramin, phenylarsine oxide, aplidin, alendronate, etidronate, and gallium nitrate, 
used in clinical trials; Vanadate, fluoride and okadaic acid are used in primary laboratory 
research. 
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3.6.2 Inhibitor Studies in Cell Lysates: 1-D Gel Analysis 
HeLa cell lysates were incubated with ATP-biotin in the presence of a kinase inhibitor 
(staurosporine) or phosphatase inhibitors (sodium vanadate and sodium fluoride). As a control, 
inhibitor experiments were also performed with ATP incubation. As expected, reactions 
performed in the presence of kinase inhibitors showed only trace levels of phosphorylated 
(Figure 3.7, lane 3, Pro-Q,) and biotinylated (Figure 3.7, lane 6, SA-Cy5) proteins. 
Quantification and comparison between kinase inhibitor treated and untreated lanes revealed that 
only 18 2% of phosphorylated (Figure 3.7, lanes 3 versus 2, Pro-Q) and 27 5% of biotinylated 
(Figure 3.7, lanes 6 versus 5, SA-Cy5) proteins were visible (Figure A 3.8). The slightly elevated 
level of biotinylation remaining with kinase inhibition may be due to the natural presence of 
biotinylated proteins in cell lysates.  These experiments indicate that kinase inhibitors similarly 
reduce phosphorylation or biotinylation. Because monitoring changes in phosphorylation after 
inhibitor treatment has been used as a drug characterization tool,
(154-156)
 a future direction is use 
of ATP-biotin labeling to characterize kinase inhibitor activities. 
In contrast to the kinase inhibitor experiments, phosphatase inhibitors had differing 
effects on phosphorylation and biotinylation.  As expected with ATP phosphorylation, reactions 
containing phosphatase inhibitors showed robust phosphoprotein signal (Figure 3.7, lane 4, Pro-
Q). Comparison of the phosphatase treated and untreated reaction lanes showed that the 
phosphoprotein signal was elevated to 118 9% (Figure 3.7, lane 4 versus 2, Pro-Q).  These 
results are consistent with the use of phosphatase inhibitors to augment phosphorylation levels in 
phosphoproteomics applications.
(144, 145)
  In the case of the ATP-biotin reactions, a biotin signal 
was also observed in phosphatase inhibitor treated reactions (Figure 3.7, lane 7, SA-Cy5).  
However, comparison of the treated and untreated reaction lanes revealed that the biotin signal 
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was reduced to 81 6% (Figure 3.7, lanes 7 versus 5, SA-Cy5, Figure A 3.8). The decrease in 
biotinylation can be rationalized considering the kinase/phosphatase equilibrium in lysates. 
Because phosphorylated amino acids will be unavailable for ATP-biotin labeling, active 
phosphatases are needed to remove phosphoryl groups and promote kinase-catalyzed 
biotinylation. If phosphatase activity is reduced by inhibitors, ATP-biotin labeling will not occur 
on already phosphorylated sites, reducing the level of biotinylation.  Therefore, these 
experiments are consistent with the hypothesis that active phosphatases are critical for robust 
kinase-catalyzed labeling in lysates.   
 
 
 
 
 
 
 
 
Figure 3.7: Inhibitor Studies with 1-D Gel Analysis: Gel analysis of phosphoproteins (ProQ, 
top) or biotinylated phosphoproteins (SA-Cy5, bottom) from HeLa cell lysates incubated with 
ATP or ATP-biotin in the absence or presence of kinase or phosphatase inhibitors. The contents 
of each reaction are indicated below each lane. Additional trials are shown in Figure A 3.7. 
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3.6.3 Inhibitor Studies in Cell Lysates: 2-D Gel Analysis 
To further test the sensitivity of biotinylation to phosphatase inhibitors, two dimensional 
(2-D) gel analysis was performed (Figure 3.8). 2-D gel analysis is a classical method that offers 
visualization of many more proteins in lysates than 1-D methods.
(157, 158)
 In addition, 2-D gel 
methods have been used widely in phosphoproteomics analysis.
(159, 160)
  HeLa cell lysates were 
incubated with either ATP or ATP-biotin in the absence or presence of phosphatase inhibitors 
(sodium vanadate and sodium fluoride). After reaction, proteins were separated by their 
isoelectric points (pI) in the first dimension, followed by molecular weight in the second 
dimension. As expected, ATP-labeled lysates treated with phosphatase inhibitors contained more 
phosphoproteins compared to untreated reactions (Figure 3.8 A, see boxed area). In contrast, 
ATP-biotin-labeled lysates showed a greater number of biotinylated proteins in the untreated 
reaction than the phosphatase inhibitor-treated reaction (Figure 3.8 B, see boxed area). The 
reduction in ATP-biotin labeling upon phosphatase inhibitor treatment is consistent with the 1-D 
gel analysis (Figure 3.7), which provide further evidence for the hypothesis that active 
phosphatases are needed for robust kinase-catalyzed biotinylation.  
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Figure 3.8: Inhibitor Studies with 2-D Gel Analysis (A) Reactions of HeLa cell lysates and 
ATP without (untreated) or with phosphatase inhibitors (phosphatase inhibitor treated). Proteins 
were visualized with Pro-Q diamond phosphoprotein stain. (B) Reactions of HeLa cell lysates 
and ATP-biotin without (untreated) or with phosphatase inhibitors (phosphatase inhibitor 
treated). Biotinylated proteins were visualized with SA-Cy5.  The boxed region of the images 
highlights changes due to inhibitor treatment.  
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A comparison of the boxed areas within the 2-D gel images shows that the phosphatase 
inhibitor-treated ATP labeling (Figure 3.8 A, right) and untreated ATP-biotin labeling (Figure 
3.8 B, left) showed similarities.  We note that the differences in charge state of the 
phosphorylated and biotinylated proteins (see Figure 3.1) likely influence migration in the gels, 
making direct comparison of ATP and ATP-biotin labeled reactions difficult by 2-D methods. 
The comparison is further complicated by the use of different visualization methods (Pro-Q 
versus SA-Cy5). However, the combined data from 1-D and 2-D methods is consistent with the 
hypothesis that robust kinase-catalyzed biotinylation occurs without the need for phosphatase 
inhibitor treatment. Therefore, kinase-catalyzed biotinylation is appropriate for 
phosphoproteomics application using untreated lysates.   
3.7 Conclusion and Future Work 
We have shown that the phosphorylbiotin product of kinase-catalyzed biotinylation is 
stable to phosphatases.  In vitro experiments suggest that both Ser/Thr and Tyr phosphatase are 
similarly ineffective at phosphorylbiotin hydrolysis.  These results are consistent with prior work 
documenting that the product of ATP-γS labeling, a thiophosphorylated protein, is also 
insensitive to phosphatase degradation.
(74, 85, 86, 141)
  The combined results suggest that 
phosphoproteins containing a phosphate modification will generally display phosphatase 
insensitivity. ATP-γS has been used for phosphoprotein labeling and detection directly in lysates, 
without the need for phosphatase inhibitors.
(80, 81, 87, 124, 142)
  The use of untreated lysates 
combined with the added functionality of the biotin group makes ATP-biotin labeling attractive 
for phosphoproteomics applications.  In particular, the likelihood of detecting low abundance 
phosphoproteins is enhanced due to the stability of the biotin tag to phosphatases and the ability 
to purify labeled proteins directly.  Use of kinase-catalyzed biotinylation for detection of low 
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abundance phosphoproteins is currently under investigation.  In addition, the sensitivity of ATP-
biotin labeling to both kinase and phosphatase inhibitors indicates that kinase-catalyzed labeling 
has future application to phosphoproteomic-based drug characterization efforts.  In conclusion, 
the stability of the phosphorylbiotin product of ATP-biotin labeling to phosphatases suggests that 
kinase-catalyzed biotinylation will be an excellent tool for phosphoproteomics research.  
In future work, we hope to monitor phosphatase activity using kinase-catalyzed labeling. 
For that first, phosphatase knock down cell line will be generated. The strategy would involve 
labeling of untreated versus phosphatase knock down lysates with ATP-biotin. This method is 
based on the fact that phosphatase activity is required for robust biotinylation, by removing 
phosphates that generates sites for biotin labeling. After gel purification, those proteins that are 
substrates to the knocked down phosphatase would be identifiable to due to a reduction of biotin 
label compared to the untreated sample. This analysis will be coupled with MS-based protein 
characterization to provide a simple method to identify substrates. Hence, kinase-catalyzed 
labeling could lead to the identification of phosphatase substrates, which is a key step to 
characterizing phosphatase biology and cell signaling. 
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3.8 Experimental  
3.8.1 Materials 
ATP-biotin was synthesized as explained in Chapter 2, section 2.6.3 and 2.6.4. Adenosine 
5’-triphosphate disodium (ATP), glycerol, sodium hydroxide (NaOH), potassium chloride (KCl), 
magnesium chloride (MgCl2), sodium chloride (NaCl), sodium dodecyl sulfate (SDS), glacial 
acetic, acetonitrile, staurosporine and SA-Cy5 conjugate were purchased from Fisher. HPLC 
grade trifluoroacetic acid (TFA) and acetonitrile were obtained from VWR and EM Millipore, 
respectively. N, N-dimethylformamide (DMF) was purchased from Acros Organics. D2O and 
CD3OD were obtained from Cambridge Isotope Labs. Ammonium bicarbonate, β-casein and 
myelin basic protein (MBP) were bought from Sigma. PKA, CK2, Abl, CIP, PP1, TC PTP 
enzymes, sodium fluoride, sodium orthovanadate and Abl peptide were purchased from New 
England Biolabs. Kemptide and CK2 peptides were bought from Promega. Triton X-100 was 
purchased from Fluka. HeLa cells were obtained from the National Cell Culture Center 
(www.nccc.org). Protease inhibitor cocktail V was purchased from Calbiochem, and Bovine 
serum albumin (BSA) was obtained from Santa Cruz Biotechnology. Immobilion P PVDF 
membrane was purchased from Millipore. Sypro Ruby and Pro-Q diamond stain was obtained 
from Invitrogen. 2-D gel starter kit, rehydration/equilibration trays, ReadyStrip IPG strip (pH 3-
10), and Ready Gel Tris-HCl Gel were purchased from Bio-Rad. 
3.8.2 Instrumentation 
The absorbance values for Bradford assay were measured with a fluorimeter (GENios 
Plus Tecan). The SDS-PAGE apparatus was purchased from BioRad (Protean III) and a mini-gel 
setup was used. Western blotting was carried out using the Mini-Transblot Electrophoretic 
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Transfer Cell apparatus from BioRad. Protein IEF cell (Bio-Rad, used with permission from 
Honn lab) was used for 2-D gel analysis. The peptides were analyzed using a Waters 1525 binary 
HPLC pump and Waters 2998 photodiode array detector. Reverse phase C-18 column (YMC 
America, INC 250*4.6 mm, 4μm, 8 nm) was used to separate peptide mixtures. The separated 
proteins were visualized using a Typhoon 9210 scanner (Amersham Biosciences). 
3.8.3 Kinase-Catalyzed Phosphorylation and Biotinylation 
Phosphorylated peptides or biotinylated phosphopeptides were created by incubating 
ATP or ATP-biotin (2 mM) with PKA (20 units/µL) and Kemptide peptide substrate (400 μM, 
LRRASLG), CK2 (20 units/μL) and CK2 peptide substrate (400 µM, RRREEETEEE), or Abl 
(20 units/µL) with Abl peptide substrate (400 μM, EAIYAAPFAKKK). The final volume of the 
reactions was 20 µL and the manufacturer-supplied buffers were used at a 1X concentration 
(NEB). The reaction mixtures were incubated at 30 ºC for 2 hours. After reaction, the mixtures 
were heated at 95ºC for 1 minute to denature the kinase. The reactions were split into two 10 µL 
portions. One 10 μL sample was used directly for HPLC analysis, as described below, while the 
second 10 μL sample was treated with phosphatase, as described below.  
Phosphorylated or biotinylated proteins were created by incubating ATP or ATP-biotin (2 
mM) with PKA (25 units/µL) and myelin basic protein (MBP, 0.2 mM), CK2 (5 units/µL) and β-
casein (0.2 mM), or Abl (5 units/µL) and MBP (0.2 mM) in the manufacturer-provided buffer 
(1X, NEB). As a control, reactions were performed without kinases. The final volume of the 
reactions was 10 µL. The reaction mixtures were incubated at 30˚C for 2 hours.  After the 
reaction, the mixture was heated at 95 ºC for 1 minute to denature the kinase.  Only with CK2 
reactions, ATP or ATP-biotin was removed using a 10 kDa Centriprep spin column (Millipore); 
we found that ATP or ATP-biotin interfered with subsequent treatment with CIP.  The reactions 
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were split into two 5 µL portions. One 5 μL sample was diluted up to 20 μL and used for SDS-
PAGE analysis, as described below, while the second 5 μL sample was treated with phosphatase, 
as described below. 
3.8.4 Phosphatase-Catalyzed Dephosphorylation  
Protein or peptide phosphorylation and biotinylation were performed as described in 
section 3.8.3. Then phosphatases were added to the appropriate reaction mixtures. For PKA 
reactions, PP1 (1.0 units/μL, final concentration) in the manufacturer-provided buffer (1X, NEB) 
was added and the reaction mixture was incubated at 30˚C for 2 hours. For CK2 reactions, CIP 
(2.5 units/μL, final concentration) in the manufacturer-provided buffer (1X, NEB) was added and 
the reaction was incubated at 37 ºC for 2 hours. For Abl reactions, TCPTP (2.5 units/μL, final 
concentration) in the manufacturer-provided buffer (1X, NEB) was added and the reaction was 
incubated at 30˚C for 2 hours. The final volume of the reaction mixtures was 20 µL. The crude 
protein products were analyzed by SDS-PAGE with subsequent gel imaging, as described below, 
while the peptide reactions were analyzed by HPLC analysis, as described below. 
3.8.5 HPLC Analysis 
For HPLC analysis, peptides were pre-equilibrated in Buffer A (50 µL; 99.9% water with 
0.1% trifluoroacetic acid). Reverse phase chromatographic separation of peptides was performed 
using a C18 column (YMC America INC; 250×4.6 mm, 4µm, 8 nm). The elution gradient started 
with 95% Buffer A in Buffer B (99.9% acetonitrile with 0.1% trifluoroacetic acid), and 
decreased to 70% Buffer A over 15 min.  Due to overlap of several peaks, the PKA/PP1 reaction 
used a different gradient starting at 90% Buffer A in Buffer B, and decreasing to 70% Buffer A 
over 15 min. The flow rate was 1 mL/min and the peptide absorbance was detected at 214 nm. 
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The percentage of observed phosphopeptide was calculated by dividing the area under the 
phosphopeptide peak by the total area under both the phosphopeptide and unmodified peptide 
peaks.  Figure 3.4 B and 3.4 C show the average percentage and standard error of observed 
phosphopeptide from three independent trials (Figures A 3.1-3.3).  
3.8.6 Starting a New Cell Culture 
The strain of HeLa cells used was HeLa S3 obtained from ATCC (American Type 
Culture Collection). These cells were stored into aliquots (1.0 mL, 10 × 10
6
 cells) in cryogenic 
vials and stored in a liquid nitrogen storage tank upon receipt. When starting a new cell culture, 
an aliquot was removed from the liquid nitrogen tank and thawed quickly in a 37 °C water bath. 
The solution of cells was then transferred to a 15 mL centrifuge tube and centrifuged at 1000 
rpm for approximately 5 minutes. The supernatant was carefully discarded and the pellet of cells 
was resuspended into 5 mL of Ham’s F-12 media (F-12 Nutrient Mixture, Invitrogen) containing 
10% v/v fetal bovine serum (FBS, Invitrogen). The cells were grown in a 37°C incubator under a 
5% CO2 environment with 95% relative humidity. The cell concentration during growth was 
maintained between 0.5-1.0 × 10
6
 cells per mL. 
3.8.7 Long Term Cell Storage 
Cells near confluency (approximately 1 × 10
6
 cells per mL) were collected by 
centrifugation at 1000 rpm for 5 minutes. The cell pellet (approximately 10 × 10
6
 cells) was 
resuspended in 1.5mL of fresh Ham’s F-12 media with 10% v/v FBS containing a final 
concentration of 10% v/v DMSO. The cells were slowly cooled in a cryogenic vial (Corning) and 
then stored in a liquid nitrogen storage tank (Thermolyne). 
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3.8.8 Collection of Cells for Experiment 
To HeLa cells at confluency, triple express (5-10 mL) was added to the flask to cover the 
surface and incubated at 37 °C for 10 minutes. The released cells (make sure cells were lifted and 
floating) were transferred to a centrifuge tube and centrifuged at 1000 rpm for 5 minutes. The 
supernatant was discarded and cells were gently washed with 1X PBS (phosphate buffered 
saline) consisting of 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4. The 
cell pellet was stored at -80 °C until needed, or used immediately. 
3.8.9 Large-Scale HeLa Cell Lysis Procedure 
Frozen HeLa cells (National Cell Culture Center, 10 × 10
9
 cells) were thawed and kept on 
ice. HeLa cells were lysed in lysis buffer (10 mL; 50 mM Tris, pH 8.0, 150 mM NaCl, 10% 
glycerol, 0.5% Triton X-100 and 1X protease inhibitor cocktail V).  Cells were incubated with 
rotation at 4 °C for 10 minutes.  The soluble fraction was separated from the cell debris by 
spinning at 12,000 rpm at 4 °C for 15 minutes. The supernatant was collected and the 
concentration of total protein in the lysate was determined via a Bradford assay (generally 5-6 
mg/mL total protein). The lysate supernatant was stored at -80 °C. 
3.8.10 Bradford Assay 
The Bradford reagent dye (Bio-Rad Protein Assay, manufactured by Bio-Rad 
Laboratories) was prepared by diluting 1 part dye reagent concentrate with 4 parts of ddH2O and 
filtering through a 0.22µm pore size filter (Millex-GP, Millipore) to remove particles. To create a 
standard curve, several dilutions of bovine serum albumin (BSA, Fisher Scientific) ranging from 
0.5 to 5.0 mg/mL were prepared in H2O, which were within the linear range of this assay. 
Several dilutions of the lysate were also prepared, typically around 1/50 of the original 
94 
 
concentration of the unknown to ensure the resulting concentration fell within the linear range of 
the assay. Each standard solution (10 µL) and each unknown dilution (10 µL) was pipetted into 
separate wells of a flat-bottom transparent 96-well microtiter plate (Assay Plate, Costar). The 
diluted Bradford reagent dye (200µL) was added to each well and the plate was incubated at 
room temperature for at least 5 minutes. The absorbance was measured with a fluorimeter 
(GENios Plus) at a wavelength of 595 nm. A standard curve was generated from the known 
concentrations of the BSA standards using Microsoft Excel to plot the known concentrations of 
the standards against the corresponding measured absorbance values. A best-fit linear equation 
was generated each time the assay was run in order to minimize any errors that may have 
resulted from fluctuations in the instrument over time. To determine the concentration of the 
unknown sample, the observed absorbance value of the unknown dilution was used with the 
equation of the best-fit line to calculate the concentration of the diluted lysate. The resulting 
concentration of the diluted sample was then multiplied by the dilution factor to obtain the 
concentration of the original lysate.  
3.8.11 Kinase and Phosphatase Inhibitor Studies  
For the lysate reactions, HeLa cell lysates (100 μg of total protein) were incubated with 
either ATP or ATP-biotin (2 mM) in the presence kinase inhibitor (Staurosporine, 0.10 mM) or 
phosphatase inhibitors (sodium fluoride and sodium orthovanadate, 0.10 mM each) in the 
manufacturer-provided buffer for PKA (1X, NEB) for 2 hours at 30 °C. The final volume of the 
reactions was 25 µL. The products were analyzed by SDS-PAGE (Chapter 2, section 2.6.9) with 
subsequent gel imaging (Chapter 2, section 2.6.10 and 2.6.13) and quantification of the entire 
lane (Chapter 2, section 2.6.14). The percentage of phosphoproteins or biotinylated 
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phosphoproteins observed after inhibitor treatment was calculated by dividing the protein signal 
after treatment to the protein signal before treatment. 
3.8.12 Two-Dimentional Gel Analysis 
The reactions with lysates with or without phosphatase inhibitors were performed as 
described in section 3.8.11. Protein sample after reaction (100 µg) was mixed with 125 µL of 
manufacturer (Bio-Rad) provided rehydration/sample buffer (2% CHAPS, 8 M urea, 50 mM 
DTT, 0.2% (w/v) Bio-Lyte 3/10 ampholytes and trace Bromophenol Blue). Then the mixture was 
loaded into the rehydration/equilibration tray channel, except for 1 cm at each end. The process 
was repeated for remaining samples, taking care not to introduce any air bubbles. ReadyStrip 
IPG strip (pH 3-10) was peeled from the coversheet and the strip was gently placed onto the 
sample (gel side down, taking care not to introduce any air bubbles). The IPG strip was left to 
rehydrate for one hour. Then 2 mL of mineral oil was overlaid to prevent evaporation. The 
rehydration/equilibration tray was covered with the plastic lid and left overnight (12-16 hours) to 
rehydrate the strips and maximize sample absorption. The next day, a paper wick was placed at 
both ends of the IEF focusing tray channels covering the wire electrode and the paper wick was 
wetted with 10 μL of nanopure water (Bio-Rad). The cover was removed from 
rehydration/equilibration tray and the strip was held vertically for 10 seconds to drain the mineral 
oil. Then the IPG strip was transferred to the focusing tray (gel side down) and the strip was 
covered with 2 mL of mineral oil. The focusing tray was placed into the PROTEIN IEF cell and 
focusing was performed (250 V for 20 min, 4000 V for 2 hours and at 4000 V for 10 000 
Vhours, 50 μA per strip and temperature maintain at 20 ˚C). After electrophoresis was 
completed, the IPG strip was removed from the focusing tray and the strip was held vertically for 
10 seconds to drain the mineral oil. Then the strip was transferred into a new 
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rehydration/equilibration tray (gel side up) and equilibrated for 10 minutes in buffer 1 containing 
0.375 M Tris-HCl (pH 8.8), 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS and 2% (w/v) DTT. 
Next, the strip was incubated with buffer 2 containing 0.375 M Tris-HCl (pH 8.8), 6 M urea, 
30% (v/v) glycerol, 2% (w/v) SDS and 2.5% (w/v) iodoacetamide. The IPG strip was removed 
from the rehydration/equilibration tray and was dipped into the graduated cylinder containing 1X 
Tris/glysine/SDS running buffer. Then an agarose solution (Bio-Rad) was poured into the top of 
the SDS-PAGE gel as stacking layer and the IPG strip was placed within the agarose layer 
(taking care not to introduce any air bubbles). The gel was run at a constant 200 V for 45 
minutes. 
3.8.13 Biotin Visualization 
The biotin visualization was performed as described in Chapter 2, section 2.6.10. 
3.8.14 Sypro Ruby Stain 
The Sypro Ruby staining was performed as described in Chapter 2, section 2.6.12. 
3.8.15 Pro-Q Staining  
The Pro-Q staining was performed as described in Chapter 2, section 2.6.13. 
3.8.16 Gel Image Quantification 
Gel bands were quantified using ImageQuant 5.1 by drawing the same size rectangular 
shape around comparable bands.  The percentage of phosphoproteins or biotinylated 
phosphoproteins observed after phosphatase treatment was calculated by dividing the protein 
signal after treatment to the protein signal before treatment. The percentages displayed in Figure 
3.5 are average percentages and standard error of observed phosphoprotein or biotinylated 
97 
 
phosphoprotein from three independent trials. To calculate phosphatase activity, the average 
percentage of phosphoproteins or biotinylated phosphoproteins observed after phosphatase 
treatment was subtracted from 100%. 
Footnote: Portions of the text in this chapter were reprinted or adapted with permission from 
Licensee: chamara senevirathne 
License Date: Mar 11, 2013 
License Number: 3106010371572 
Publication: ChemBioChem 
Title: Biotinylated Phosphoproteins from Kinase-Catalyzed Biotinylation are Stable to 
Phosphatases: Implications for Phosphoproteomics 
Type Of Use: Dissertation/Thesis 
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Chapter 4 
Phosphoproteomic Analysis using Kinase-Catalyzed Biotinylation  
Protein phosphorylation plays a fundamental role in protein function, and aberrant 
phosphorylation level and elevated kinase activity are responsible for the disease formation. Here 
we report development of a new phosphoproteomic enrichment tool combining kinase-catalyzed 
biotinylation with avidin affinity chromatography. Given the limitations of metal ion affinity 
chromatography with full-length phosphoprotein enrichment, kinase-catalyzed biotinylation may 
provide new opportunities for future proteomics research. 
4.1 Current Methods Used to purify Phosphopeptides and Phosphoproteins 
 
Since phosphorylation has a significant role in protein function, the detection and 
isolation of phosphopeptides and phosphoproteins are important goals for proteomic 
research.
(117)
 Mass spectrometric (MS) analysis has been widely used to identify protein 
phosphorylation.
(116, 118, 161, 162)
 MS analysis can be coupled with different separation systems and 
mass analyzers to increase sensitivity and accuracy.
(120, 121)
 Despite many improvements, MS has 
limitations. For example, the ion suppression of the charged phosphate in MS analysis results in 
difficulty detecting phosphopeptides in complex mixtures.
(122)
 To minimize the influence of ion 
suppression, unphosphosphorylated peptides are often removed from the mixtures prior to MS 
analysis. As a result, multiple phosphopeptide purification methods have been developed to 
enhance phosphoproteomics analysis. Phosphoprotein and phosphopeptide enrichment 
techniques can be grouped into four main classes: immunoprecipitation, chemical modification, 
affinity chromatography, and modified ATP analogs 
(83, 106)
 (Figure 4.1). 
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Figure 4.1: Overview of Phosphopeptide and Phosphoprotein Isolation Methods. Schematic 
representation of current methods of phosphopeptide and phosphoprotein purification is shown 
here. The purification methods are classified into four major groups; immunoprecipitation, 
affinity chromatography, chemical modification and modified ATP analogs strategies.  
 
4.1.1: Immunoprecipitation 
Phosphoproteins can be immunoprecipitated by antibodies generated specifically against 
phosphopeptides.
(108)
 For phosphoproteomics applications, antibodies recognizing a single 
phosphotyrosine amino acid have been used successfully, while the poor binding affinity of 
antibodies recognizing phosphoserine or phosphothreonine has limited their use.
(110, 115)
 The 
antibody is immobilized to solid phase resin through covalent bond before immunoprecipitation. 
A mixture of protein sample is incubated with the immobilized antibody, and proteins containing 
a phosphotyrosine will bind with the antibody (Figure 4.2). Unbound proteins are removed 
during washing steps and only the phosphotyrosine containing proteins are retained. Then pure 
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phosphoproteins are eluted from the resin by applying denaturing conditions. The isolated 
phosphoproteins can be analyzed by MS after digestion.   
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Immobilized Antibody Purification of Phosphoproteins. Phosphotyrosine specific 
antibodies are attached to a solid resin. Incubation of the sample results in the binding of 
phosphotyrosine proteins only and unbound proteins can be washed away. The isolated proteins 
are eluted, digested and analyzed with MS. 
 
 
4.1.2: Affinity Chromatography 
Affinity chromatography is the most popular and widely used method in phosphopeptide 
isolation. Affinity chromatography can be subdivided in to two strategies; Immobilized Metal 
Affinity Chromatography (IMAC) and Metal Oxide Chromatography (MOC). Various metal 
ions (Ga
3+
, Fe
3+
 and Al
3+
) 
(105, 163-165)
 and, metal oxides (TiO2, ZrO2 and Al2O3) 
(166-168)
 facilitate 
phosphopeptide enrichment for IMAC and MOC, respectively. In IMAC, the metal ion is usually 
bound to the resin using iminodiacetic acid (IDA) or nitrilotriacetic acid (NTA) (Figure 4.3), 
whereas MOC uses the metal oxide as the resin (Figure 4.4). Both methods purify 
phosphopeptides using a similar type of mechanism. Application of peptide mixtures leads to 
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binding through electrostatic interactions between the negatively charged phosphates and 
positively charged metal. Unmodified peptides can be removed from the resin upon washing. 
Then phosphopeptides can be eluted from the resin and analyzed by MS. However, it is widely 
reported that metal ion chromatography is biased towards phosphopeptides containing negatively 
charged aspartic and glutamic acid residues,
(169)
 which enhance binding affinity to the positively 
charged metal. In addition, full-length phosphoprotein enrichment remains technically 
challenging with metal ion chromatography.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Immobilized Metal Affinity Chromatography (IMAC) Purification. Incubation 
of peptide mixture with IMAC column results in binding of phosphopeptides to the resin.  
Washing removes unphosphorylated peptides to elute pure phosphopeptides. Purified 
phosphopeptides can be analyzed by MS. 
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Figure 4.4: Immobilized Metal Oxide Chromatography (MOC) Purification. Incubation of 
peptide mixture with MOC column results in binding of phosphopeptide to the resin.  Washing 
removes unphosphorylated peptides to elute pure phosphopeptides. Purified phosphopeptides can 
be analyzed by MS. 
 
 
4.1.3: Chemical Modification 
In terms of chemical modification strategies, two examples include β-elimination of the 
phosphate groups of phosphoserine and phosphothreonine
(170, 171)
 and covalent phosphate 
modification methods (via a phosphoamidate).
(172-174)
 For the β-elimination method (Figure 4.5), 
alkali treatment of phosphorylated serine or threonine 1 formed dehydroalanine 2, which can be 
treated with a biotin (path A) or bifunctional tagging groups (path B).
(170)
 Introducing a biotin tag 
facilitates direct affinity purification (path A, compound 3).
(171)
 On the other hand, incubation 
with ethanedithiol attaches a thiol group (path B, compound 4), which can be cross-linked with 
NHS activated biotin for subsequent purification (path B, compound 5) or, the free thiol can be 
directly attached to solid support resin via a disulfide linker (path A, compound 6), which will 
release purified peptides upon reduction.  Dehydroalanine intermediate (2) formation with O-
linked sugars and alkylated cysteine under alkaline conditions is the major drawback of this 
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method. In addition, because a thiol group is introduced, all the cysteines should be blocked by 
oxidation initially. Finally, this method is suitable only for phosphoserine and phosphothreonine 
as phosphotyrosine is resistance to β-elimination.  
 
 
 
Figure 4.5: Purification of Phosphopeptide using Phosphate Elimination. Treatment of alkali 
leads to formation of dehydroalanine intermediate (2). (A) Nucleophilic addition of a biotin-tag 
to the intermediate (3) facilitates subsequent purification. (B) Addition of ethanedithiol 
introduces free thiol on the peptide (4) which can be trapped by NHS-biotin (5) or solid support 
disulfide (6) functionalities. Purified peptides can be analyzed by MS. 
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Unlike the β-elimination method, the phosphoamidate methods (Figure 4.6) enriches all 
the three type of phosphorylated peptides.
(172)
 In this method all amino and carboxylic 
functionality has to be protected (intermediate 8 and 9) to overcome intramolecular or 
intermolecular reactions. Then a thiol containing linker is attached to the phosphate group 
through a phosphoamidate bond (intermediate 11). The modified phosphopeptide can be attached 
to solid resin upon incubation with immobilized iodoacetyl groups (intermediate 12) and 
unmodified peptides are washed away. Finally, pure phosphopeptide (compound 13) can be 
cleaved off from the solid resin. 
 
 
Figure 4.6: Purification of Phosphopeptide using Phosphoamidate Chemistry. Amino and 
carboxylic groups are first blocked to avoid any side reactions (intermediate 8 and 9). Then a 
free thiol group is introduced on the phosphate via a phosphoamidate bond (11). The peptide is 
attached to the solid resin (12) to remove unphosphorylated peptides. Phosphopeptides (13) can 
be obtained upon TFA treatment which hydrolyze phosphoamidate bond. Purified 
phosphopeptides can be analyzed by MS. 
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4.1.4: Modified ATP Analog 
A fourth strategy involves ATP analogs along with lysates containing analog-sensitive 
kinase mutants to label phosphoproteins for subsequent identification.
(83, 87)
 Here, ATP-γS 
modified on the base was used with a mutant kinase. Incubation of ATP analog and mutant 
kinase with cell lysate lead to protein labeled with a thiophosphate. Then the mixture was reacted 
with PNMB (para-nitrobenzylmethansulfonate, Figure 4.7 A). Both the thiophosphates, cysteines 
react to form nitrobenzylated proteins. However, only the nitrobenzyl thiophosphorylated 
proteins can be purified with a specific antibody that recognizes this modification. Enriched 
proteins were then subjected to digestion and subsequent MS identification. As an alternative to 
specific antibody purification, thiophosphoproteins are digested and bound on solid support by 
reacting with immobilized iodoacteamide (Figure 4.7 B).
(87)
 Washing removes all the unbound 
peptides, whereas thiophosphopeptides and cysteine containing peptide remain on beads. 
Phosphopeptides are released upon elution with oxidative conditions (HOOSO3H) and cysteine 
containing peptides remain bound to the beads. This is a powerful method to identify substrates 
for a particular kinase. 
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Figure 4.7: Purification of Phosphopeptide using Modified ATP-γS and Mutant Kinases. 
Incubation of cell lysates with mutant kinases and modified ATP-γS lead to formation of 
thiophosphorylated proteins. (A) Reaction of thiophosphorylated proteins with PNMB facilitates 
the purification of phosphproteins with specific antibody against this modification. (B) 
Thiophosphorylated proteins are digested and bound to solid resin together with cysteine 
containing peptides. Only the phosphopeptides are released from the resin upon oxidation with 
HOOSO3H acid. Isolated peptides can be analyzed by MS. 
 
 
 
4.1.5: Our Strategy with Modified ATP Analog 
Enrichment strategies that complement these phosphopeptide purification strategies 
would promote a deeper study of the phosphoproteome. As an alternative method for 
phosphoprotein enrichment, we reported use of γ-modified ATP analogues for labeling kinase 
substrates.
(91-94)
 We demonstrated that an ATP analogue with biotin attached to the γ-phosphate 
(ATP-biotin 2, Figure 2.2) acts as a cosubstrate for kinases and transfers biotin along with the 
phosphate group (Figure 2.2 B) to substrate peptides and proteins. Specifically, cellular kinases 
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accept the ATP-biotin as a cosubstrate. Based on these studies, we envisioned applying kinase-
catalyzed biotinylation to the enrichment of phosphopeptides and/or phosphoproteins from cell 
lysates. 
 
4. 2: Purification of Phosphopeptides: β-casein Model Study 
4.2.1: Avidin Purification with Regular Elution  
We were interested in using kinase-catalyzed biotinylation for enrichment of 
phosphopeptides from cell lysates to facilitate MS analysis. To develop a purification protocol 
based on kinase-catalyzed biotinylation, bovine β-casein was modified by ATP-biotin in the 
presence of CK2 (Figure 4.8). The reaction mixture was reduced and alkylated, and then digested 
with trypsin to create a mixture of peptides containing biotinylated phosphopeptides. The 
digested mixture was loaded onto a NeutrAvidin column (Thermo Fisher). The column was 
washed, and biotinylated peptides were eluted with mild heating (45 °C for 5 minutes) in the 
presence of 5 mM competitive biotin (Figure 4.8, condition a). Peptides were separated by 
reverse phase chromatography and introduced into a Thermo Fisher LTQ-XL mass spectrometer. 
After ionization, abundant species were fragmented with CID or ETD to produce MS2 spectra. 
MS data analysis was performed using Proteome Discoverer 1.3 (Thermo Fisher) and searches 
were conducted using Mascot (ver 2.3; Matrix Sciences) to score MS2 spectra simultaneously 
against a bovine protein database. The presence of a phosphoryl biotin modification (+508 Da) 
on serine, threonine, or tyrosine was included in the search as a dynamic modification. One 
modified peptide containing a single phosphorylated amino acid was identified with high 
confidence (Table 4.1 and 4.2, Table A 4.1 and Figure A 4.1). 
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4.2.2: TiO2 Purification  
 
At the same time we were interested in comparing our methodology with another 
phosphopeptide enrichment technique. We selected TiO2 affinity chromatography because it is 
widely used for phosphopeptide enrichment.
(166-168)
 Full-length β-casein was incubated with ATP 
and CK2 and the same digest protocol was followed. The peptide mixture was loaded onto a 
TiO2 tip column, washed, eluted (5% ammonium hydroxide and 5% pyrrolidine, Figure 4.9) and 
subjected to MS analysis. In this case we searched for the presence of a phosphate modification 
(+80 Da) on serine, threonine, or tyrosine. A total of 253 MS2 spectra were scored as 
phosphopeptides, which correspond to 12 different sequences (Table 4.1 and 4.2, Table A 4.2, 
Figure A 4.2 and Figure A 4.3). Among these peptides, 11 unique sites of phosphorylation were 
identified, which is similar to previous MS analyses of casein phosphopeptides using TiO2 
enrichment.
(116, 117, 175)
 
4.2.3: Avidin Purification with Acidic Elution  
Previous work established that biotin can interfere with MS analysis due to ion 
suppression.
(172)
 As a result, competitive biotin elution with avidin might not be suitable for high 
efficiency phosphopeptide MS analysis. To avoid the biotin group during the MS analysis step, 
we sought a different condition that would elute phosphopeptides from the avidin column, 
instead of biotinylated phosphoproteins. We rationalized that a low pH elution would cleave the 
acid-labile phosphoramidate bond (Figure 2.2 B and Figure 4.8, condition b) and release 
phosphopeptides from the avidin bead, which would improve subsequent MS analysis. 
To validate the use of acidic elution conditions, we explored whether TFA cleavage 
would increase the number of observed β-casein phosphopeptides. As described, biotinylated β-
casein peptides were loaded onto an avidin column. In this case, phosphopeptides were eluted 
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after cleavage with 50% TFA (Figure 4.8, condition b). MS was performed and analyzed 
identically to the TiO2 sample, where serine, threonine, or tyrosine residues with a phosphate 
group (+80 Da) were identified. This time, 14 spectral counts were identified corresponding to 3 
different sequences and 3 unique sites of phosphorylation (Table 4.1 and 4.2, Table A 4.3, and 
Figure A 4.4). While the acidic conditions improved enrichment, the number of phosphopeptides 
identified was not comparable to TiO2 affinity purification. 
One barrier to kinase-catalyzed biotinylation of β-casein may be that potential sites have 
already been phosphorylated. To further enhance the biotin/avidin purification strategy, we 
speculated that a greater number of phosphosites would be biotinylated, resulting in more 
efficient enrichment, if we created conditions where kinases and phosphatases are in equilibrium. 
To test this hypothesis, calf intestinal alkaline phosphatase (CIP) was added to the reaction 
mixture during kinase-catalyzed biotinylation of β-casein. Phosphopeptide purification and MS 
analysis were then performed. In this case, we observed 259 spectral counts corresponding to 10 
different phosphopeptides (Table 4.1 and 4.2, Table A 4.4, Figure A 4.5 and Figure A 4.6). From 
the peptides, 14 unique sites of phosphorylation were identified, which is similar to the results 
with TiO2 purification. The data indicated that kinase-catalyzed biotinylation should be 
performed under equilibrium conditions to expose all phosphorylation sites to biotinylation. 
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Figure 4.8: Isolation of Phosphopeptide using ATP-biotin and Avidin Affinity Purification. 
Kinase-catalyzed biotinylation generates biotinylated proteins, which were digested and loaded 
onto an avidin affinity column. Biotinylated peptides were bound to the resin and all other 
peptides were washed away. Phosphopeptides were eluted using two conditions: (a) Biotin 
elution generated biotinylated peptides/proteins for MS analysis; (b) 50% TFA elution generated 
phosphopeptides/proteins for MS analysis due to cleavage of the biotin group.  
 
 
 
Figure 4.9:  TiO2 Affinity Purification. Casein or cell lysates were incubated with ATP and 
digested with trypsin. The mixture was loaded onto a TiO2 column and unphosphorylated 
peptides were washed away. Elution with ammonium hydroxide and pyrrolidine resulted in 
release of the resin bound phosphopeptides for MS analysis. 
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4.2.4: β-Casein Model Study Analysis 
β-casein was used as a model phosphoprotein to establish optimal conditions for the 
biotinylation and subsequent MS analysis. We found that optimal biotinylation occurred only in 
the presence of phosphatase activity. Because purified casein is naturally phosphorylated, 
biotinylation cannot occur on sites already in the phosphorylated state. The presence of 
phosphatase activity in the reaction ensures that biotinylation can occur on all phosphorylation 
sites, even those previously phosphorylated. Because cell lysates naturally contain kinases and 
phosphatases, the presence of phosphatases in the biotinylation reaction mimics the natural 
environment of the cell,
(1)
 leading to robust biotinylation and optimal enrichment. In chapter 3, 
we found that the phosphorylbiotin group on peptide and protein substrates was relatively 
insensitive to active phosphatases, which is critical for robust kinase-catalyzed labeling 
demonstrated here.
(1)
 
In addition to maintaining equilibrium phosphorylation conditions during the 
biotinylation reaction, we found that removal of the biotin group prior to MS analysis was 
essential. The biotin group likely leads to ion suppression in the MS instrument,
(172)
 which would 
reduce the number of modified peptides observed. Alternatively, the biotin group can be lost 
during post-enrichment manipulations via hydrolysis of the acid-labile phosphoramidate,
(171)
 
which would also reduce the number of observed biotinylated peptides. The optimized strategy 
takes advantage of the acid-labile phosphoramidate bond where phosphopeptides are eluted from 
avidin affinity resin after biotin cleavage. With biotin cleavage, phosphopeptides are recovered 
after enrichment, making the MS analysis identical to that used with other methods, such as TiO2 
chromatography. 
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Table 4.1: Comparison of Casein phophopeptides identified using Avidin versus TiO2 affinity 
chromatography.    
 
Protein/Peptide 
Avidin 
biotin 
elution 
Avidin 
acid 
elution 
Avidin 
acid elution 
CIP included 
TiO2 
α-S1-Casein         
DIGsEsTEDQAMEDIK     13 1 
DIGsEStEDQAMEDIK       2 
DIGSEsTEDQAMEDIK     2   
VNELsKDIGsEStEDQAMEDIK     1   
VPQLEIVPNsAEER   1 17 16 
VPQLEIVPNsAEERLHSMK       4 
YKVPQLEIVPNsAEER   9 26 16 
YKVPQLEIVPNsAEERLHSMK       1 
α-S2-Casein         
NANEEEYsIGsssEEsAEVATEEVK   2  
NAVPITPTLNREQLsTsEENSKK       6 
NAVPITPTLNREQLStsEENSKK       1 
NAVPITPTLNREQLsTSEENSKK       1 
KTVDMEsTEVFTKK       3 
TVDMEsTEVFTK     3 6 
TVDMEStEVFTK     10   
TVDMEsTEVFTKK     11 7 
TVDmEStEVFTKK      4 
TVDMEsTEVFTKKTK          2 
β-Casein         
FQsEEQQQtEDELQDK     14 7 
FQsEEQQQTEDELQDK 4   96 78 
FQSEEQQQtEDELQDK      1 
IEKFQsEEQQQtEDELQDK   4 16 10 
IEKFQsEEQQQTEDELQDK    47 82 
IEKFQSEEQQQtEDELQDK       1 
KIEKFQsEEQQQTEDELQDK       4 
κ-Casein         
sPAQILQWQVLSNTVPAK     1   
Total phosphopeptides 4 14 259 253 
Number of different peptides 1 3 10 12 
Number of multiply phosphorylated peptides 0 4 44 29 
Number of singly phosphorylated peptides 4 10 215 224 
Number of each phosphorylated amino acid 4(pS) 14(pS), 4(pT) 268(pS),40(pT) 257(pS)26(pT) 
Number of unique phosphorylated sites 1 3 14 11 
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To more thoroughly compare the biotin versus metal ion purification methods, we 
searched for similarity between phosphopeptides identified in the two methods (Table 4.1). Eight 
phosphorylated sites were found in common comparing both methods; these included S50 and 
T56 of β-casein and S61, S63, T64, S130, S158 and T159 of α-casein (Figures A 4.2 and 4.5). 
Interestingly, several additional phosphosites where identified in α-casein (S56, S68, S71, S72, 
S73 and S76) and κ-casein (S90) using avidin purification, which were not observed with the 
TiO2 method. Three phosphosites (S144, T145 and S146) were identified only with the TiO2 
method. The ratio of singly to multiply phosphorylated peptides from TiO2 and avidin 
enrichment were 8:1 and 4.5:1, respectively, which is similar to prior reports.
(176, 177)
 Of the total 
phosphorylated peptides recovered from the biotinylation method, 86% were phosphorylated at 
serine while 14% were modified at threonine. Similarly, the TiO2 method identified 90% and 
10% of phosphopeptides modified on serine and threonine, respectively.  
To assess how accurately the biotinylation reaction reflects the endogenous 
phosphorylation profile, we compared the casein phosphorylation sites observed here to those 
identified in prior reports. Phosphorylated S50, T56 (β-casein), S56, S61, S63, S71, S72, S73, 
S76, S130 and S158 (α-casein) were also identified in previous studies.(116-118)Biotin-avidin 
purification identified 14 phosphorylated sites, including S50 and T56 of β-casein, S56, S61, 
S63, T64, S68, S71, S72, S73, S76, S130, S158 and T159 of α-casein and S90 of κ-casein. The 
biotinylation method identified eleven sites that were previously reported (S50, T56 (β-casein), 
S56, S61, S63, S71, S72, S73, S76, S130 and S158 (α-casein)).(116-118, 175) Three series of 
adjacent sites were absent (S30, S32, S33, S34 (β-casein), 23, 24, 25, 28, and 79, 81, 82, 83 (α-
casein)), which may suggest that biotinylation is less effective when a series of consecutive sites 
exists. We note that TiO2 purification also did not identify these series of sites. In addition, prior 
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reports observe similarly different profiles, which may reflect variance in experimental 
conditions or casein samples. Three phosphorylated sites were only observed with avidin 
purification (T64, S68 (α-casein) and S90 (κ-casein)). The κ- casein isoform is in low abundance 
in milk, which made prior removal of α- and β-casein necessary for reported profiling.(178) It is 
notable that a novel, presumably low abundance, serine phosphorylation site in κ-casein is 
observed with biotin-avidin purification. The data with casein indicate that the biotinylation 
strategy enriches for similar phosphorylation sites compared to other reports and reasonably 
reflects the endogenous phosphorylation profile. In addition, the fact that a novel 
phosphorylation site on the low abundance κ-casein protein is observed suggests the method 
provides sensitive detection. In total, this study has established kinase-catalyzed biotinylation for 
phosphopeptide enrichment and subsequent MS analysis. 
 
4.3: Purification of Phosphopeptides: HeLa cell lysates 
4.3.1: Avidin Purification  
Having established a purification technique for biotin-labeled phosphopeptides, we 
applied the method to phosphoproteomic analysis of cell lysates. Briefly, HeLa cell lysates were 
incubated with ATP-biotin to label endogenous substrates with endogenous kinases. The 
biotinylated phosphoproteins were reduced and alkylated, followed by digestion and purification 
using avidin beads. After TFA cleavage and elution of phosphopeptides, MS data analysis was 
performed with dynamic modification of +80 Da on serine, threonine, and tyrosine residues. 
Overall, spectral counts of 447 located on 147 proteins were identified (Table 4.2 and Table A 
4.5). While 153 different phosphopeptides were observed, 304 unique sites of phosphorylation 
were characterized. 
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4.3.2: TiO2 Purification  
For comparison, the recovery of phosphopeptides from HeLa cell lysates using TiO2 
affinity chromatography was also determined. Lysates were incubated with ATP, reduced, 
alkylated, digested, and enriched using a TiO2 tip column. MS analysis was performed and 
results indicated that 490 spectral counts were detected on 188 different proteins (Table 4.2 and 
Table A 4.6). In this case, 220 different phosphopeptides and 309 unique sites of 
phosphorylation were identified, similar to previous reports.
(118)
 Comparing the avidin and TiO2 
methods, both enriched similar number of phosphopeptides and unique phosphorylation sites. 
 
Table 4.2: Summary of the phosphopeptides/proteins identified using avidin purification and 
TiO2 purification 
    a
 FDR = false discovery rate as a percentage 
    b 
Casein + ATP-biotin = sample was treated in the presence of CIP  
 
Sample Enrichment 
Peptide 
FDR
a
 
Total 
Proteins 
Modified 
Proteins 
Spectral 
count 
Unique 
Peptides 
Unique 
Sites 
Peptide enrichment       
Casein        
ATP TiO2 0.9 3 3 253 12 
 
11 
ATP-biotin 
 
Avidin with 
biotin elution 0.8 4 1 4 1 
 
1 
ATP-biotin 
 
Avidin with 
TFA elution 0.6 3 2 14 3 
 
3 
ATP-biotin
b
 
 
Avidin with 
TFA elution 0.8 4 4 259 10 
 
14 
HeLa cell lysate       
ATP TiO2 1.3 317 188 490 220 309 
ATP-biotin Avidin 1.1 277 147 447 153 
 
304 
Protein enrichment       
Casein        
ATP-biotin Avidin 0.6 4 3 69 6 
 
5 
HeLa cell lysate      
 
 
ATP-biotin Avidin 1.2 468 118 341 126 
 
237 
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4.3.3: HeLa Cell Lysate Study Analysis 
The optimized conditions established with β-casein were used to enrich phosphopeptides 
from HeLa cell lysates. These experiments were performed in duplicate to increase the number 
of phosphoproteins identified. Comparing the identified peptides, each replicate resulted in the 
identification of distinct phosphopeptides; 40 (26%) or 51 (23%) phosphoproteins were common 
for the two trials using avidin or TiO2 enrichment, respectively (Figure 4.10 A). More 
importantly, a comparison of the biotinylation and TiO2 methods indicated that only 2 peptides 
(1.3 %) were identified in common (Figure 4.10 B). The enrichment of a distinct subset of 
phosphopeptides is in contrast to a prior report showing 33-35% overlap between TiO2, Fe(III), 
and covalent phosphate modification methods.
(169)
 A 19% overlap was observed when comparing 
TiO2 to SnO2 enrichment.
(176)
 The data suggest that kinase-catalyzed biotinylation enriches a 
distinct subset of phosphopeptides compared to other methods.  
To explain the limited overlap between the biotinylation and TiO2 methods, the phosphorylated 
amino acid residues on the observed peptides were analyzed. The percentage of singly versus 
multiply phosphorylated peptides was quite similar, with biotinylation and TiO2 methods 
showing preference for singly phosphorylated peptides (85% versus 70% singly phosphorylated 
peptides from TiO2 versus avidin purification, respectively, Tables A 4.5 and A 4.6). On the 
other hand, the percentage of phosphorylation at serine, threonine and tyrosine was different for 
avidin and TiO2 enrichment (46, 42, and 12% compared to 86, 12, and 2%, respectively); both 
methods enrich serine and threonine over tyrosine, although the biotinylation method enriched 
for serine and threonine equally and was more effective at phosphotyrosine enrichment. The ratio 
of singly to multiply phosphorylated peptides from TiO2 and avidin enrichment was 5.8:1 and 
2.3:1, respectively. In total, the data show that kinase-catalyzed biotinylation in cell lysates has a 
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comparable efficiency of phosphopeptide identification compared to the widely used TiO2 
affinity chromatography method. 
 
 
 
 
 
 
 
 
 
Figure 4.10: Peptide Data Analysis. (A) Venn diagrams showing the overlapping peptides 
identified in duplicate from avidin purification (left) and TiO2 enrichment (right). (B) Venn 
diagram showing the overlapping peptides identified in the avidin and TiO2 purification 
strategies. Only 2 individual phosphopeptides are found in common (1.3%). (C) Venn diagram 
showing the overlapping peptides identified using avidin purification and either peptide and 
protein isolation. Only 21 individual phosphopeptides are found in common (17%). 
 
 
We also compared the amino acid composition of the identified phosphopeptides (Figure 
4.11). With TiO2 enrichment, a bias towards phosphopeptides containing the acidic amino acids, 
Asp and Glu, was observed. The bias of metal ion affinity chromatography in favor of acidic 
peptides is well documented in prior reports 
(169)
 and is likely derived from the nonspecific 
interaction of the negatively charged acidic side chains with the positively charged metal ion. 
Unlike the TiO2 method, avidin enrichment showed no acidic peptide bias. As a comparison, the 
amino acid composition of all peptides derived from human proteins was analyzed (Figure 4.11, 
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gray bars) using the UniProtKB database (http://www.uniprot.org). As expected, the TiO2 
method enriches peptides with a higher percentage of aspartic and glutamic acid residues 
compared to the human protein database. In addition, both methods showed an elevated 
enrichment of alanine-containing peptides. However, the avidin method did not show a 
significant bias towards any other amino acid, which distinguishes it from metal-based or 
chemical phosphate modification methods.
(169)
 
 
 
 
 
 
Figure 4.11: Amino Acid Analysis. Amino acid composition of the identified phosphopeptides 
from HeLa cell lysates with TiO2 (closed bars, black) and avidin (open bars, white) enrichment, 
respectively. For comparison, the amino acid composition of all human proteins obtained from 
the UniProtKB database is shown (gray bars). 
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Based on the amino acid analyses, one reason the two methods enrich distinct proteins 
may be due to the slight bias of TiO2 enrichment toward singly modified peptides (85% versus 
70%). However, previous reports showed that IMAC had a similar increase in multiply 
phosphorylated peptides (9%), yet displayed 35% overlap in phosphopeptide population 
compared to TiO2 enrichment.
(169)
 Therefore, the limited overlap between the avidin and TiO2 
purification strategies is likely independent of the multiplicity of phosphorylation. In contrast, 
IMAC, TiO2, and chemical covalent phosphate modification methods showed a similar bias 
toward Asp, Glu, Ser but against Tyr,
(169)
 which suggests that amino acid bias is a contributor to 
their 35% overlap. Therefore, the results suggest that kinase-catalyzed biotinylation enriches a 
different subset of phosphopeptides from HeLa cell lysates compared to metal ion affinity due to 
its effective purification of Thr and Tyr phosphorylated peptides and lack of obvious amino acid 
bias. In addition, the biotinylation method isolates only dynamically phosphorylated proteins, but 
TiO2 enriches both dynamically and statically phosphorylated proteins. 
A necessary requirement of the avidin purification method is that ATP-biotin must be 
added to cell lysates to generate biotinylated phosphoproteins. Others have used modified ATP 
cosubstrates for labeling of lysates and detection of phosphopeptides and phosphoproteins.
(81)
 
Most notably, Shokat and colleagues have developed a chemical modification strategy using 
ATP analog-sensitive kinase mutants to label phosphoproteins.
(82, 83, 179)
 Substrates identified 
using ATP-analog sensitive kinases were confirmed in secondary cell biology studies, 
demonstrating their biological relevance.
(180, 181)
 Because kinase-catalyzed biotinylation utilizes a 
similar lysate-labeling reaction to these prior successful strategies, the avidin purification method 
described here is expected to isolate biologically relevant substrates. 
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4.4: Purification of Full-Length Proteins  
Having established phosphopeptide enrichment using kinase-catalyzed biotinylation, we 
were interested in extending our methodology towards purification of full-length 
phosphoproteins. To enable MS analysis of intact proteins (for example, top-down or medium-
down proteomics),
(182, 183)
 a method to purify phosphoproteins from complex mixtures is needed. 
Metal affinity chromatography has been used exclusively for phosphopeptide enrichment, 
presumably because full length proteins interact with TiO2 independent of phosphorylation 
state.
(184)
 On the other hand, avidin affinity chromatography is established to enrich full-length 
proteins from cellular mixtures.
(171, 185)
 
4.4.1: Avidin Purification with β-Casein Model Study 
To initially test compatibility with full-length phosphoprotein enrichment, ATP-biotin 
was incubated with full-length β-casein and CK2. The biotinylation reaction mixture was then 
loaded onto an avidin affinity column, washed, eluted, and separated by SDS-PAGE (Figure 4.12 
and Figure A 4.7). Biotinylated casein was visualized using Western blot analysis and an anti-
biotin antibody, indicating that β-casein was labeled with biotin (Figure 4.12, lane 2, bottom gel). 
The flow through (Figure 4.12, lane 3) and final washing steps (Figure 4.12, lanes 4 and 5) did 
not show the presence of protein, which indicates biotinylated casein bound to the beads. Finally, 
phosphorylated caseins were obtained after cleavage of the biotin tag with TFA (Figure 4.12, 
lane 6). The peptides resulting from in-gel digestion of the purified phosphoproteins (Figure 
4.12, lane 6, top gel) were analyzed by LC/MS/MS. Sixty-nine spectral counts were observed 
with 6 different peptides and 5 unique phosphorylation sites (Table 4.2 and Table A 4.7). Of the 
total phosphorylated peptides recovered, 80% were phosphorylated at serine, and 20% at 
threonine. The ratio of singly to multiply phosphorylated peptides from protein enrichment was 
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3:1. Given that these casein experiments were performed without phosphatase incubation, the 
phosphoprotein enrichment identified a similar number of unique phosphorylated sites (5 unique 
sites, Table 4.1 and 4.2) compared to phosphopeptide enrichment (3 unique sites, Table 4.1 and 
4.2). These results establish a protocol for enzymatic biotinylation as a means to purify intact 
phosphoproteins from protein mixtures. 
 
 
 
 
 
 
Figure 4.12: Capturing Biotinylated Proteins from β-Casein (A) β-casein (lane 1) was 
biotinylated with CK2 and ATP-biotin (lane 2), loaded onto an avidin column (flow through, 
lane 3), washed (lane 4 and 5) and eluted using 50% TFA (lane 6). The proteins were visualized 
with SYPRO ruby stain (top) and a biotin-specific antibody (α- biotin, bottom). Two trials are 
shown in Figure A 4.7. 
 
4.4.2: Avidin Purification with HeLa Cell Lysates 
The phosphoprotein enrichment method was then applied towards HeLa cell lysates to 
confirm that the biotinylation reaction is appropriate to a proteomic application. HeLa cell 
lysates were incubated with ATP-biotin and biotinylated proteins were purified using avidin 
beads. As a control, lysates incubated with ATP did not show significant enrichment of proteins 
(Figure A 4.9), indicating that ATP-biotin and kinase-catalyzed biotinylation are required. 
Biotinylated proteins in the lysates were separated and visualized by SDS-PAGE (Figure 4.13 
and Figure A 4.8). While many protein bands were observed by SYPRO Ruby stain (Figure 4.13, 
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lanes 1 and 2, top), only a subset of proteins were biotinylated (Figure 4.13, lane 2, bottom). 
Phosphoproteins obtained after TFA cleavage of the biotin tag (Figure 4.13, lane 6) were 
subjected to in-gel digestion and LC/MS/MS analysis. The analysis indicated that 118 proteins 
were phosphorylated with 341 spectral counts (Table 4.2 and Table A 4.8). From 126 different 
phosphopeptides, 237 unique phosphorylation sites were identified. The protein purification 
method identified 43%, 36% and 21% of phosphopeptides modified on serine, threonine and 
tyrosine, respectively and the ratio of singly to multiply phosphorylated peptides was 1.4:1. 
These results establish that kinase-catalyzed biotinylation followed by avidin purification is able 
to enrich full-length phosphoproteins for MS analysis of intact proteins. 
 
 
 
 
 
 
Figure 4.13: Capturing Biotinylated Proteins from HeLa cell Lysates: HeLa cell lysates (lane 
1) were biotinylated with ATP-biotin (lane 2), loaded onto an avidin column (flow through, lane 
3), washed (lane 4 and 5) and eluted with 50% TFA (lane 6). The proteins were visualized with 
sypro ruby stain (top) and a biotin-specific antibody (α- biotin, bottom). 
 
4.4.3: Full-Length Proteins Analysis 
While enrichment of phosphopeptides from complex mixtures is widely reported, 
particularly using metal ion affinity chromatography, the isolation of intact phosphoproteins is 
poorly documented. Metal ion chromatography is not compatible with full-length protein 
purification. However, intact phosphoproteins have been enriched using a chemical approach 
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involving β-elimination/Micheal addition to attach biotin to phosphoproteins, followed by avidin 
purification and gel analysis.
(186)
 Unfortunately, this strategy has not been combined with MS-
based phosphoproteomic analysis. To facilitate analysis of full-length phosphoproteins, the 
kinase-catalyzed biotinylation method was applied to the enrichment of intact casein as well as 
proteins from HeLa cell lysates. Like with phosphopeptide enrichment, the presence of 
phosphatases and elution using biotin cleavage provided optimal results. We found that a similar 
number of phosphoproteins were observed using full-length protein enrichment compared to 
phosphopeptide enrichment; 118 phosphoproteins were identified with full-length protein 
enrichment compared to 147 and 188 phosphoproteins identified with avidin and TiO2 
phosphopeptide enrichment, respectively. A comparison of the avidin-based peptide and protein 
enrichment experiments revealed that 21 peptides (17%, Figure 4.10 C) were in common, which 
is similar to the overlap of the two peptide purification trials (26 %, Figure 4.10 A). Additionally, 
the peptide and intact protein enrichment data are very similar in their Ser/Thr/Tyr 
phosphorylation percentages (46, 42, and 12% versus 43, 36 and 21%) and singly to multiply 
phosphorylated peptide ratios (2.3:1 versus 1.4:1). These comparisons reveal that the peptide and 
protein enrichment strategies are performing consistently. With the availability of a 
phosphoprotein purification strategy, studies relying on intact proteins, such as 2-D gel analysis 
or top-down proteomics, can be readily applied to analysis of the phosphoproteome. 
 
4.5: Conclusions and Future Direction 
In conclusion, we have established kinase-catalyzed biotinylation for phosphoproteomic 
analysis. This avidin-based purification method provides a useful alternative to metal ion affinity 
chromatography by maintaining the same efficiency of enrichment. The fact that distinct 
phosphopeptides were identified using avidin and TiO2 enrichment strongly suggests that the two 
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methods can be coupled to more fully characterize the phosphoproteome. We also utilized the 
biotinylation method to isolate intact phosphoproteins from complex mixtures. The ability to 
enrich either phosphopeptides or phosphoproteins using kinase-catalyzed biotinylation will 
expand the studies possible for phosphoproteomics research. 
As a future direction of this method, dynamic regulation of the phosphorylation can be 
study with the purification method. In addition, protein purification coupled to 
immunoprecipitation can be used to identification of intact protein using top-down MS analysis.  
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4.6: Experimental 
4.6.1 Materials 
ATP-biotin was synthesized as explained in Chapter 2, section 2.6.3 and 2.6.4. Adenosine 
5’-triphosphate disodium (ATP), glycerol, sodium hydroxide (NaOH), potassium chloride (KCl), 
magnesium chloride (MgCl2), sodium chloride (NaCl), sodium dodecyl sulfate (SDS), glacial 
acetic acid, and acetonitrile were purchased from Fisher. Proteomics grade trypsin, monoclonal 
Anti-Biotin-Peroxidase antibody produce in mouse (A0185), ammonium bicarbonate, β-casein, 
tris (2-carboxyethyl) phosphine (TCEP), and iodoacetamide (IAM) were bought from Sigma. 
CK2 and CIP enzymes were purchased from New England Biolabs. Triton X-100 was purchased 
from Fluka. HeLa cells were obtained from the National Cell Culture Center. Protease inhibitor 
cocktail was purchased from Calbiochem, and Bovin serum albumin (BSA) was obtained from 
Santa Cruz Biotechnology. Pierce
R
 detergent removal spin columns (cat. number 87777) and 
ICAT-TM catridge-cation exchange column was purchased from Thermo Scientific and Applied 
Biosystems, respectively. Immobilion P PVDF membrane was purchased from Millipore. 
SYPRO Ruby stain was obtained from Invitrogen. Biotinylated phosphopeptides/ proteins were 
enriched using NeutraAvidin Agarose Resin (Thermo Scientific) or Phos-TiO kit (GL Sciences). 
4.6.2 Instrumentation 
The purified final product was lyophilized using VirTis BT 3.3 EL Benchtop lyophilizer. 
A SPD131 DDA ThermoSavant speed vac was used to evaporate solvents in vacuo. Quantitative 
mass spectrometric analysis was performed on MALDI-TOF MS (Bruker Ultraflex). The 
absorbance values for Bradford assay was measured with a fluorimeter (GENios Plus Tecan). 
Microcentrifuges and mini vortex mixer was purchased from VWR and Eppendorf respectively. 
The SDS-PAGE apparatus was purchased from BioRad (Protean III) and a mini-gel setup was 
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used. Western blotting was carried out using the Mini-Transblot Electrophoretic Transfer Cell 
apparatus from BioRad. Peptides were ionized with the ADVANCE ion source (Michrom) and 
introduced into an LTQ-XL mass spectrometer (Thermo Fisher Scientific). The separated 
proteins were visualized using a Typhoon 9210 scanner (Amersham Biosciences). 
4.6.3 HeLa Cell Lysis Procedure 
The HeLa cell lysis was performed as described in Chapter 3, section 3.7.9. 
4.6.4 Bradford Assay 
The Bradford assay was performed as described in Chapter 3, section 3.7.10. 
4.6.5 Kinase-catalyzed Phosphorylation or Biotinylation 
Phosphorylated or biotinylated proteins were prepared as follows. β-casein (0.2 mM) was 
mixed with CK2 (20 units/μL) and either ATP or ATP-biotin (2 mM) in the manufacturer 
supplied kinase reaction buffer for 2 hours at 30 °C with or without calf intestinal phosphatase 
(CIP, 20 units/μL). The total reaction volume was 10 μL. For HeLa cell lysates, 25 μg of total 
protein was incubated with either ATP or ATP-biotin (2 mM) in the manufacturer supplied 1X 
CK2 buffer for 2 hours at 30 °C in a total 20 μL volume. To generate a peptide digest for MS 
analysis, the sample was reduced, alkylated and trypsin digested (see section 4.6.6 for details). 
The protein or peptide samples were used immediately. 
4.6.6 Trypsin Digestion Procedure 
  SDS (dissolved in H2O, 0.1% final concentration) was added to the protein sample 
(section 4.6.5) and the mixture was vortexed and spun down. Then, TCEP (dissolved in 50 mM 
ammonium bicarbonate) was added to the sample to a final concentration of 5 mM, and the 
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sample was vortexed, spun down, and incubated at room temperature for 45 minutes. 
Iodoacetamide (dissolved in 50 mM ammonium bicarbonate) was added to the sample to a final 
concentration of 15 mM and vortexd, spun down, and incubated in the dark for 30 minutes. 
Trypsin (dissolved in 1 mM hydrochloric acid, 1:20 w/w ratio trypsin:protein) was then added to 
the sample and vortexed, spun down, and incubated for 16 hours at 37 °C for optimum 
enzymatic digestion. 
4.6.7 Isolation of Biotinylated Peptides/Proteins 
A NeutrAvidin bead slurry (250-300μL) was centrifuged (1000 x g, 1 min, RT) to collect 
the beads. The beads were then washed five times with 200 μL of wash buffer (0.025 M Tris-
HCl, pH 7.4, 0.15 M NaCl, 0.0001 M EDTA, 5% glycerol).  Biotinylated peptides or proteins 
(section 4.8.5) were diluted with wash buffer (0.025 M Tris-HCl, pH 7.4, 0.15 M NaCl, 0.0001 
M EDTA, 5% glycerol), up to 200 μL. Then the samples were incubated with the washed 
NeutrAvidin beads for 2 hours at 4 ºC with rocking. The beads were collected (1000 x g, 1 min, 
RT) and washed five times with 200 μL of wash buffer prior to elution. 
To elute the phosphopeptides/proteins using biotin competition, elution buffer (40 μL, 
0.025 M Tris-HCl, pH 7.4, 1% SDS, 0.005 M biotin) was added to the beads and the mixture was 
heated to 45 ºC for 5 minutes. Eluted biotinylated phosphopeptide samples were passed through 
an ICAT
TM
 cation exchange column (Applied Biosystems) using the manufacturer protocol prior 
to MS analysis. 
To elute phosphopeptides/proteins using acidic cleavage conditions, 50% TFA in water 
(40 μL) was added to the beads and the mixture was heated to 45 ºC for 5 minutes. The 
supernatant containing phosphopeptides/phosphoproteins was collected after centrifugation 
(1000 x g, 2 min, RT). The TFA was evaporated using a Speedvac and then used for gel analysis 
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after neutralizing with 1.5 M Tris-base (pH 8.8). Or, the remaining solution was passed through a 
detergent removal column (Thermo Fisher) using the manufacturer’s protocol prior to MS 
analysis. 
4.6.8 TiO2 Isolation of Phospho Peptides 
Phosphopeptide isolation was performed using a Phos-TiO kit (GL Sciences) using the 
manufacturer recommended protocol. Peptides were generated after phosphorylation and trypsin 
digestion as described in section 4.6.5 and 4.6.6 respectively.  The peptide sample (total protein 
mass for casein and HeLa lysate was 48 μg and 25 μg, respectively, before trypsin digest) was 
mixed with 100 μL of buffer B (1 mL of 100% lactic acid) and 3 mL of buffer A (1 mL of 2% 
TFA solution and 4 mL of acetonitrile), and loaded onto the TiO2 Spin Tip. The Spin Tip was 
centrifuged (1000 x g, 10 min, RT). The sample in the tube was reapplied to the Spin Tip again 
to assure complete binding. The Spin Tip was rinsed (3000 x g, 2min, RT) with 20 μL of buffer 
B followed by 20 μL of buffer A. The peptides were eluted (1000 x g, 5min, RT) with 5% 
ammonium hydroxide solution in water (50 μL), followed by 5% pyrrolidine solution in water 
(50 μL). The combined, eluted sample was evaporated using a Speedvac prior to MS analysis. 
4.6.9 Western Blotting 
The biotin visualization was performed as described in Chapter 2, section 2.6.10. Here, 
the membrane was western blotted with anti-biotin IgG (Sigma) in a 1:500 dilution. 
4.6.10 Sypro Ruby Stain 
The Sypro Ruby staining was performed as described in Chapter 2, section 2.6.12. 
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4.6.11 In-Gel Protein Digestion 
Gel slices were excised and cut into 1 mm
3
 cubes. Gel pieces were washed with a 1:1 
mixture of 50 mM ammonium bicarbonate and acetonitrile (250 μL). Proteins were reduced with 
10 mM TCEP in 25 mM ammonium bicarbonate buffer (200 μL, to cover gel pieces) for 40 
minutes at room temperature, and the solution was discarsted. Then the cysteine residues were 
subsequently alkylated by adding 50 mM iodoacetamide in 25 mM ammonium bicarbonate 
buffer (200 μL, to cover gel pieces) for 10 minutes at room temperature in dark, and the solution 
was removed. In-gel digestion was performed overnight at 37 °C after the addition of sequencing 
grade trypsin (dissolved in 1 mM hydrochloric acid, 1:20 w/w ratio trypsin: protein, Promega) in 
25 mM ammonium bicarbonate and 10% acetonitrile (200 μL, to cover gel pieces). The digestion 
solution was also collected. Peptides were sequentially extracted from the gel using 0.1% formic 
acid and acetonitrile (1:1 mixture, 200 μL) for 10 minutes at room temperature, followed by 
acetonitrile (200 μL) alone for 10 minutes at room temperature. Volatile buffers and salts were 
removed by desiccation using a Speedvac concentrator. 
4.6.12 Mass Spectrometric Analysis  
(Analysis was performed by Joseph Caruso at the Institute of Environmental Health) 
Digested samples (secion 4.6.7 and 4.6.8) not separated by SDS-PAGE were either 
purified using a Pierce Detergent Removal Spin column (Thermo Fisher) or manually desalted 
by reverse phase chromatography using a Michrom peptide cap-trap (Thermo Fisher Scientific), 
and dried in a Speedvac. For LC/MS/MS, peptides were re-suspended in 5% acetonitrile, 0.1% 
formic acid and 0.005% trifluoroacetic acid (TFA). Reverse phase chromatographic separation of 
peptides was performed with a Paradigm MS4 HPLC (Michrom Bioresources) at 500 nL/min 
over a Magic C18AQ column (Michrom; 0.1x150 mm, 3μm, 200 Å). The gradient started at 95% 
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Buffer A [2% acetonitrile, 0.1% formic acid] and 5% Buffer B [95% acetonitrile, 0.1% formic 
acid], and increased to 10% Buffer B over 2 min, and then 35% Buffer B over 45 min. Mass 
analysis was performed using a LTQ-XL linear ion trap mass spectrometer (Thermo Fisher). 
Abundant peptides were selected for fragmentation in either collision-induced dissociation (CID) 
or electron transfer dissociation (ETD) mode. For CID, the seven most abundant ions in the MS1 
scan (m/z 400-1800) were selected for fragmentation, and for ETD the top five ions in the MS1 
scan (m/z 400-2000) were selected. Settings for CID and ETD included an isolation width of 2 
Da, normalized collision energy of 35, activation Q of 0.25 and an activation time of 30 ms 
(CID) or 100 ms (ETD). Dynamic exclusion was turned on (repeat count = 1; repeat duration = 5 
s; list size = 500; exclusion duration = 20 s). When samples were run in CID mode, a MS3 scan 
was triggered if a neutral loss of a phosphate group was detected within the top 3 fragment ions 
of the MS2 scan. The neutral loss list consisted of 49.0, 32.7 and 24.5 for doubly-, triply- and 
quadruply-charged phosphopeptides, respectively. Peak lists were generated from the RAW files 
using Proteome Discoverer (ver 1.3; Thermo Fisher) and exported into Mascot (ver 2.3; Matrix 
Science). Search criteria included static modification of cysteine (carbamidomethylation, 
+57.02), and dynamic modifications of Met (oxidation, +15.99), protein N-terminus (acetylation, 
+42.01), and Ser, Thr and Tyr (phosphorylation, +79.97). MS2 and MS3 spectra were searched 
against tryptic peptide sequences (up to 1 missed cleavage) within the latest bovine (NCBI) or 
human (UniProtKB) databases. Charge states of +2, +3 and +4 were assigned for CID MS2 
spectra, and the ETD Spectrum Charger node within Proteome Discoverer was used to determine 
the charge state of peptides analyzed by ETD. A simultaneous search was performed against a 
scrambled database to estimate the false discovery rate (FDR). Reported peptides scored above a 
1.3% FDR threshold. Mascot search results were exported to Scaffold (ver 3.6; Proteome 
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Software) and a subset database was researched using the X! Tandem algorithm. Phosphosite 
localization probabilities were generated using ScaffoldPTM (ver 2.0; Proteome Software).  
4.6.13 Data Analysis  
Peptide and proteins cutoffs used for Scaffold are listed in each supplementary table. 99% 
protein and 90% (Table A 4.7), 80% (Table A 4.1, A 4.2 and A 4.3) and 55% (Table A 4.4) 
peptide probability cutoffs were used with casein samples in Scaffold. For HeLa lysates, 90% 
protein and 55% peptide probability cutoffs (Table A 4.8) and 50% protein and 80% (Table A 
4.5) or 79% (Table A 4.6) peptide probability cutoffs were used for full length and peptide 
enrichment experiments, respectively. 
Frequency of amino acid composition (Figure 4.11) was calculated by dividing the times 
a particular amino acid was observed by the total number of amino acids.  
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APPENDIX A 
2.1 Compound Characterization 
 
 
 
 
 
 
 
 
Figure A 2.1: HRMS of biotin-PEG amine 8 
 
 
 
 
 
  
 
 
 
 
 
 
Figure A 2.2: The IR spectrum (4000-650 cm
-1
) of biotin-PEG amine 8 
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Figure A 2.3: 
1
H-NMR of biotin-PEG amine 8 recorded in D2O solvent 
Figure A 2.4: 
13
C-NMR of biotin-PEG amine 8 recorded in D2O solvent 
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Figure A 2.5: HRMS of ATP-biotin 2 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2.6: The UV absorbance spectrum (200-600 nm) of ATP-biotin 2  
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Figure A 2.7: 
1
H-NMR of ATP-biotin 2 recorded in D2O solvent 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2.8: 
13
C-NMR of ATP-biotin 2 recorded in D2O solvent 
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Figure A 2.9: 
31
P-NMR of ATP-biotin 2 recorded in D2O solvent 
 
2.2 Complete Gel Images for Peptide Labeling 
(A) Reaction with AKT 
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(B) Reaction with CAMK4 
 
 
 
 
 
 
 
 
 
 
(C) Reaction with CHK1 
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(D) Reaction with FLT1 
 
 
 
 
 
 
 
 
 
 
 
(E) Reaction with GSK3β 
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(F) Reaction with MARK1 
 
 
 
 
 
 
 
 
 
 
 
(G) Reaction with MST1 
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(H) Reaction with PAK1 
 
 
 
 
 
 
 
 
 
 
 
(I) Reaction with RSK1 
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(J) Reaction with SRC 
 
 
 
 
 
 
 
 
 
Figure A 2.10: Full gel images for peptide labeling experiment with 10 different kinases. 
Phosphorylated peptides or biotinylated phosphopeptides were created by incubating ATP or 
ATP-biotin with AKT1 and AKT(PKB) substrate (CKRPRAASFAE) (A), CAMK4 and 
Autocamtide (KKALRRQETVDAL-amide) (B), CHK1 and CHKtide 
(KKKVSRSGLYRSPSMPENLNRPR) (C), FLT1 and IGF1Rtide (KKKSPGEYVNIEFG) (D), 
GSK3β and GSK3 substrate (YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE) (E), MARK1 and 
CHKtide (KKKVSRSGLYRSPSMPENLNRPR) (F), MST1 and Axltide (KKSRGDYMTMQIG) 
(G), PAK1 and PAKtide (RRRLSFAEPG) (H), RSK1 and S6K substrate (KRRRLASLR) (I), or 
SRC and SRC substrate (KVEKIGEGTYGVVYK-amide) (J), in the manufacturer provide buffer 
(1X, Promega).  Crude reaction mixtures were separated on a 16% Tris-tricine peptide gel and 
transferred to a PVDF membrane. Peptides are visualized with Coomassie Brilliant Blue (top 
gel) and biotinylated peptides with SA-Cy5 conjugate (bottom gel) with reaction contents 
indicated above each lane. Trials 1, 2, and 3 represent three independent trials. Reaction with 
CAMK4 labeling was seen only with single trial.  
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2.3 Complete Gel Images for Protein Labeling 
(A) Reaction with ASK1 
 
 
 
 
 
 
 
 
 
 
 
(B) Reaction with Aurora A 
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(C) Reaction with CDK1 
 
 
 
 
 
 
 
 
 
 
 
 
(D) Reaction with CK1 
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(E) Reaction with DAPK1 
 
 
 
 
 
 
 
 
 
 
 
 
(F) Reaction with ERK1 
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(G) Reaction with GRK5 
 
 
 
 
 
 
 
 
 
 
 
 
(H) Reaction with HIPK1 
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(I) Reaction with JAK3 
 
 
 
 
 
 
 
 
 
 
 
 
(J) Reaction with MLK1 
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(K) Reaction with NEK2 
 
 
 
 
 
 
 
 
 
 
 
 
 
(L) Reaction with TGFβR2 
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(M) Reaction with TRKA 
 
 
 
 
 
 
 
 
 
 
Figure A 2.11: Full gel images for protein labeling experiment with 13 different kinases. 
Phosphorylated proteins or biotinylated phosphoproteins were created by incubating ATP or 
ATP-biotin with ASK1 and MBP (A), Aurora A and MBP (B), CDK1 and Histone H1 protein 
(C), CK1 and dephosphorylated Casein protein (D), DAPK1 and MBP (E), ERK1 and MBP (F), 
GRK5 and Casein protein (G), HIPK1 and MBP (H), JAK3 and poly (Glu4, Tyr1) peptide 
substrate (I), MLK1 and MBP (J), NEK2 and MBP (K), TGFβR2 and MBP (L), or TRKA and 
poly (Glu4, Tyr1) peptide substrate (M) in the manufacturer provide buffer (1X, Promega). Crude 
reaction mixtures were separated on 16% SDS-PAGE and transferred in to PVDF membrane. 
Proteins are visualized with Sypro Ruby Stain (top gel) and biotinylated proteins with SA-Cy5 
conjugate (bottom gel) with reaction contents indicated above each lane. Trial 1, 2, and 3 
represented three independent trials. MBP stand for Myelin Basic Protein. Complete gel images 
for remaining three kinases (Abl, CK2, and PKA) can be found on Appendix 3.2. The 
experiments with ASK1, CDK1, CK1, GRK5, HIPK1, and MLK1 were performed by graduate 
student Maheeka Embogama.  The experiment with CDK1, CK1, GRK5, MLK1 western blots 
indicate biotin labeling of BSA, which is a component in the buffer used in kinase reaction. Both 
JAK3 and TRKA labeling was seen only in a single trial. Molecular weight of protein as follows: 
MBP (~18 kDa), Casein (~24 kDa), and Histone H1 (~22 kDa). 
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2.4 Complete HPLC Traces  
(A) Reaction with Abl  
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
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iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2.12: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using Abl enzyme and the Abl peptide 
substrate (EAIYAAPFAKKK). i, ii, and iii are three independent trials. 
(B) Reaction with AKT1  
i 
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ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2.13: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using AKT1 enzyme and the AKT (PKB) 
substrate (CKRPRAASFAE). i, ii, and iii are three independent trials. 
152 
 
(C) Reaction with CAMK4  
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
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Figure A 2.14: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using CAMK4 enzyme and the Autocamtide 
(KKALRRQETVDAL-amide). i, ii, and iii are three independent trials. 
(D) Reaction with CK2  
i 
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iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2.15: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using CK2 enzyme and the CK2 peptide 
substrate (RRREEETEEE). i, ii, and iii are three independent trials. 
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(E) Reaction with FLT1  
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ii 
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iii 
 
 
 
 
 
 
 
 
Figure A 2.16: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using FLT1 enzyme and the IGF1Rtide 
(KKKSPGEYVNIEFG). i, ii, and iii are three independent trials. 
(F) Reaction with GSK3β 
i 
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Figure A 2.17: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using GSK3β enzyme and the GSK3 substrate 
(YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE). i, ii, and iii are three independent trials. Note: 
Because the starting peptide was already phosphorylated, the separation of mono and di-
phosphorylated peptides was poor. 
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(G) Reaction with PAK1  
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ii 
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Figure A 2.18: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using PAK1 enzyme and the PAKtide 
(RRRLSFAEPG). i, ii, and iii are three independent trials. 
(H) Reaction with PKA  
i 
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Figure A 2.19: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using PKA enzyme and the kemptide 
(LRRASLG). i, ii, and iii are three independent trials. 
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(I) Reaction with RSK1 
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ii 
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Figure A 2.20: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using RSK1 enzyme and the S6K substrate 
(KRRRLASLR). i, ii, and iii are three independent trials. Note: phodphopeptide was eluted after 
the unphosphorylated starting peptide. 
(J) Reaction with SRC  
i  
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Figure A 2.21: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), or 
biotinylation (panel 3). Reactions were performed using SRC enzyme and the SRC peptide 
substrate (KVEKIGEGTYGVVYK-amide). i, ii, and iii are the three independent trials. Note: 
biotin-amine peak (tR~12.6 min) was not observed in the biotinylation reaction (panel 3). 
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2.5 Complete Gel Images for Protein Quantification 
(A) Reaction with ASK1 
 
 
 
 
 
 
 
 
 
 
 
 
(B) Reaction with Aurora A 
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(C) Reaction with CAMK4 
 
 
 
 
 
 
 
 
 
 
 
 
(D) Reaction with CDK1 
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(E) Reaction with CHK1 
 
 
 
 
 
 
 
 
 
 
 
 
(F) Reaction with CK1 
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(G) Reaction with DAPK1 
 
 
 
 
 
 
 
 
 
 
 
 
(H) Reaction with ERK1 
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(I) Reaction with GRK5 
 
 
 
 
 
 
 
 
 
 
 
 
(J) Reaction with HIPK1 
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(K) Reaction with JAK3 
 
 
 
 
 
 
 
 
 
 
 
 
(L) Reaction with MARK1 
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(M) Reaction with MLK1 
 
 
 
 
 
 
 
 
 
 
 
 
(N) Reaction with MST1 
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(O) Reaction with NEK2 
 
 
 
 
 
 
 
 
 
 
 
 
(P) Reaction with TGFβR2 
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(Q) Reaction with TRKA 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2.22: Full gel images for protein quantification experiment with 16 different kinases. 
Phosphorylated proteins or biotinylated phosphoproteins were created by incubating ATP or 
ATP-biotin with ASK1 and MBP (A), Aurora A and MBP (B), CAMK4 and MBP (C), CHK1 
and MBP (D), CDK1 and Histone H1 protein (E), CK1 and dephosphorylated Casein protein (F), 
DAPK1 and MBP (G), ERK1 and MBP (H), GRK5 and Casein protein (I), HIPK1 and MBP (J), 
JAK3 and poly (Glu4, Tyr1) peptide substrate (K), MARK1 and MBP (L), MLK1 and MBP (M), 
MST1 and MBP (N), NEK2 and MBP (O),  TGFβR2 and MBP (P), or TRKA and poly (Glu4, 
Tyr1) (Q) peptide substrate in the manufacturer provide buffer (1X, Promega). Reaction products 
were treated with 50% TFA to obtain phosphoproteins for quantification. Crude reaction 
mixtures were separated on 16% SDS-PAGE. Proteins were visualized with Sypro Ruby Stain 
(top gel) and phosphoproteins with Pro-Q diamond stain (bottom gel) with reaction contents 
indicated above each lane. Trial 1, 2, and 3 represent three independent trials. MBP stands for 
Myelin Basic Protein. Quantification of ERK1 and TGFβR2 was done with only two trials as the 
other one was outlier. The experiment with CAMK4 was performed by Maheeka Embogama. 
Sypro Ruby and Pro-Q stains are independent gels load from same crude reaction mixtures. 
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2.6 Michaelis-Menten Kinetics Plots 
(A) Reaction with Abl 
 
 
 
 
 
 
 
Figure A 2.23: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with Abl and Abl peptide (EAIYAAPFAKKK). Average of three independent trials with 
standard error is shown here. m1=Vmax and m2=KM. 
(B) Reaction with AKT1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.24: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with AKT1 and AKT (PKB) peptide substrate (CKRPRAASFAE). Average of three independent 
trials with standard error is shown here. m1=Vmax and m2=KM. 
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(C) Reaction with ASK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.25: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with ASK1 and MBP. Average of three independent trials with standard error is shown here. 
m1=Vmax and m2=KM. 
 
(D) Reaction with Aurora A 
 
 
 
 
 
 
 
 
 
Figure A 2.26: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with Aurora A and MBP. Average of three independent trials with standard error is shown here. 
m1=Vmax and m2=KM. 
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(E) Reaction with CAMK4 
 
 
 
 
 
 
 
 
 
 
Figure A 2.27: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with CAMK4 and Autocamtide (KKALRRQETVDAL-amide). Average of three independent 
trials with standard error is shown here. m1=Vmax and m2=KM. 
(F) Reaction with CDK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.28: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with CDK1 and Histone H1 protein. Average of three independent trials with standard error is 
shown here. m1=Vmax and m2=KM. 
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(G) Reaction with CHK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.29: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with CHK1 and CHKtide (KKKVSRSGLYRSPSMPENLNRPR). Average of three independent 
trials with standard error is shown here. m1=Vmax and m2=KM. 
(H) Reaction with CK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.30: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with CK1 and dephosphorylated Casein protein. Average of three independent trials with 
standard error is shown here. m1=Vmax and m2=KM. 
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(I) Reaction with CK2 
 
 
 
 
 
 
 
 
 
 
Figure A 2.31: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with CK2 and CK2 peptide (RRREEETEEE). Average of three independent trials with standard 
error is shown here. m1=Vmax and m2=KM. 
(J) Reaction with DAPK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.32: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with DAPK1 and MBP. Average of three independent trials with standard error is shown here. 
m1=Vmax and m2=KM. 
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(K) Reaction with ERK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.33: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with ERK1 and MBP. Average of three independent trials with standard error is shown here. 
m1=Vmax and m2=KM. 
(L) Reaction with FLT1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.34: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with FLT1 and IGF1Rtide (KKKSPGEYVNIEFG). Average of three independent trials with 
standard error is shown here. m1=Vmax and m2=KM. 
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(M) Reaction with GRK5 
 
 
 
 
 
 
 
 
 
 
Figure A 2.35: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with GRK5 and Casein protein. Average of three independent trials with standard error is shown 
here. m1=Vmax and m2=KM. 
(N) Reaction with GSK3β 
 
 
 
 
 
 
 
 
 
 
Figure A 2.36: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with GSK3β and GSK3 substrate (YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE). Average of three 
independent trials with standard error is shown here. m1=Vmax and m2=KM. 
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 (O) Reaction with HIPK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.37: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with HIPK1 and MBP. Average of three independent trials with standard error is shown here. 
m1=Vmax and m2=KM. 
(P) Reaction with JAK3 
 
 
 
 
 
 
 
 
 
 
Figure A 2.38: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with JAK3 and poly (Glu4, Tyr1) peptide substrate. Average of three independent trials with 
standard error is shown here. m1=Vmax and m2=KM. 
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(Q) Reaction with MARK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.39: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with MARK1 and CHKtide (KKKVSRSGLYRSPSMPENLNRPR). Average of three 
independent trials with standard error is shown here. m1=Vmax and m2=KM. 
(R) Reaction with MLK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.40: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with MLK1 and MBP. Average of three independent trials with standard error is shown here. 
m1=Vmax and m2=KM. 
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(S) Reaction with MST1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.41: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with MST1 and Axltide (KKSRGDYMTMQIG). Average of three independent trials with 
standard error is shown here. m1=Vmax and m2=KM. 
(T) Reaction with NEK2 
 
 
 
 
 
 
 
 
 
 
Figure A 2.42: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with NEK2 and MBP. Average of three independent trials with standard error is shown here. 
m1=Vmax and m2=KM. 
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(U) Reaction with PAK1 
 
 
 
 
 
 
 
 
 
 
Figure A 2.43: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with PAK1 and PAKtide (RRRLSFAEPG). Average of three independent trials with standard 
error is shown here. m1=Vmax and m2=KM. 
(V) Reaction with PKA 
 
 
 
 
 
 
 
 
 
 
Figure A 2.44: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with PKA and kemptide (LRRASLG). Average of three independent trials with standard error is 
shown here. m1=Vmax and m2=KM. 
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(W) Reaction with RSK1 
 
 
 
 
 
 
 
 
 
Figure A 2.45: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with RSK1 and S6K substrate (KRRRLASLR). Average of three independent trials with 
standard error is shown here. m1=Vmax and m2=KM. 
(X) Reaction with SRC 
 
 
 
 
 
 
 
 
 
 
Figure A 2.46: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with SRC and SRC substrate (KVEKIGEGTYGVVYK-amide). Average of three independent 
trials with standard error is shown here. m1=Vmax and m2=KM. 
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(Y) Reaction with TGFβR2 
 
 
 
 
 
 
 
Figure A 2.47: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with TGFβR2 and MBP. Average of three independent trials with standard error is shown here. 
m1=Vmax and m2=KM. 
(Z) Reaction with TRKA 
 
 
 
 
 
 
 
 
 
Figure A 2.48: Michaelis-Menten plots for ADP-Glo assay of ATP (left) or ATP-biotin (right) 
with TRKA and poly (Glu4, Tyr1) peptide substrate. Average of three independent trials with 
standard error is shown here. m1=Vmax and m2=KM. 
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2.7 Supporting HPLC Traces for Biotinylation 
Figure A 2.49: HPLC traces for the CK2 peptides after biotinylation. Reactions were performed 
using CK2 enzyme and the CK2 peptide substrate (RRREEETEEE) and subjected to HPLC 
analysis with (top spectra) or without (bottom spectra) heat deactivation and pre-equlibration 
with buffer. Without these treatments, ATP-biotin remained intact (tR=10.3), where the biotin-
amine linker (tR=12.6) attached to phosphate on peptide was removed. The peptide appears at 7.6 
min, while the phosphopeptide appears at 7.1 min.  
 
2.8 Mechanism for Biotin-amine Cleavage 
 
 
 
Figure A 2.50: Release of biotin-amine linker attached to phosphate on peptides during pre-
equilibration and HPLC analysis at low pH and high pressure. The cleavage is facilitate by 
neighboring group participating.   
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2.9 ADP-Glo Assay Controls-HPLC Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2.51: HPLC traces for the ATP (A, tR=42.1 min) ADP (A, tR=38.2 min), AMP (A, 
tR=32.6 min), ATP-biotin (B, tR=28.0 min), adenine (C, tR=6.9 min), and adenosine (D, tR=7.1 
min). 
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2.10 ADP-Glo Assay Controls-Time dependent Luminescence Data 
 
 
 
 
 
 
 
 
 
 
 
Figure A 2.52: ATP ( ) or ATP-biotin (  ) incubated with kinase detection reagent and 
luminescence signal was measure every 2.5 min with five different concentration (1 µM, 3 µM, 
10 µM, 30 µM, and 100 µM). Mean of the three independent trials is shown with standard errors.  
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APPENDIX B 
3.1 Complete HPLC Traces  
(A) Reaction with PKA and PP1 
HPLC trace for reactions performed using PKA and PP1 (Trial 1). 
 
  
 
 
 
 
 
 
 
 
 
 
HPLC trace for reactions performed using PKA and PP1 (Trial 2). 
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HPLC trace for reactions performed using PKA and PP1 (Trial 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3.1: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), 
phosphorylation followed by phosphatase treatment (panel 3), biotinylation (panel 4) or 
biotinylation followed by phosphatase treatment (panel 5). Reactions were performed using 
PKA, the PKA substrate peptide (LRRASLG), and PP1. All the three independent trials are 
shown here with the percentage of phosphopeptide in the reaction. 
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(B) Reaction with CK2 and CIP 
HPLC trace for reactions performed using CK2 and CIP (Trial 1). 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC trace for reactions performed using CK2 and CIP (Trial 2). 
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HPLC trace for reactions performed using CK2 and CIP (Trial 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3.2: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), 
phosphorylation followed by phosphatase treatment (panel 3), biotinylation (panel 4) or 
biotinylation followed by phosphatase treatment (panel 5). Reactions were performed using 
CK2, the CK2 peptide (RRREEETEEE), and CIP. A, B, and C are the three independent trials 
with the percentage of phosphopeptide in the reaction. 
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(C) Reaction with Abl and TCPTP 
HPLC trace for reactions performed using Abl and TCPTP (Trial 1). 
 
  
 
 
 
 
 
 
 
 
 
HPLC trace for reactions performed using Abl and TCPTP (Trial 2). 
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HPLC trace for reactions performed using Abl and TCPTP (Trial 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3.3: HPLC traces for the peptides (panel 1) after phosphorylation (panel 2), 
phosphorylation followed by phosphatase treatment (panel 3), biotinylation (panel 4) or 
biotinylation followed by phosphatase treatment (panel 5). Reactions were performed using Abl, 
the Abl substrate peptide (EAIYAAPFAKKK), and TC PTP. A, B, and C are the three 
independent trials with the percentage of phosphopeptide in the reaction. 
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3.2 Complete Gel Images  
              (A) Reaction with PKA and PP1 
 Gel images for reactions performed using PKA and PP1 (Trial 1). 
 
 
 
 
 
 
 
 
 
 
 
Gel images for reactions performed using PKA and PP1 (Trial 2). 
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  Gel images for reactions performed using PKA and PP1 (Trial 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3.4: Full gel images for full length protein experiments containing PKA, MBP 
substrate, and PP1, with reaction contents indicated under each lane. The three independent 
trials, showing 2%, 5%, and 12% phosphoproteins remain (Pro-Q, lane 7), and 74%, 63%, and 
79% biotinylated phosphoproteins remain (SA-Cy5, lane 9) after phosphatase treatment. The 
ATP kinase reaction (lane 6) is set to 100% in Pro-Q, while the ATP-biotin kinase reaction (lane 
8) is set to 100% SA-Cy5. 
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(B) Reaction with CK2 and CIP 
Gel images reactions performed using CK2 and CIP (Trial 1). 
 
 
 
 
 
 
 
 
 
 
 
Gel images reactions performed using CK2 and CIP (Trial 2). 
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Gel images reactions performed using CK2 and CIP (Trial 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3.5: Full gel images for full length protein experiments containing CK2, β-casein 
substrate, and CIP, with reaction contents indicated under each lane. The three independent 
trials, showing 9%, 4%, and 5% phosphoproteins remain (Pro-Q, lane 7), and 70%, 108%, and 
66% biotinylated phosphoproteins remain (SA-Cy5, lane 9) after phosphatase treatment. The 
ATP kinase reaction (lane 6) is set to 100% in Pro-Q, while the ATP-biotin kinase reaction (lane 
8) is set to 100% SA-Cy5. 
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(C) Reaction with Abl and TCPTP 
Gel images for reactions performed using Abl and TC PTP (Trial 1). 
 
 
 
 
 
 
 
 
 
 
 
Gel images for reactions performed using Abl and TC PTP (Trial 2). 
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 Gel images for reactions performed using Abl and TC PTP (Trial 3).
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3.6: Full gel images for full length protein experiments containing Abl, MBP substrate, 
and TC PTP, with reaction contents indicated under each lane. The three independent trials, 
showing 11%, 7%, and 2% phosphoproteins remain (Pro-Q, lane 7), and 70%, 68%, and 111% 
biotinylated phosphoproteins remain (SA-Cy5, lane 9) after phosphatase treatment. The ATP 
kinase reaction (lane 6) is set to 100% in Pro-Q, while the ATP-biotin kinase reaction (lane 8) is 
set to 100% SA-Cy5. 
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3.3 Gel Images Related to Inhibitors Studies. 
Gel images for reactions performed using presence of kinase or phosphatase inhibitors (Trial 1). 
 
 
 
 
 
 
 
 
 
 
 
Gel images for reactions performed using presence of kinase or phosphatase inhibitors (Trial 2). 
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Gel images for reactions performed using presence of kinase or phosphatase inhibitors (Trial 3). 
 
 
 
 
 
 
 
 
 
 
Figure A 3.7: Gel analysis of phosphoproteins (ProQ, top) or biotinylated phosphoproteins (SA-
Cy5, bottom) from HeLa cell lysates incubated with ATP or ATP-biotin in the absence or 
presence of kinase or phosphatase inhibitors. The contents of each reaction are indicated below 
each lane. Addition of kinase inhibitor showed 15%, 18%, and 22% phosphopeptides (Pro-Q, 
lane 3), and 31%, 33%, and 16% biotinylated phosphoproteins (SA-Cy5, lane 6). Addition of 
phosphatase inhibitors showed 136%, 109%, and 110% phosphopeptides (Pro-Q, lane 4), and 
83%, 90%, and 69% biotinylated phosphoproteins (SA-Cy5, lane 7).  The ATP kinase reaction 
(lane 2) is set to 100% in Pro-Q, while the ATP-biotin kinase reaction (lane 5) is set to 100% 
SA-Cy5. 
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3.4 Quantification of Gel Images Related to Inhibitors Studies 
 
 
 
 
 
 
 
 
 
 
Figure A 3.8: Gel bands were quantified using ImageQuant 5.1 by drawing the same size 
rectangular shape around comparable bands. The percentage of phosphoproteins or biotinylated 
phosphoproteins observed after kinase or phosphatase inhibitor treatment was calculated by 
dividing the protein signal after treatment (Pro-Q, lane 3 or 4 and SA-Cy5, lane 6 or 7) to the 
protein signal before treatment (Pro-Q, lane 2 and SA-Cy-5, lane 5). The contents of each 
reaction are indicated below each lane. The ATP kinase reaction (lane 2) is set to 100% in part 
A, while the ATP-biotin kinase reaction (lane 5) is set to 100% in part B. 
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Trial 1 
Trial 2 
Trial 3 
3.4 Two-Dimension Gel Images  
(A) Gel images for reactions performed using ATP in the presence of phosphatase inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3.9: Reaction of HeLa cell lysates and ATP with phosphatase inhibitors (phosphatase 
inhibitor treated). Proteins were visualized with Pro-Q diamond phosphoprotein stain. All the 
three independent trials are displayed here. 
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Trial 1 
Trial 2 
Trial 3 
(B) Gel images for reactions performed using ATP in the absence of phosphatase inhibitors 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
Figure A 3.10: Reaction of HeLa cell lysates and ATP without phosphatase inhibitors 
(untreated). Proteins were visualized with Pro-Q diamond phosphoprotein stain. All the three 
independent trials are displayed here.  
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Trial 1 
Trial 2 
Trial 3 
(C) Gel images for reactions performed using ATP-biotin in the presence of phosphatase inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3.11: Reaction of HeLa cell lysates and ATP-biotin with phosphatase inhibitors 
(phosphatase inhibitor treated). Biotinylated proteins were visualized with SA-Cy5.  All the three 
independent trials are displayed here. 
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Trial 1 
Trial 2 
Trial 3 
(D) Gel images for reactions performed using ATP-biotin in the absence of phosphatase inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 3.12: Reaction of HeLa cell lysates and ATP-biotin without phosphatase inhibitors 
(untreated). Biotinylated proteins were visualized with SA-Cy5.  All the three independent trials 
are displayed here.  
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APPENDIX C 
Table A 4.1: Phosphopeptides identified by MS analysis after kinase-catalyzed biotinylation of 
casein, followed by purification of the trypsin digestion using NeutrAvidin affinity 
chromatography and elution with biotin
a
  
Accession 
number 
Protein name 
Peptide sequence MW (Da) 
 
SC
b
 
 
PP
c
 IS
d
/IDS
e
 LP
f
 
 
IM
g
 
   
  
  
 
gi|30794310 Casein, beta  25,000 
  
  
 
 FQsEEQQQTEDELQDK  
 
4 
 
80 34/44 100 
 
CID 
 
a
 Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a 
+508 m/z modification, which is consistent with the presence of a biotinylated phosphate. 99% 
protein and 80% peptides cutoffs were used to generate the Scaffold coverage which scored 
above 0.8% FDR threshold. 
b
SC=Spectral Count. 
c 
PP= Peptide probability (written as 
percentage).
 d 
IS= Ion Score. 
e
 IDS= Identity Score. 
f
LP= Localization Probability(written as a 
percentage). 
g
IM= Ionization Method. CID=Collision Induced Dissociation.  
 
Annotated spectra from Scaffold 
Peptide sequence: FQsEEQQQTEDELQDK 
Figure A 4.1: The annotated spectrum of casein proteins identified by MS/MS analysis after 
ATP-biotin treatment, followed by avidin purification and biotin elution.  Only one peptide was 
observed.  
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Table A 4.2: Phosphopeptides identified by MS analysis after purification of a trypsin digestion 
of casein using TiO2 affinity chromatography
a
  
Accession  
number Proteins/peptides name MW (Da) 
 
SC
b
 
 
PP
c
 IS
d
/IDS
e
 LP
f
 
 
IM
g
 
gi|30794348 Casein, alpha s1  24 500      
 DIGsEStEDQAMEDIK  
 
2 
 
95 44/46 100,14 
               
CID 
 DIGsEsTEDQAMEDIK  
 
1 
 
75 31/46 100,92 
 
CID 
 VPQLEIVPNsAEER  
 
16 
 
95 87/48 100 
 
both 
 VPQLEIVPNsAEERLHSMK  
 
4 
 
95 88/49 100 
 
both 
 YKVPQLEIVPNsAEER  
 
16 
 
95 121/49 100 
 
both 
 YKVPQLEIVPNsAEERLHSMK  
 
1 
 
95 53/49 99 
 
ETD 
gi|27806963 Casein, alpha-S2  26 000 
  
  
 
 KTVDMEsTEVFTKK  
 
3 
 
95 111/49 100 
 
ETD 
 NAVPITPTLNREQLsTsEENSKK  
 
6 
 
95 74/49 93,87 
 
ETD 
 NAVPITPTLNREQLStsEENSKK  
 
1 
 
93 59/49 31,70 
 
ETD 
 NAVPITPTLNREQLsTSEENsKK  
 
1 
 
95 65/49 64,94 
 
ETD 
 TVDMEsTEVFTK  
 
6 
 
95 77/49 90 
 
both 
 TVDMEsTEVFTKK  
 
7 
 
95 91/49 99 
 
both 
 TVDmEStEVFTKK  
 
4 
 
95 61/49 33 
 
ETD 
 TVDMEsTEVFTKKTK  
 
2 
 
92 43/49 83 
 
ETD 
gi|30794310 Casein, beta  25 000 
  
  
 
 FQsEEQQQTEDELQDK  
 
78 
 
95 108/49 100 
 
both 
 FQsEEQQQtEDELQDK  
 
7 
 
94 88/49 100,100 
 
both 
 FQSEEQQQtEDELQDK  
 
1 
 
82 34/46 99 
 
CID 
 IEKFQsEEQQQTEDELQDK  
 
82 
 
95 77/46 100 
 
both 
 IEKFQsEEQQQtEDELQDK  
 
10 
 
95 51/46 100,100 
 
CID 
 IEKFQSEEQQQtEDELQDK  
 
1 
 
94 48/49 100 
 
CID 
 KIEKFQsEEQQQTEDELQDK  
 
4 
 
95 112/49 100 
 
ETD 
 
a
 Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a 
+80 m/z modification, which is consistent with the presence of a phosphate group. 99% protein 
and 80% peptides cutoffs were used to generate the Scaffold coverage which scored above 0.9% 
FDR threshold. 
b
 SC=Spectral Count. 
c
 PP= Peptide probability (written as percentage).
 d
 IS= Ion 
Score. 
e
 IDS= Identity Score. 
f
LP= Localization Probability (written as a percentage, multiple 
numbers corresponding to the value of each site). 
g
IM= Ionization Method. CID=Collision 
Induced Dissociation, ETD= Electron Transfer Disscociation, both=CID and ETD. 
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Sequence of Casein Protein 
 
 
 
 
 
 
 
 
 
 
 
Figure A 4.2: Primary sequences of casein proteins identified in the TiO2 purification after ATP 
treatment.  Amino acids highlighted in yellow represent peptides observed in the MS/MS 
analysis, while amino acids in green were modified through either phosphorylation (S or T) or 
oxidation (M). 99% protein and 80% peptides cutoffs were used to generate the Scaffold 
coverage, which scored above 0.9% FDR threshold. 
 
Annotated spectra from Scaffold 
Peptide sequence: DIGsEsTEDQAMEDIK 
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Peptide sequence: DIGsEStEDQAMEDIK 
Peptide sequence: VPQLEIVPNsAEER 
Peptide sequence: VPQLEIVPNsAEERLHSMK 
Peptide sequence: YKVPQLEIVPNsAEER 
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Peptide sequence: YKVPQLEIVPNsAEERLHSMK 
Peptide sequence: NAVPITPTLNREQLsTsEENSKK 
Peptide sequence: NAVPITPTLNREQLStsEENSKK 
Peptide sequence: NAVPITPTLNREQLsTSEENsKK 
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Peptide sequence: KTVDMEsTEVFTKK 
Peptide sequence: TVDMEsTEVFTKK 
 
Peptide sequence: TVDmEStEVFTKK 
 
Peptide sequence: TVDMEsTEVFTK 
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Peptide sequence: TVDMEsTEVFTKKTK 
Peptide sequence: FQsEEQQQTEDELQDK 
Peptide sequence: FQsEEQQQtEDELQDK 
 
Peptide sequence: FQSEEQQQtEDELQDK 
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Peptide sequence: IEKFQSEEQQQtEDELQDK 
Peptide sequence: IEKFQsEEQQQtEDELQDK 
Peptide sequence: IEKFQsEEQQQTEDELQDK 
Peptide sequence: KIEKFQsEEQQQTEDELQDK 
 Figure A 4.3: The annotated spectrum of casein proteins identified by MS/MS analysis after 
ATP treatment, followed by TiO2 purification.  While twelve unique peptide spectra were 
observed, several had variable phosphorylation states.  All 21 spectra representing the observed 
phosphorylated states are shown.   
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Table A 4.3: Phosphopeptides identified by MS analysis after kinase-catalyzed biotinylation of 
casein, followed by purification of the trypsin digestion using NeutrAvidin affinity 
chromatography and acidic elution
a
   
Accession 
number Proteins/Peptides name  MW (Da) 
 
SC
b
 
 
PP
c
 IS
d
/IDS
e
 LP
f
 
 
IM
g
 
gi|30794348 Casein, alpha s1  24,500 
  
  
 
 VPQLEIVPNsAEER  
 
1 
 
94 42/46 100 
 
CID 
 YKVPQLEIVPNsAEER  
 
9 
 
95 62/48 100 
 
both 
   
  
  
 
gi|30794310 Casein, beta  25,000 
  
  
 
 IEKFQsEEQQQtEDELQDK  
 
4 
 
81 37/46 100,100 
 
CID 
 
a
 Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a 
+80 m/z modification, which is consistent with the presence of a phosphate group. 99% protein 
and 80% peptides cutoffs were used to generate the Scaffold coverage which scored above 0.6% 
FDR threshold. 
b
 SC=Spectral Count. 
c
 PP= Peptide probability (written as percentage).
 
 
d
 IS= 
Ion Score. 
e
 IDS= Identity Score. 
f 
LP= Localization Probability (written as a percentage, 
multiple numbers corresponding to the value of each site). 
g 
IM= Ionization Method. 
CID=Collision Induced Dissociation, ETD= Electron Transfer Disscociation, both=CID and 
ETD. 
 
Annotated spectra from Scaffold 
Peptide sequence: YKVPQLEIVPNsAEER 
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Peptide sequence: VPQLEIVPNsAEER 
 
Peptide sequence: IEKFQsEEQQQtEDELQDK 
Figure A 4.4: The annotated spectrum of casein proteins identified by MS/MS analysis after 
ATP-biotin treatment, followed by avidin purification and acidic elution.  Three peptides were 
observed 
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Table A 4.4: Phosphopeptides identified by MS analysis after kinase-catalyzed biotinylation of 
casein in the presence of calf intestinal phosphatase, followed by purification of the trypsin 
digestion using NeutrAvidin affinity chromatography and acidic elution
a
  
Accession 
 numbers Proteins/Peptides name 
MW 
(Da) 
 
SC
b
 
 
PP
c
 IS
d
/IDS
e
 LP
f
 
 
IM
g
 
gi|30794348 Casein, alpha s1  24,500      
 DIGSEsTEDQAMEDIK  
 
2 
 
95 50/46 85 
 
CID 
 DIGsEsTEDQAMEDIK  
 
13 
 
95 52/46 100,99 
 
CID 
 VNELsKDIGsEStEDQAMEDIK  
 
1 
 
56 29/46 100,100,29 
 
CID 
 VPQLEIVPNsAEER  
 
17 
 
95 71/46 100 
 
CID 
 YKVPQLEIVPNsAEER  
 
26 
 
95 113/46 100 
 
CID 
   
  
  
 
gi|27806963 Casein, alpha-S2  26,000      
 NANEEEYsIGsssEEsAEVATEEVK  
 
2 
 
55 28/46 
72,83,87, 
79,57 
 
CID 
 TVDMEsTEVFTK  
 
3 
 
95 64/46 99 
 
CID 
 TVDMEStEVFTK  
 
10 
 
95 64/46 81 
 
CID 
 TVDMEsTEVFTKK  
 
11 
 
95 71/46 99 
 
CID 
   
  
  
 
gi|30794310 Casein, beta 25,000      
 FQsEEQQQTEDELQDK  
 
96 
 
95 81/46 100 
 
CID 
 FQsEEQQQtEDELQDK  
 
14 
 
95 51/46 100,100 
 
CID 
 IEKFQsEEQQQTEDELQDK  
 
47 
 
95 62/46 100 
 
CID 
 IEKFQsEEQQQtEDELQDK  
 
16 
 
94 48/46 100,100 
 
CID 
   
  
  
 
gi|27881412 Casein, kappa  21,252      
 sPAQILQWQVLSNTVPAK  
 
1 
 
80 37/46 100 
 
CID 
 
a
 Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a 
+80 m/z modification, which is consistent with the presence of a phosphate group. 99% protein 
and 55% peptides cutoffs were used to generate the Scaffold coverage which scored above 0.8% 
FDR threshold. 
b
 SC=Spectral Count. 
c
 PP= Peptide probability (written as percentage). 
d
 IS= Ion 
Score. 
e
 IDS= Identity Score.  
f 
LP= Localization Probability (written as a percentage, multiple 
numbers corresponding to the value of each site). 
g 
IM= Ionization Method. CID=Collision 
Induced Dissociation. 
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Sequence of Casein Protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 4.5: Primary sequences of casein proteins identified in the Avidin purification after 
ATP-biotin treatment in the presence of CIP.  Amino acids highlighted in yellow represent 
peptides observed in the MS/MS analysis, while amino acids in green were modified through 
either phosphorylation (S or T) or oxidation (M). 99% protein and 55% peptides cutoffs were 
used to generate the Scaffold coverage, which scored above 0.8% FDR threshold. 
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Annotated spectra from Scaffold 
Peptide sequence: DIGsEsTEDQAMEDIK 
 
Peptide sequence: DIGSEsTEDQAMEDIK 
Peptide sequence: VNELsKDIGsEStEDQAMEDIK 
Peptide sequence: VPQLEIVPNsAEER 
 
221 
 
Peptide sequence: YKVPQLEIVPNsAEER 
Peptide sequence: NANEEEYsIGsssEEsAEVATEEVK 
Peptide sequence: TVDMEsTEVFTKK 
Peptide sequence: TVDMEStEVFTK 
 
 
 
222 
 
Peptide sequence: TVDMEsTEVFTK 
 
Peptide sequence: sPAQILQWQVLSNTVPAK 
Peptide sequence: FQsEEQQQTEDELQDK 
Peptide sequence: FQsEEQQQtEDELQDK 
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Peptide sequence: IEKFQsEEQQQTEDELQDK 
 
Peptide sequence: IEKFQsEEQQQtEDELQDK 
 
Figure A 4.6: The annotated spectrum of casein proteins identified by MS/MS analysis after 
ATP-biotin treatment in the presence of CIP, followed by avidin purification and acidic elution. 
While ten unique peptide spectra were observed, several had variable phosphorylation states.  All 
14 spectra representing the observed phosphorylated states are shown. 
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Table A 4.5: Phosphopeptides identified by MS analysis after kinase-catylzed biotinylation of 
HeLa cell lysates and subsequent purification of the trypsin digestion using NeutrAvidin affinity 
chromatography and acidic elution
a
 
    
Accession 
numbers Proteins/peptides name 
MW 
(Da) SCb PPc ISd/IDSe LPf IMg 
DECR_HUMAN 2,4-dienoyl-CoA reductase, mitochondrial  36,069      
 GAAFLSITTIYAETGSGFVVPSASAKAGVEAMsK 1 95 69/43 15 CID 
        
PRS4_HUMAN 26S protease regulatory subunit 4 49,186      
 MGQsQSGGHGPGGGK  1 91 22/43 98 CID 
        
RT28_HUMAN 28S ribosomal protein S28, mitochondrial  20,843      
 NVEsFASmLR  2 95 43/43 100 CID 
        
RS12_HUMAN 40S ribosomal protein S12  14,515      
 aEEGIAAGGVMDVNTALQEVLKtALIHDGLAR  13 95 82/43 100 CID 
        
RS15A_HUMAN 40S ribosomal protein S15a  14,840      
 QFGFIVLtTSAGImDHEEAR  1 95 43/43 100 CID 
        
RS17L_HUMAN 40S ribosomal protein S17 15,551      
 DNYVPEVSALDQEIIEVDPDtKEMLK  1 95 40/43 100 CID 
        
RS24_HUMAN 40S ribosomal protein S24  15,424      
 tHFGGGKTtGFGMIYDSLDYAK  6 95 57/43 97,70 CID 
        
RLA0_HUMAN 60S acidic ribosomal protein P0  34,274      
 NVASVcLQIGYPTVASVPHsIINGYKR  1 93 45/43 49 CID 
        
RLA2_HUMAN 60S acidic ribosomal protein P2 11,666      
 YVASYLLAALGGNSsPSAK  2 95 58/43 100 CID 
        
RL11_HUMAN 60S ribosomal protein L11  20,253      
 YDPSIGIYGLDFYVVLGRPGFsIADKK  1 95 37/43 100 CID 
        
RL12_HUMAN 60S ribosomal protein L12  17,819      
 VVYLRctGGEVGATSALAPK  23 95 71/43 99 CID 
        
RL14_HUMAN 60S ribosomal protein L14  23,432      
 APGtKGtAAAAAAAAAAK  7 90 59/43 100, 100 CID 
        
6PGD_HUMAN 
6-phosphogluconate dehydrogenase, 
decarboxylating  53,142      
 ALYAsKIISYAQGFmLLR  2 95 51/43 81 CID 
        
ACTS_HUMAN Actin, alpha skeletal muscle  42,052      
 KDLYANNVmsGGTTmYPGIADR  3 95 33/43 100 CID 
        
KAD2_HUMAN Adenylate kinase 2, mitochondrial  26,479      
 AtMDAGKLVSDEMVVELIEK  5 95 65/43 99 CID 
        
225 
 
AKA12_HUMAN A-kinase anchor protein 12  191,474      
 GsVEEPKPEEPK  1 95 47/43 100 CID 
        
AKP8L_HUMAN A-kinase anchor protein 8-like  71,650      
 AVLsERDLYR  3 95 39/43 87 CID 
        
APLP1_HUMAN Amyloid-like protein 1 72,176      
 EAVsGLLImGAGGGSLIVLSMLLLRR  1 95 41/43 45 CID 
        
ANR16_HUMAN 
Ankyrin repeat domain-containing protein 
16  39,284      
 FLLQsGLK  2 95 53/43 91 CID 
        
ANXA1_HUMAN Annexin A1  38,716      
 amVsEFLKQAWFIENEEQEYVQTVK  3 95 44/43 100 CID 
        
ANXA2_HUMAN Annexin A2  38,606      
 ELAsALKsALSGHLETVILGLLK  1 95 51/43 100, 100 CID 
        
ANXA3_HUMAN Annexin A3  36,377      
 HYGYSLysAIKSDTSGDYEITLLK  3 94 56/42 42,92 CID 
        
AP2A2_HUMAN AP-2 complex subunit alpha-2 103,963      
 QLsNPQQEVQNIFK  1 95 56/43 89 CID 
        
AATM_HUMAN Aspartate aminotransferase, mitochondrial 47,519      
 YyDPKtcGFDFTGAVEDISK  9 95 72/43 55,90 CID 
        
ABCE1_HUMAN 
ATP-binding cassette sub-family E member 
1  67,316      
 NTVANsPQTLLAGmNKFLSQLEITFR  1 91 43/43 43 CID 
        
ACTBL_HUMAN Beta-actin-like protein 2  42,004      
 MTQIMFEAFNTPAMyVAIQAVLSLYASGR  38 95 57/43 100 CID 
 cPEAIFQPSFLGIEsSGIHETTFNSImK  1 95 30/43 100 CID 
 EKMTQIMFEAFNtPAMYVAIQAVLSLYASGR  9 95 43/43 99 CID 
        
BMP4_HUMAN Bone morphogenetic protein 4  46,555      
 FLFNLsSIPENEVISSAELR  1 95 40/43 98 CID 
        
KCC4_HUMAN 
Calcium/calmodulin-dependent protein 
kinase type IV 51,926      
 tEIGVLLR  3 93 43/42 100 CID 
        
CATB_HUMAN Cathepsin B  37,821      
 NGPVEGAFSVYSDFLLYKsGVYQHVTGEmMGGHAIR 1 93 49/42 11 CID 
        
CIDEA_HUMAN Cell death activator CIDE-A  24,688      
 GVmASsLQELISK  1 95 46/43 63 CID 
        
CENP1_HUMAN 
CENPB DNA-binding domain-containing 
protein 1  21,053      
 SIIEEGEytPQVSLt  1 95 32/43 57,34,72 CID 
        
CE350_HUMAN Centrosome-associated protein 350  350,933      
 DNKAtSPGPtDLEtR  1 95 33/43 43,27,39 CID 
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CHKB_HUMAN Choline/ethanolamine kinase 45,272      
 EPVLsAAIATK  2 95 46/43 71 CID 
        
COPE_HUMAN Coatomer subunit epsilon  34,483      
 LVLQYAPsA  1 90 40/43 95 CID 
        
COF1_HUMAN Cofilin-1  18,503      
 asGVAVSDGVIK  2 95 51/43 100 CID 
        
COF2_HUMAN Cofilin-2  18,737      
 StLGEKLGGNVVVSLEGKPL   95 56/43 42 CID 
        
CO9A2_HUMAN Collagen alpha-2(IX) chain 65,131      
 AAAtASPR  1 95 42/42 100 CID 
        
CO6A6_HUMAN Collagen alpha-6(VI) chain  247,178      
 mIsAGLPGEMGSPGEPGPPGR  2 95 30/43 29 CID 
        
C1T9A_HUMAN 
Complement C1q and tumor necrosis factor-
related protein 9A  34,682      
 DAYMSsEDQASGGIVLQLK  1 95 33/43 34 CID 
        
CSN1_HUMAN COP9 signalosome complex subunit 1  55,538      
 MAAAFNTTVAALEDELTQLILEGLIsAR  1 95 53/43 76 CID 
 IPPAIKsANsELGGIWSVGQR  3 92 48/43 100,100 CID 
        
KCRB_HUMAN Creatine kinase B-type  42,645      
 LAVEALSSLDGDLAGRyyALK  1 95 38/43 100,100 CID 
        
CD11A_HUMAN Cyclin-dependent kinase 11A  91,363      
 EYGsPLK  1 91 39/42 100 CID 
        
CDK12_HUMAN Cyclin-dependent kinase 12  164,159      
 WSDSSKQDDSPSGASYGQDyDLsPsR  1 94 30/43 100,100,100 CID 
        
UCRI_HUMAN 
Cytochrome b-c1 complex subunit Rieske, 
mitochondrial 29,668      
 GFSYLVtGVttVGVAYAAKNAVTQFVSSmSASADVLALAK 2 95 76/42 34,37.39 CID 
        
CCHL_HUMAN Cytochrome c-type heme lyase  30,602      
 DYQFtILDVRPALDSLSAVWDR  1 94 53/43 35 CID 
        
ERCC6_HUMAN DNA excision repair protein ERCC-6  168,419      
 VPVQEIDDDFFPSsGEEAEAASVGEGGGGGRK 1 95 30/43 32 CID 
        
DUS4_HUMAN Dual specificity protein phosphatase 4  42,954      
 LmNRDENGGGAGGSGSHGTLGLPsGGK  1 95 32/43 43 CID 
        
DYM_HUMAN Dymeclin 75,939      
 AAAsPELsSPLANQSLLLLLVLANLTDASDAPNPYRQAImSFK 4 95 39/42 23,21 CID 
        
TRI23_HUMAN E3 ubiquitin-protein ligase TRIM23  64,066      
 QDEFMQPIPtIGFNVETVEYK  1 95 49/43 76 CID 
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EXOS1_HUMAN Exosome complex component CSL4  21,452      
 LcNLEEGSPGSGTYTRHGyIFsSLAGcLmK  1 91 50/43 31,38 CID 
        
GNA1_HUMAN Glucosamine 6-phosphate N-acetyltransferase  20,749      
 LNcyKItLEcLPQNVGFYK  3 95 36/43 100,100 CID 
        
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase  36,053      
 LtGMAFRVPTANVSVVDLTcR  8 95 72/43 99 CID 
        
GRAP1_HUMAN GRIP1-associated protein 1  95,991      
 SGLEELVLSEMNsPsR  1 95 50/43 45,63 CID 
        
HSP72_HUMAN Heat shock-related 70 kDa protein 2  70,023      
 SENVQDLLLLDVTPLSLGIEtAGGVmtPLIK  1 95 29/43 77,80 CID 
        
HELQ_HUMAN Helicase POLQ-like  124,136      
 LyLSFVLYTLLK  1 95 57/43 100 CID 
        
ROA2_HUMAN 
Heterogeneous nuclear ribonucleoproteins 
A2/B1  37,430      
 DyFEEyGKIDTIEIITDR  3 92 52/43 93,99 CID 
        
HNRPC_HUMAN 
Heterogeneous nuclear ribonucleoproteins 
C1/C2  33,671      
 SMNsRVFIGNLNTLVVK  2 95 51/43 78 CID 
        
H14_HUMAN Histone H1.4  21,867      
 sEtAPAAPAAPAPAEK  1 95 40/43 100, 100 CID 
        
H1X_HUMAN Histone H1x  22,488      
 NQPGKYsQLVVETIR  6 95 62/43 21 CID 
        
SETD2_HUMAN Histone-lysine N-methyltransferase SETD2  287,597      
 KsSEFLK  1 95 48/42 45 CID 
        
HSDL2_HUMAN Hydroxysteroid dehydrogenase-like protein 2  45,397      
 tAQPHPKLLGtIYTAAEEIEAVGGK  5 95 75/43 99, 100 CID 
        
K1C17_HUMAN Keratin, type I cytoskeletal 17 48,107      
 TIEELQNKILtATVDNANILLQIDNAR  15 95 56/43 98 CID 
        
K1C18_HUMAN Keratin, type I cytoskeletal 18  48,059      
 NHEEEVKGLQAQIAsSGLTVEVDAPK  5 93 44/43 100 CID 
        
K2C1_HUMAN Keratin, type II cytoskeletal 1  66,040      
 MsGEcAPNVSVSVSTSHTTISGGGSR  2 95 31/43 43 CID 
        
K2C6A_HUMAN Keratin, type II cytoskeletal 6A  60,046      
 AIGGGLSSVGGGSSTIKyTTtSSssR  2 93 56/43 42,57,57,81 CID 
        
K2C7_HUMAN Keratin, type II cytoskeletal 7 51,387      
 TLNETELtELQsQISDTSVVLSmDNSR  17 95 61/43 99,87 CID 
        
K2C79_HUMAN Keratin, type II cytoskeletal 79  57,836      
 QTYSTKGGFSSNSASGGsGsQAR  1 95 28/43 78,83 CID 
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LARP1_HUMAN La-related protein 1  123,513      
 GEGSDsKESPK  1 95 35/43 100 CID 
        
LIPM_HUMAN Lipase member M  48,234      
 EFLyQTR  1 90 40/43 76 CID 
        
LDH6B_HUMAN L-lactate dehydrogenase A-like 6B 41,944      
 LMISSIVQYsPHcKLIIVSNPVDILTYVAWK  1 95 91/43 18 CID 
        
LDHB_HUMAN L-lactate dehydrogenase B chain  36,639      
 GytNWAIGLSVADLIESMLK  2 95 43/43 100,100 CID 
 IHPVstMVKGMYGIENEVFLSLPcILNAR  5 95 66/43 79,73 CID 
        
LONF1_HUMAN 
LON peptidase N-terminal domain and RING 
finger protein 1  86,726      
 mSsPAVARTsPGGSR  1 95 49/43 67,63 CID 
        
L12R1_HUMAN 
Loss of heterozygosity 12 chromosomal 
region 1 protein 22,223      
 MGsEQSSEAESRPNDLNSSVTPSPAK  1 95 34/43 77 CID 
        
GMPPB_HUMAN Mannose-1-phosphate guanyltransferase beta  39,834      
 ALILVGGyGtR  1 95 28/43 43,21 CID 
        
MA7D3_HUMAN MAP7 domain-containing protein 3  98,431      
 ESMEAsPEAmVK  1 95 33/43 45 CID 
        
MALD1_HUMAN MARVEL domain-containing protein 1  18,915      
 WLmVNVAHDVLAAALYGAATGImSDQmQRHsycNLK 1 95 46/42 99,99 CID 
        
MARE1_HUMAN 
Microtubule-associated protein RP/EB family 
member 1  30,000      
 mAVNVYStsVTSDNLSRHDmLAWINESLQLNLTK 1 95 54/42 41,23 CID 
        
M4K2_HUMAN 
Mitogen-activated protein kinase kinase kinase 
kinase 2  91,558      
 VVRNPYtGATFLLAALPTSLLLLQWyEPLQK  1 95 25/43 54,62 CID 
        
MYL6_HUMAN Myosin light polypeptide 6  16,930      
 HVLVTLGEKmtEEEVEmLVAGHEDSNGcINYEAFVR 1 95 45/43 98 CID 
        
ML12B_HUMAN Myosin regulatory light chain 12B  19,780      
 NAFAcFDEEATGTIQEDYLRELLttMGDR  1 95 46/43 71,73 CID 
        
MTMRC_HUMAN Myotubularin-related protein 12  86,150      
 LINssDELQDNFR  1 95 56/43 99,99 CID 
        
MTMR8_HUMAN Myotubularin-related protein 8  78,921      
 SVTLGtVVGSsK  3 95 46/43 100,50 CID 
        
NAA10_HUMAN N-alpha-acetyltransferase 10 26,459      
 GLAAEDSGGDsK  1 95 31/43 100 CID 
        
NPHP3_HUMAN Nephrocystin-3  150,870      
 NLAVLSyEGGDFEK  1 95 29/43 43 CID 
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AHNK_HUMAN 
Neuroblast differentiation-associated protein 
AHNAK  629,104      
 AGAISASGPELQGAGHsKLQVTMPGIK  1 95 30/43 100 CID 
        
NPM_HUMAN Nucleophosmin  32,576      
 VtLATLKmsVQPTVsLGGFEITPPVVLR  3 95 51/43 100,100,100 CID 
        
NDKB_HUMAN Nucleoside diphosphate kinase B  17,298      
 ymNSGPVVAmVWEGLNVVK  2 95 41/43 88 CID 
 YmNsGPVVAmVWEGLNVVK  1 95 69/43 13 CID 
        
O10P1_HUMAN Olfactory receptor 10P1  34,743      
 mAGENHTTLPEFLLLGFsDLK  1 95 33/43 21 CID 
        
OR6B1_HUMAN Olfactory receptor 6B1  35,301      
 LALGSWAIGFGIsLAK  3 91 46/43 44 CID 
        
PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A  18,013      
 MVNPtVFFDIAVDGEPLGR  8 95 48/43 100 CID 
        
PAL4G_HUMAN Peptidyl-prolyl cis-trans isomerase A-like 4G  18,166      
 HtGSGILSMANAGPNTNGSQFFIcTAK  1 92 45/43 88 CID 
        
PPIF_HUMAN 
Peptidyl-prolyl cis-trans isomerase F, 
mitochondrial  22,040      
 AcSKGsGDPSSSSSSGNPLVYLDVDANGKPLGR 3 95 72/43 78 CID 
        
PEX19_HUMAN Peroxisomal biogenesis factor 19  32,807      
 ETLsGLAKNAtDLQNSSmSEEELTK  2 95 51/43 60,83 CID 
        
PGK1_HUMAN Phosphoglycerate kinase 1  44,615      
 AsLsKLGDVYVNDAFGTAHR  13 95 58/43 100,100 CID 
 TGQATVASGIPAGWMGLDcGPEsSK  5 95 34/43 83 CID 
        
PFD2_HUMAN Prefoldin subunit 2  16,648      
 SSGsGAGKGAVSAEQVIAGFNR  1 95 35/43 25 CID 
        
PFD3_HUMAN Prefoldin subunit 3  22,659      
 NLSTAtKNLDSLEEDLDFLR  1 95 48/43 28 CID 
        
PAWR_HUMAN PRKC apoptosis WT1 regulator protein  36,568      
 mATGGYRtsSGLGGSTTDFLEEWK  1 95 66/43 47,47 CID 
        
PROF1_HUMAN Profilin-1  15,054      
 mAGWNAyIDNLmADGTcQDAAIVGYK  20 95 46/43 100 CID 
        
PDCD5_HUMAN Programmed cell death protein 5 14,285      
 EAEmRNsILAQVLDQSAR  1 95 53/43 100 CID 
        
PHB2_HUMAN Prohibitin-2 33,298      
 TIAtsQNRIYLtADNLVLNLQDESFTR  2 95 59/43 41,84,45 CID 
        
PSME2_HUMAN Proteasome activator complex subunit 2  27,402      
 AFYAELYHIISsNLEKIVNPK  1 90 49/43 100 CID 
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PSA2_HUMAN Proteasome subunit alpha type-2  25,899      
 GysFsLttFSPSGKLVQIEYALAAVAGGAPSVGIK  1 95 53/43 92,86,84,73 CID 
        
PSA5_HUMAN Proteasome subunit alpha type-5  26,411      
 LFQVEYAIEAIKLGSTAIGIQtsEGVcLAVEK  1 95 60/43 95,95 CID 
        
PSB7_HUMAN Proteasome subunit beta type-7  29,966      
 FRPDMEEEEAKNLVsEAIAAGIFNDLGSGSNIDLcVISK 6 95 89/42 43 CID 
        
AHNK2_HUMAN Protein AHNAK2  616,628      
 VEVTSPNLDVsLPSmEVDIQAPGAKLDStR  1 91 22/43 82 CID 
 smEASVDVtAPK  1 95 53/43 100100 CID 
        
DPY30_HUMAN Protein dpy-30 homolog  11,250      
 MEPEQMLEGQtQVAENPHSEYGLTDNVER  1 95 22/43 100 CID 
        
MIDA_HUMAN Protein midA homolog, mitochondrial  49,239      
 DHVEVcPDAGVIIEELSQRIALtGGAALVADyGHDGtK 1 95 31/43 63,90,85 CID 
        
MUTED_HUMAN Protein Muted homolog  21,610      
 msGGGTETPVGcEAAPGGGsK  1 95 33/43 99,99 CID 
        
PPR29_HUMAN Protein phosphatase 1 regulatory subunit 29  89,689      
 RDSTYsQLSPR  3 95 42/43 23 CID 
        
VPRBP_HUMAN Protein VPRBP 169,011      
 DENsQLVAIVLR  1 90 43/43 100 CID 
        
PLP2_HUMAN Proteolipid protein 2 16,691      
 MADsERLsAPGcWAAcTNFSR  18 95 60/43 100100 CID 
        
PSYR_HUMAN Psychosine receptor  39,335      
 yLAVVYPLK  1 95 56/43 100 CID 
        
ASXL3_HUMAN Putative Polycomb group protein ASXL3  241,919      
 EAAAAAAVAAAASIVsGAmGsPGEGGKtR  1 95 31/43 23,27,67 CID 
        
CAF17_HUMAN Putative transferase CAF17, mitochondrial  38,156      
 yLQGVPEGVRDLPPGVALPLESNLAFMNGVSFTK 1 94 27/43 100, CID 
        
CX069_HUMAN Putative uncharacterized protein CXorf69  9,236      
 EALGSGHYVGGsIRSMAAAALSGLAVR  1 95 25/43 19 CID 
        
VSIG7_HUMAN 
Putative V-set and immunoglobulin domain-
containing protein 7  13,301      
 ILFLVVIAAGAQSQVQLmQsGAEVKKPGASVR  1 95 36/43 31 CID 
        
RB11B_HUMAN Ras-related protein Rab-11B  24,489      
 NNLSFIETSALDSTNVEEAFKNILtEIyR  4 95 63/43 94,83 CID 
        
RAB21_HUMAN Ras-related protein Rab-21  24,348      
 HVSIQEAESYAESVGAKHyHTSAK  1 95 58/43 32 CID 
        
231 
 
RFC2_HUMAN Replication factor C subunit 2 39,158      
 yRPVKLNEIVGNEDTVSR  1 95 51/43 100 CID 
        
RTBDN_HUMAN Retbindin 24,615      
 mDcRVHmRPIGLTWVLQLtLAWILLEAcGGsRPLQAR 1 95 32/42 80,96 CID 
        
RHG23_HUMAN Rho GTPase-activating protein 23  162,197      
 LsPPAAPEERPAADTRSIVSGYSTLSTmDR  1 95 35/43 78 CID 
        
ARHGI_HUMAN Rho guanine nucleotide exchange factor 18  130,784      
 GTLLsDGsPALSR  1 93 44/43 73,78 CID 
        
PRPS2_HUMAN Ribose-phosphate pyrophosphokinase 2  34,770      
 LLsAGAtKVYAILTHGIFSGPAISR  2 95 42/43 86,58 CID 
        
RYR2_HUMAN Ryanodine receptor 2 564,570      
 SSTLQQLIsETmVR  1 95 41/43 47 CID 
        
SALL4_HUMAN Sal-like protein 4  112,231      
 SSLPstFIR  2 95 52/43 100,100 CID 
        
PP1RA_HUMAN 
Serine/threonine-protein phosphatase 1 
regulatory subunit 10  99,059      
 LSHDNmEEKVPWVcPRPLVLPSPLVTPGsNsQER 1 95 28/43 82,80 CID 
        
SPB6_HUMAN Serpin B6  42,623      
 TYIGEIFTQILVLPYVGKELNMIImLPDEttDLR  1 95 53/42 21,19 CID 
        
MTAP_HUMAN S-methyl-5'-thioadenosine phosphorylase 31,236      
 AEsFMFRtWGADVINmTTVPEVVLAK   95 51/43 100,100 CID 
        
STMN1_HUMAN Stathmin  17,303      
 ASGQAFELILsPR  2 95 54/43 100 CID 
        
SMC5_HUMAN 
Structural maintenance of chromosomes 
protein 5  128,810      
 YVVKTSFYsNK  2 95 32/43 100 CID 
 YVVKTSFySNK  4 95 29/43 81 CID 
        
SODC_HUMAN Superoxide dismutase [Cu-Zn]  15,935      
 DGVADVSIEDSVISLSGDHcIIGRtLVVHEK  1 95 57/43 91 CID 
        
TCPH_HUMAN T-complex protein 1 subunit eta  59,368      
 QQLLIGAyAKALEIIPR  1 95 39/43 100 CID 
        
THEM5_HUMAN Thioesterase superfamily member 5  27,678      
 GLKLPSGLAVsSDK  1 95 30/43 100 CID 
        
THIO_HUMAN Thioredoxin  11,737      
 QIESKtAFQEALDAAGDK  9 95 63/43 79 CID 
        
ELOC_HUMAN 
Transcription elongation factor B polypeptide 
1  12,473      
 mDGEEKtYGGcEGPDAmYVK  2 95 51/43 29 CID 
 EHALtSGTIKAmLSGPGQFAENETNEVNFR  2 95 65/43 24 CID 
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BTF3_HUMAN Transcription factor BTF3  22,168      
 VQAsLAANTFTLTGHAEtKQLtEmLPSILNQLGADSLTSLR 3 95 80/42 100,64,69 CID 
        
TFR1_HUMAN Transferrin receptor protein 1  84,874      
 mmDQARsAFSNLFGGEPLSYTR  2 95 45/43 65 CID 
        
TAGL2_HUMAN Transgelin-2  22,392      
 ENFQNWLKDGtVLcELINALYPEGQAPVK  2 95 51/43 100 CID 
        
T200A_HUMAN Transmembrane protein 200A  54,358      
 SsMALGPGAGQLLSPGAARR  1 95 31/43 100 CID 
        
TPIS_HUMAN Triosephosphate isomerase  30,791      
 VVLAYEPVWAIGTGKtAtPQQAQEVHEK  2 90 51/43 96,86 CID 
        
UBP36_HUMAN Ubiquitin carboxyl-terminal hydrolase 36  122,653      
 tGSSSLPGRPSVIPDHSKK  2 95 37/43 100 CID 
        
UB2D2_HUMAN Ubiquitin-conjugating enzyme E2 D2  16,736      
 SQWSPALTISKVLLsIcsLLcDPNPDDPLVPEIAR  1 95 33/43 30,30 CID 
        
CL043_HUMAN Uncharacterized protein C12orf43  28,171      
 LFFtSVPGGREK  1 95 50/43 100 CID 
        
MYO1F_HUMAN Unconventional myosin-If  124,847      
 SSQAPtRAAPAPPR  1 95 33/43 100 CID 
        
SC22B_HUMAN Vesicle-trafficking protein SEC22b  24,594      
 VLLtmIARVADGLPLAASmQEDEQSGR  4 95 48/43 100 CID 
        
WEE2_HUMAN Wee1-like protein kinase 2  62,926      
 LFLQsGGK  2 93 43/42 100 CID 
        
ZBT7A_HUMAN 
Zinc finger and BTB domain-containing protein 
7A  61,440      
 aGGVDGPIGIPFPDHsSDILSGLNEQR  1 95 32/43 72 CID 
        
 
 
 
 
 
 
 
 
233 
 
 
Total phosphoproteins 147 
Spectral count 447 
Number of different phosphopeptides 153 
Number of multiply phosphorylated peptides 135 
Number of singly phosphorylated peptides 312 
Number of each phosphorylated amino acid observed 256(pS), 234(pT), 66(pY) 
Number of unique phosphorylated amino acids 304 
 
a
 Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a 
+80 m/z modification, which is consistent with the presence of a phosphate group. 50% protein 
and 80% peptides cutoffs were used to generate the Scaffold coverage which scored above 1.1% 
FDR threshold.  
b
 SC=Spectral Count. 
c
 PP= Peptide probability (written as percentage). 
d
 IS= 
Ion Score. 
e
 IDS= Identity Score. 
f 
LP= Localization Probability (written as a percentage, 
multiple numbers corresponding to the value of each site). 
g 
IM= Ionization Method. 
CID=Collision Induced Dissociation. 
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Table A 4.6: Phosphopeptides identified by MS analysis after purification of a HeLa cell lysate 
trypsin digestion using TiO2 affinity chromatography 
a
  
Accession  Protein/peptide name 
MW 
(Da) SCb PPc ISd/IDSe LPf IMg 
U5S1_HUMAN 
116 kDa U5 small nuclear 
ribonucleoprotein component 109,420      
 mDTDLYDEFGNYIGPELDsDEDDDELGRETK 3 95 82/46 51 CID 
        
RS27_HUMAN 40S ribosomal protein S27  9,443      
 PLAKDLLHPsPEEEK  1 87 49/48 100 ETD 
        
RLA0L_HUMAN 60S acidic ribosomal protein P0-like  34,347      
 EESEEsDEDmGFGLFD  9 95 65/46 100 CID 
        
RLA2_HUMAN 60S acidic ribosomal protein P2  11,647      
 EESEEsDDDMGFGLFD  4 95 68/46 100 CID 
 KEESEEsDDDMGFGLFD  34 95 7846 100 CID 
        
RL17_HUMAN 60S ribosomal protein L17  21,379      
 VRYsLDPENPTK  3 95 63/48 100 both 
 VRySLDPENPTK  1 88 49/48 100 ETD 
        
RL3_HUMAN 60S ribosomal protein L3  46,092      
 HGsLGFLPR  1 89 33/45 100 CID 
        
MEPCE_HUMAN 
7SK snRNA methylphosphate capping 
enzyme  74,338      
 tsSKsEAGARGGGQGsK  1 84 50/48 
92,71, 
81,82 ETD 
        
ANLN_HUMAN Actin-binding protein anillin  124,184      
 TPIsPLKTGVSKPIVK  1 89 50/48 29 ETD 
        
CAP1_HUMAN Adenylyl cyclase-associated protein 1  51,838      
 EMNDAAMFyTNR  1 86 35/46 100 CID 
 SGPKPFSAPKPQTsPSPK  6 95 63/48 92 ETD 
        
AK1C1_HUMAN Aldo-keto reductase family 1 member C1  36,771      
 dAGLAKSIGVsNFNR  1 95 58/48 32 ETD 
        
ANR53_HUMAN 
Ankyrin repeat domain-containing 
protein 53  59,514      
 AtALsKTPEQR  1 79 46/47 100,100 CID 
        
AGAP2_HUMAN 
Arf-GAP with GTPase, ANK repeat and 
PH domain-containing protein 2 124,659      
 gSKSSAGTGAsVsAAAtAAAAGGGGSTASTSGGVGAGAGAR 1 94 63/49 
22,32, 
22 ETD 
        
ARGL1_HUMAN Arginine and glutamate-rich protein 1 33,199      
 ASsPPDRIDIFGR  1 84 47/48 100 ETD 
        
ABCF1_HUMAN 
ATP-binding cassette sub-family F 
member 1  95,910      
 LSVPTsDEEDEVPAPKPR  3 95 56/48 99 both 
        
ACLY_HUMAN ATP-citrate synthase  120,825      
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 AKPAMPQDSVPsPR  1 86 48/48 100 ETD 
        
ATN1_HUMAN Atrophin-1  124,756      
 ASPGGVStSSSDGKAEK  1 86 49/48 12 ETD 
        
SYEP_HUMAN Bifunctional aminoacyl-tRNA synthetase  170,575      
 EYIPGQPPLSQSSDSsPTRNSEPAGLETPEAK 1 84 36 26 CID 
        
UIMC1_HUMAN BRCA1-A complex subunit RAP80  79,709      
 vKEVSEsRNLEK  1 82 52/48 50 ETD 
        
BRD4_HUMAN Bromodomain-containing protein 4  152,199      
 LNLPDYyKIIK  1 95 6048 94 ETD 
        
CLCA4_HUMAN Calcium-activated chloride channel regulator 4  101,267      
 KIEAtRcSAGIsGR  1 82 46/48 63,67 ETD 
        
KAP0_HUMAN 
cAMP-dependent protein kinase type I-alpha 
regulatory subunit  PE=1 SV=1 42,964      
 TDSREDEIsPPPPNPVVK  1 83 36/46 99 CID 
        
KAP2_HUMAN 
cAMP-dependent protein kinase type II-alpha 
regulatory subunit   45,501      
 AATIVATSEGsLWGLDR  1 79 46/48 26 CID 
        
CSKI2_HUMAN Caskin-2 126,768      
 GLLQGEALsEGGRR  1 84 47/48 100 ETD 
        
CTNA1_HUMAN Catenin alpha-1  100,055      
 TPEELDDsDFETEDFDVR  2 95 76/46 45 ETD 
        
CHD8_HUMAN 
Chromodomain-helicase-DNA-binding protein 
8 290,503      
 SQEILSQGNPFmGVSATAVSsssAGGQPPQSAPK 1 86 68/48 27,26,65 ETD 
        
CTF18_HUMAN 
Chromosome transmission fidelity protein 18 
homolog 107,366      
 GDAAssPAPAAsVGsSQGGARK  1 95 51/48 83,84,76,65 ETD 
        
CCD46_HUMAN Coiled-coil domain-containing protein 46 112,733      
 SSQIIAELQttIsSLK  1 95 58/46 57,66,23 ETD 
        
COHA1_HUMAN Collagen alpha-1(XVII) chain  150,404      
 rGSSySSsmsTGGGGAGsLGAGGAFGEAAGDR 1 85 57/49 54,41,67,29 ETD 
        
CNTP4_HUMAN Contactin-associated protein-like 4 145,259      
 GsVTGAVLK  1 83 53/46 100 ETD 
        
CORO7_HUMAN Coronin-7 100,588      
 DGALVGtAcKDKQLR  1 92 54/48 100 ETD 
        
CXXC5_HUMAN CXXC-type zinc finger protein 5  32,960      
 sLRRSRPLSHYSSFGSSGGSGGGsMmGGEsADK 1 86 70/49 48,37 ETD 
        
CNGB3_HUMAN Cyclic nucleotide-gated cation channel beta-3  92,235      
 LFKtLLGGTGKASLAR  1 79 45/48 99 ETD 
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DC1L1_HUMAN 
Cytoplasmic dynein 1 light intermediate chain 
1  56,562      
 DFQEYVEPGEDFPAsPQRR  1 95 39/46 99 ETD 
        
CYTSA_HUMAN Cytospin-A  124,587      
 StcPsAAPsASAPAMTTVENKsK  1 95 44/49 62,63,60,60 ETD 
        
DSC3_HUMAN Desmocollin-3  99,953      
 gWITIDEIsGSIITSK  1 84 48/48 81 ETD 
        
DNMT1_HUMAN DNA (cytosine-5)-methyltransferase 1  183,151      
 LVMAGETtNSRGQR  1 79 47/48 17 ETD 
        
MCM2_HUMAN DNA replication licensing factor MCM2 101,880      
 AIPELDAYEAEGLALDDEDVEELTAsQR  1 93 40/46 98 CID 
 GLLYDsDEEDEERPARK  1 80 36/46 89 CID 
 GLLYDsDEEDEERPAR  1 81 32/46 99 CID 
 RGLLYDsDEEDEERPAR  1 95 55/46 23 CID 
        
DMRT1_HUMAN 
Doublesex- and mab-3-related transcription 
factor 1  39,455      
 AGGFGKASGALVGAASGSSAGGsSRGGGSGSGASDLGAGSK 1 95 75/49 13 ETD 
        
HUWE1_HUMAN E3 ubiquitin-protein ligase HUWE1 481,874      
 GSGTAsDDEFENLR  1 95 49/46 100 CID 
        
EF1B_HUMAN Elongation factor 1-beta 24,746      
 YGPADVEDTTGSGATDSKDDDDIDLFGsDDEEESEEAK 8 95 98/45 99 CID 
        
EF1D_HUMAN Elongation factor 1-delta  31,104      
 KPATPAEDDEDDDIDLFGsDNEEEDKEAAQLR 2 95 57/46 95 both 
        
ENPL_HUMAN Endoplasmin 92,454      
 EEsDDEAAVEEEEEEKKPK  2 95 45/46 100 CID 
 VEEEPEEEPEETAEDTTEDTEQDEDEEMDVGtDEEEETAK 1 95 102/45 27 CID 
        
EIF2A_HUMAN Eukaryotic translation initiation factor 2A  64,973      
 SDKsPDLAPTPAPQSTPR  4 89 51/48 92 both 
        
EIF3B_HUMAN 
Eukaryotic translation initiation factor 3 
subunit B  92,465      
 ALENGDADEPSFsDPEDFVDDVsEEELLGDVLK 5 95 55/46 78, 100 CID 
        
EIF3C_HUMAN 
Eukaryotic translation initiation factor 3 
subunit C  105,329      
 QPLLLsEDEEDTKR  1 94 56/48 100 ETD 
        
EIF3G_HUMAN 
Eukaryotic translation initiation factor 3 
subunit G  35,594      
 GIPLATGDtSPEPELLPGAPLPPPKEVINGNIK  2 95 48/46 71 CID 
        
EIF3J_HUMAN 
Eukaryotic translation initiation factor 3 
subunit J  29,045      
 aAAAAAAGDSDsWDADAFSVEDPVR  15 95 115/46 100 CID 
        
IF4G3_HUMAN Eukaryotic translation initiation factor 4 176,638      
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gamma 3 
 DITEEIMSGGGsR  1 92 53/48 39 ETD 
        
IF2P_HUMAN Eukaryotic translation initiation factor 5B 138,813      
 NKPGPNIEsGNEDDDASFK  2 93 39/46 100 CID 
        
FAS_HUMAN Fatty acid synthase  273,409      
 QGVQVQVstSNISSLEGAR  2 95 60/49 79,95 ETD 
        
FBSP1_HUMAN F-box/SPRY domain-containing protein 1  30,615      
 aAPAPGAGAAsGGAGcSGGGAGAGAGSGsGAAGAGGR 1 86 71/49 38,42 ETD 
        
FOXK1_HUMAN Forkhead box protein K1 75,439      
 EGsPIPHDPEFGSK  1 81 45/48 100 ETD 
        
FREM2_HUMAN FRAS1-related extracellular matrix protein 2  351,137      
 TGTDLsK  1 95 65/49 96 ETD 
        
F16A2_HUMAN FTS and Hook-interacting protein  105,552      
 DGAGLGLSGGsPGAstPVLLTR  1 90 52/49 45,37,66 ETD 
        
GRIN3_HUMAN 
G protein-regulated inducer of neurite 
outgrowth 3  82,420      
 LsDscGsIsKADHSGSLDPTNK  1 80 47/49 68,88,78,57 ETD 
        
CXA3_HUMAN Gap junction alpha-3 protein  47,411      
 asKASRASsGR  1 89 50/47 95, 100 ETD 
        
GLYG2_HUMAN Glycogenin-2  55,166      
 lVVLItPQVssLLR  1 88 38/46 100,100,100 CID 
        
GCC2_HUMAN 
GRIP and coiled-coil domain-containing 
protein 2 184,642      
 KtVETLQQQLsK  1 95 60/48 88,65 ETD 
        
RAD_HUMAN GTP-binding protein RAD  33,227      
 MtLNGGGSGAGGsR  1 81 50/48 96,46 ETD 
        
HS90A_HUMAN Heat shock protein HSP 90-alpha  84,645      
 ESEDKPEIEDVGsDEEEEK  2 95 49/46 100 CID 
 ESEDKPEIEDVGsDEEEEKK  2 95 49/46 100 both 
 EEKESEDKPEIEDVGsDEEEEKK  2 92 76/46 100 both 
 ESEDKPEIEDVGsDEEEEKKDGDK  1 95 48/46 100 ETD 
        
HSP72_HUMAN Heat shock-related 70 kDa protein 2  70,005      
 lyQGGPGGGsGGGGSGAsGGPtIEEVD  1 95 64/49 85,98,97,99 ETD 
        
HDGF_HUMAN Hepatoma-derived growth factor  26,771      
 AGDLLEDsPKRPK  8 95 66/46 100 both 
        
HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U  90,567      
 LQAALDDEEAGGRPAMEPGNGsLDLGGDSAGR 5 95 54/46 100 CID 
        
HNRL2_HUMAN 
Heterogeneous nuclear ribonucleoprotein U-
like protein 2  85,087      
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 sGDETPGSEVPGDKAAEEQGDDQDSEK  1 95 51/46 100 CID 
        
H1X_HUMAN Histone H1x  22,470      
 sVELEEALPVTTAEGMAK  6 95 96/46 100 CID 
        
RBBP7_HUMAN Histone-binding protein RBBP7  47,802      
 asKEMFEDTVEER  4 95 58/46 100 CID 
        
CUX1_HUMAN Homeobox protein cut-like 1  164,172      
 TSAScSPAPESPMSSsEsVK  1 81 49/49 92,16 ETD 
        
HXA3_HUMAN Homeobox protein Hox-A3  46,351      
 vEmANLLNLtER  1 79 45/48 100 CID 
        
HXB3_HUMAN Homeobox protein Hox-B3 44,323      
 ESRQTsK  1 79 45/47 43 CID 
        
CDC37_HUMAN Hsp90 co-chaperone Cdc37  44,450      
 vDYSVWDHIEVsDDEDETHPNIDTASLFR  1 85 37/46 73 CID 
        
LV001_HUMAN Ig lambda chain V region 4A  12,362      
 ALIYSTsNK  2 95 44/45 38 CID 
        
IGS10_HUMAN Immunoglobulin superfamily member 10  290,823      
 TSALMEAEVGKHTsstsKR  1 81 49/49 70,82,70,93 ETD 
        
INT3_HUMAN Integrator complex subunit 3  118,056      
 GAAAAAAASGAAGGGGGGAGAGAPGGGRLLLSTsLDAK 1 85 49/49 25 ETD 
        
HABP4_HUMAN Intracellular hyaluronan-binding protein 4  45,767      
 GGRsPAGASGHRAGAGGR  1 89 50/48 99 ETD 
        
KLD10_HUMAN Kelch domain-containing protein 10  49,081      
 RGGGAAGAGGGGSGAGGGsGGSGGR  1 95 63/48 44 ETD 
        
K2C1_HUMAN Keratin, type II cytoskeletal 1  66,022      
 GGGGGGYGSGGSSYGSGGGsYGsGGGGGGGR 1 95 47/49 20 ETD 
        
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal  65,416      
 GGSIsGGGyGsGGGK  1 82 46/48 96,100,100 ETD 
        
K2C6A_HUMAN Keratin, type II cytoskeletal 6A  60,028      
 sLyGLGGSKRISIGGGScAIsGGYGsR  1 95 55/49 62,26,25 ETD 
        
KLF3_HUMAN Krueppel-like factor 3  38,811      
 RASPGLSMPssSPPIK  1 81 48/48 34,38 ETD 
        
LMNA_HUMAN Lamin-A/C 74,123      
 SGAQASSTPLSPtRITR  3 95 88/48 100 both 
        
LARP1_HUMAN La-related protein 1  123,495      
 GLSAsLPDLDSENWIEVK  4 95 48/46 82 CID 
        
BAT2_HUMAN Large proline-rich protein BAT2  228,848      
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 GGGtGGPNHPPAPRGR  1 92 53/48 100 ETD 
        
LSG1_HUMAN Large subunit GTPase 1 homolog  75,208      
 yILKDyVsGK  1 81 51/48 100,100,100 ETD 
        
LMBL3_HUMAN Lethal(3)malignant brain tumor-like protein 3  88,319      
 MtESASstSGQEFDVFSVmDWKDGVGtLPGSDLK 1 91 37/45 93,91,84,83 CID 
        
LRFN2_HUMAN 
Leucine-rich repeat and fibronectin type-III 
domain-containing protein 2  84,715      
 NELLDFtASLAR  1 80 47/48 50 ETD 
        
LA_HUMAN Lupus La protein  46,821      
 FAsDDEHDEHDENGATGPVKR  2 95 98/49 100 ETD 
        
KDM2B_HUMAN Lysine-specific demethylase 2B  152,599      
 ESDHSRsssPtAGPSTEGAEGPEEK  1 86 68/49 63,53,79,66 ETD 
        
KDM3B_HUMAN Lysine-specific demethylase 3B  191,594      
 GGNAsGEPGLDQR  2 93 54/47 100 ETD 
        
MISSL_HUMAN 
MAPK-interacting and spindle-stabilizing 
protein-like  24,251      
 sDEFSLADALPEHsPAK  2 95 54/46 100 CID 
        
MED1_HUMAN 
Mediator of RNA polymerase II transcription 
subunit 1 168,464      
 LAsPmKPVPGtPPSSKAKSPISSGSGGSHmSGTSSSsGMK 1 83 81/49 34,34,21 ETD 
        
ICLN_HUMAN Methylosome subunit pICln 26,197      
 FEEESKEPVADEEEEDsDDDVEPITEFR  9 95 78/46 100 CID 
        
MFAP1_HUMAN Microfibrillar-associated protein 1  51,941      
 SLAALDALNtDDENDEEEYEAWKVR  1 95 62/46 99 CID 
        
MAP4_HUMAN Microtubule-associated protein 4  120,988      
 DMEsPTKLDVTLAK  5 95 100/48 96 both 
 DMSPLSETEMALGKDVtPPPETEVVLIK  1 95 43/46 93 CID 
        
MTUS2_HUMAN 
Microtubule-associated tumor suppressor 
candidate 2  150,178      
 IDQNtVVTR  1 79 45/47 97 CID 
        
MUC16_HUMAN Mucin-16 2,353,421      
 IEmEStFSVAHGLKGTSTSQDPIVSTEK  1 90 55/49 13 ETD 
        
MBNL1_HUMAN Muscleblind-like protein 1  41,799      
 AAQYQVNQAAAAQAAATAAAMtQsAVKsLK  1 82 46/49 70,66,41 ETD 
        
MEF2A_HUMAN Myocyte-specific enhancer factor 2A  54,794      
 NRQVTFtK  1 79 45/47 50 CID 
        
NAT10_HUMAN N-acetyltransferase 10 115,690      
 aIEEQmVAAKDVVMEPTMKTLsDDLDEAAK  1 91 57/49 90 ETD 
        
SIRT1_HUMAN NAD-dependent deacetylase sirtuin-1  81,665      
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 aDEAALALQPGGsPSAAGADR  1 95 66/46 99 CID 
        
NACA_HUMAN 
Nascent polypeptide-associated complex 
subunit alpha 23,365      
 VQGEAVSNIQENTQTPTVQEEsEEEEVDETGVEVK 4 95 96/45 98 CID 
        
NEO1_HUMAN Neogenin  159,999      
 sGSAPQSPGAsIR  1 95 56/47 16 ETD 
        
CHL1_HUMAN Neural cell adhesion molecule L1-like protein  135,042      
 LtVNssNsIK  1 90 51/48 
100,100,99, 
99 ETD 
        
AHNK_HUMAN 
Neuroblast differentiation-associated protein 
AHNAK  629,086      
 GGVTGsPEASISGSKGDLK  2 90 52/48 86 ETD 
 GKGGVTGsPEASISGSKGDLK  2 95 59/48 38 ETD 
 LKsEDGVEGDLGETQSR  2 95 62/48 100 ETD 
 DIDISsPEFK  1 95 37/46 100 CID 
 GKGGVTGSPEAsISGSKGDLK  1 83 36/46 24 CID 
        
NIBL1_HUMAN Niban-like protein 1  82,666      
 AAPEAsSPPASPLQHLLPGK  1 85 48/48 29 ETD 
 AKQVVSVVQDEEVGLPFEASPEsPPPASPDGVTEIR 1 88 37/45 21 ETD 
        
NCOA1_HUMAN Nuclear receptor coactivator 1  156,739      
 VNPsVNPSISPAHGVAR  1 82 47/48 79 ETD 
        
NUCKS_HUMAN 
Nuclear ubiquitous casein and cyclin-
dependent kinases substrate  27,279      
 EMLMEDVGsEEEQEEEDEAPFQEK  3 95 49/46 100 CID 
        
NUCL_HUMAN Nucleolin  76,598      
 KEDsDEEEDDDsEEDEEDDEDEDEDEDEIEPAAmK 7 95 96/48 100,100 CID 
 AAAAAPAsEDEDDEDDEDDEDDDDDEEDDsEEEAMETTPAK 1 95 76/45 100,100 CID 
 AIRLELQGPRGsPNAR  4 95 85/48 100 ETD 
 LELQGPRGsPNAR  3 95 78/45 100 ETD 
        
NPM_HUMAN Nucleophosmin  32,557      
 cGSGPVHISGQHLVAVEEDAEsEDEEEEDVK 9 95 61/46 100 CID 
        
NPM3_HUMAN Nucleoplasmin-3  19,325      
 aAGTAAALAFLsQESR  6 95 72/46 100 CID 
        
NP1L4_HUMAN Nucleosome assembly protein 1-like 4 42,806      
 EFITGDVEPTDAESEWHsENEEEEK  1 95 43/46 53 CID 
        
OSB10_HUMAN Oxysterol-binding protein-related protein 10  83,953      
 GVSSRSAAAGLGGGGSRssPGsVAAsPSGGGGR 1 95 56/49 46,46,31,82 ETD 
        
OSBL8_HUMAN Oxysterol-binding protein-related protein 8  101,181      
 tPMVSVPKmK  1 82 51/47 99 ETD 
        
PHAR3_HUMAN Phosphatase and actin regulator 3  62,536      
 tSsVERGKER  1 83 46/47 85,81 ETD 
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PAIRB_HUMAN 
Plasminogen activator inhibitor 1 RNA-binding 
protein  44,948      
 TDKSSAsAPDVDDPEAFPALA  3 95 53/46 100 CID 
 SSAsAPDVDDPEAFPALA  1 82 32/46 76 CID 
        
DDX46_HUMAN Probable ATP-dependent RNA helicase DDX46  117,348      
 AALGLQDsDDEDAAVDIDEQIESMFNSK  1 79 35/46 100 ETD 
        
SYTC2_HUMAN 
Probable threonyl-tRNA synthetase 2, 
cytoplasmic  92,631      
 NELSGTLsGLTR  1 93 54/47 14 ETD 
        
PA2G4_HUMAN Proliferation-associated protein 2G4  43,769      
 sGEDEQQEQTIAEDLVVTK  8 95 86/49 100 both 
        
TEBP_HUMAN Prostaglandin E synthase 3  18,680      
 DWEDDsDEDMSNFDR  6 95 78/46 100 CID 
        
DEK_HUMAN Protein DEK  42,658      
 EEsEEEEDEDDEEEEEEEKEK  2 95 43/46 100 CID 
 sAsAPAAEGEGTPTQPASEKEPEMPGPR  1 79 36/46 43 CID 
        
PDIA6_HUMAN Protein disulfide-isomerase A6  48,104      
 DGELPVEDDIDLsDVELDDLGKDEL  8 95 79/46 100 CID 
        
DOP1_HUMAN Protein dopey-1  277,342      
 MTIAASAsLTTINLGATKNLR  1 84 50/49 18 ETD 
        
DPY30_HUMAN Protein dpy-30 homolog  11,232      
 iVENEKINAEKsSK  1 80 46/48 77 ETD 
        
MUTED_HUMAN Protein Muted homolog  21,592      
 MsGGGtEtPVGcEAAPGGGsKKR  1 95 44/49 100,99,99,99 ETD 
        
PP14C_HUMAN Protein phosphatase 1 regulatory subunit 14C  17,825      
 MsVAtGsSETAGGASGGGAR  1 81 46/48 100,27,66 ETD 
        
PP1R7_HUMAN Protein phosphatase 1 regulatory subunit 7  41,548      
 IRAIENIDtLTNLEsLFLGKNK  1 90 51/49 73,58 ETD 
        
SHSA7_HUMAN Protein shisa-7 56,197      
 sPALPPDPtAR  1 80 44/47 99 ETD 
        
SYS1_HUMAN Protein SYS1 homolog  17,598      
 EIPLNsAPK  1 89 35/45 100 CID 
        
PTMA_HUMAN Prothymosin alpha  12,185      
 sDAAVDTSSEITTK  2 95 46/46 100 CID 
        
HS902_HUMAN Putative heat shock protein HSP 90-alpha A2  39,348      
 ESKDKPEIEDVGsDEEEEKK  2 95 101/49 100 ETD 
        
PSG7_HUMAN 
Putative pregnancy-specific beta-1-
glycoprotein 7  46,984      
 ENKDVSTFtcEPK  1 91 52/48 54 ETD 
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RBM15_HUMAN Putative RNA-binding protein 15  107,175      
 GGEDSTsR  1 79 45/46 33 CID 
        
RB15B_HUMAN Putative RNA-binding protein 15B  97,190      
 GGKAsGDPGAsGmsPR  1 85 50/48 100,100,100 ETD 
        
S22AX_HUMAN 
Putative solute carrier family 22 member 
ENSG00000182157  58,972      
 gPALLDAAIPRLGPTRAPAEALGVLsPSYLAPLTR 1 95 61/49 23 ETD 
        
CE060_HUMAN Putative uncharacterized protein C5orf60  39,233      
 GKASPTsFHVSPR  1 79 45/48 26 CID 
        
G3BP1_HUMAN 
Ras GTPase-activating protein-binding protein 
1  52,145      
 SSsPAPADIAQTVQEDLR  18 95 113/48 96 both 
 YQDEVFGGFVTEPQEEsEEEVEEPEER  6 95 84/48 100 both 
        
RL3R1_HUMAN Relaxin-3 receptor 1  51,107      
 mQMADAATIAtmNKAAGGDK  1 81 47/48 34 ETD 
        
RTN2_HUMAN Reticulon-2  59,247      
 IPGTGALAsAAAAVsGsK  1 88 50/48 74,71,82 ETD 
        
RTN4_HUMAN Reticulon-4  129,917      
 mEDLDQSPLVSSSDsPPRPQPAFK  6 95 81/46 100 CID 
        
RTL1_HUMAN Retrotransposon-like protein 1  155,161      
 kEPPSGPLQEMEELPtDLLQDmEEPSSGPR  1 95 55/49 37 ETD 
        
RBM14_HUMAN RNA-binding protein 14  69,474      
 sPPRASYVAPLTAQPATYR  1 95 43/46 23 CID 
        
SEPR_HUMAN Seprase  87,697      
 TINIPyPK  1 82 32/45 100 CID 
        
SEPT2_HUMAN Septin-2  41,470      
 IYHLPDAEsDEDEDFKEQTR  3 95 63/49 100 both 
        
SRRM1_HUMAN Serine/arginine repetitive matrix protein 1 102,319      
 KETEsEAEDNLDDLEK  3 95 68/48 100 ETD 
 EKtPELPEPSVK  3 95 57/46 100 both 
        
SRRM2_HUMAN Serine/arginine repetitive matrix protein 2  299,604      
 MALPPQEDATAsPPRQK  1 79 45/48 96 CID 
 VKPEtPPRQSHSGSIsPYPK  3 95 7049 99,64 ETD 
 SATRPsPsPERSSTGPEPPAPTPLLAER  2 95 60/46 99,98 CID 
 VSGRTsPPLLDR  1 86 48/47 100 ETD 
        
DCLK1_HUMAN Serine/threonine-protein kinase DCLK1 82,208      
 KHFNtGPKPNStAAGVsVIAtTALDK  1 95 57/49 37,37,49,97 ETD 
        
ICK_HUMAN Serine/threonine-protein kinase ICK  71,412      
 SSGtMSVIsK  1 86 36/46 33,41 CID 
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OXSR1_HUMAN Serine/threonine-protein kinase OSR1  58,005      
 LHKTEDGGWEWsDDEFDEESEEGK  1 90 38/46 100 CID 
        
TAOK2_HUMAN Serine/threonine-protein kinase TAO2 138,237      
 MLLARHsLDQDLLR  1 95 49/46 100 CID 
        
SDCG1_HUMAN Serologically defined colon cancer antigen 1  122,940      
 lASKEEsSNSSDsK  1 91 51/48 29,71 ETD 
        
SMAP_HUMAN Small acidic protein  20,315      
 SAsPDDDLGSSNWEAADLGNEER  15 95 117/46 58 CID 
        
UTP20_HUMAN 
Small subunit processome component 20 
homolog  318,378      
 aAPPTAGsmAIEK  1 95 40/46 71 CID 
        
SC6A8_HUMAN 
Sodium- and chloride-dependent creatine 
transporter 1  70,506      
 sAENGIYSVSGDEKK  1 87 49/48 73 ETD 
        
SKA3_HUMAN Spindle and kinetochore-associated protein 3 46,343      
 yNSNLATPIAIK  1 92 53/47 91 ETD 
        
SF3A1_HUMAN Splicing factor 3A subunit 1  88,868      
 FGESEEVEMEVEsDEEDDKQEK  1 95 48/46 100 CID 
        
SFR19_HUMAN Splicing factor, arginine/serine-rich 19  139,255      
 RRSGAASSSSsSR  1 84 46/47 17 ETD 
        
STMN1_HUMAN Stathmin  17,285      
 ASGQAFELILsPR  1 95 68/46 100 CID 
        
STUB1_HUMAN 
STIP1 homology and U box-containing protein 
1  34,839      
 LGAGGGsPEKSPSAQELK  1 94 59/48 92 ETD 
        
SPEG_HUMAN 
Striated muscle preferentially expressed 
protein kinase 354,268      
 DmGALTctARNR  1 88 49/48 88 ETD 
        
SMC4_HUMAN 
Structural maintenance of chromosomes 
protein 4  147,170      
 TEsPATAAETASEELDNR  7 95 77/46 47 both 
        
SUN2_HUMAN SUN domain-containing protein 2  80,294      
 VDQMEGGAAGPsAsVR  1 81 50/49 100,100 ETD 
        
SMCE1_HUMAN 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily E 
member 1  46,632      
 eAAEQAERSQSsIVPEEEQAANK  1 95 52/49 64 ETD 
        
TTBK2_HUMAN Tau-tubulin kinase 2  137,397      
 fLEtcLEKMQKDTsAGK  1 95 56/49 100,35 ETD 
        
ERCC2_HUMAN 
TFIIH basal transcription factor complex 
helicase subunit  86,894      
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 GFtIIIEPFDDR  1 87 49/48 100 ETD 
        
SMCA4_HUMAN Transcription activator BRG1  184,632      
 DSDAGssTPTTSTR  1 79 45/48 25,25 CID 
        
SOX11_HUMAN Transcription factor SOX-11  46,663      
 MDPSAKPSASQsPEKSAAGGGGGSAGGGAGGAK 1 83 82/49 19 ETD 
        
TIF1B_HUMAN Transcription intermediary factor 1-beta  88,531      
 aASAAAASAAAASAASGsPGPGEGSAGGEKR 22 95 146/46 98 both 
 FSAVLVEPPPMSLPGAGLSsQELSGGPGDGP 2 95 51/46 32 CID 
        
P66A_HUMAN Transcriptional repressor p66-alpha  68,045      
 TVSAGKGSATsNWKK  1 87 49/48 14 ETD 
        
TYY1_HUMAN Transcriptional repressor protein YY1 44,694      
 DIDHETVVEEQIIGENsPPDYSEYMTGK  1 87 37/46 93 CID 
        
TLE3_HUMAN Transducin-like enhancer protein 3 83,399      
 VSPAHsPPENGLDK  1 91 52/48 96 ETD 
        
TMCO7_HUMAN 
Transmembrane and coiled-coil domain-
containing protein 7 120,731      
 AARQAVGsGAQETcGLDR  1 89 52/48 91 ETD 
        
TMCC1_HUMAN 
Transmembrane and coiled-coil domains 
protein 1  72,035      
 SGQEMtAVMQsGRPR  1 84 48/48 50,59 ETD 
        
TRIO_HUMAN Triple functional domain protein  346,885      
 lssGKADGHVK  1 79 45/47 100,100 CID 
        
NSUN2_HUMAN tRNA (cytosine-5-)-methyltransferase NSUN2  86,455      
 AGEPNsPDAEEANsPDVTAGcDPAGVHPPR 1 95 66/46 99,99 CID 
        
TBA1B_HUMAN Tubulin alpha-1B chain  50,134      
 DYEEVGVDsVEGEGEEEGEEY  2 95 83/46 100 CID 
 TIGGGDDsFNTFFSETGAGK  1 95 41/46 99 CID 
 TIGGGDDsFNTFFSETGAGKHVPR  1 95 55/46 66 CID 
        
PTN18_HUMAN 
Tyrosine-protein phosphatase non-receptor 
type 18  50,465      
 TLSAsAAEVAPR  1 93 53/48 74 ETD 
        
U520_HUMAN 
U5 small nuclear ribonucleoprotein 200 kDa 
helicase  244,496      
 EEAsDDDMEGDEAVVR  2 95 65/46 100 CID 
        
UBP2L_HUMAN Ubiquitin-associated protein 2-like  114,516      
 RYPSSISSsPQKDLTQAK  3 95 77/49 99 ETD 
        
CF174_HUMAN Uncharacterized protein C6orf174  103,184      
 NSGSGVAGGGSGGGGsyWK  1 81 46/48 66,46 ETD 
        
K0753_HUMAN Uncharacterized protein KIAA0753 109,390      
 LsyAVHLAR  1 91 34/46 100 100 CID 
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 AQRVNsTTEANIHLKDGssVNtAK  1 95 51/49 87,40,40,55 ETD 
        
CF035_HUMAN UPF0463 transmembrane protein C6orf35  14,741      
 GGIFLGTVAAAGmLAGFITTLsLAKKK  1 84 50/49 15 ETD 
        
CB029_HUMAN UPF0760 protein C2orf29  55,200      
 GGAsGPGSGSGGPGGPAGRmsLTPK  1 95 69/49 28,28 ETD 
        
YRDC_HUMAN YrdC domain-containing protein, mitochondrial  29,310      
 LFRPPsPAPAAPGAR  1 95 58/48 100 ETD 
        
ZC3HF_HUMAN 
Zinc finger CCCH domain-containing protein 
15 48,586      
 DVDETGITVAsLER  1 95 49/46 100 CID 
        
        
Z512B_HUMAN Zinc finger protein 512B 97,246      
 LPGSSKsGPGKDGSR  1 89 50/48 21 ETD 
        
Z804A_HUMAN Zinc finger protein 804A 136,872      
 StTVTVR  2 84 33/45 22 CID 
        
ZKSC2_HUMAN 
Zinc finger protein with KRAB and SCAN 
domains 2 110,922      
 KENVGNVVSLGSAVStsNKItR  1 81 47/49 65,65,54 ETD 
        
ZXDC_HUMAN Zinc finger protein ZXDC  89,970      
 GAGSNAGASQStQR  1 91 51/48 14 ETD 
        
ZRAB2_HUMAN 
Zinc finger Ran-binding domain-containing 
protein 2 37,387      
 EEsDGEYDEFGR  1 95 42/46 100 CID 
 EVEDKEsEGEEEDEDEDLSK  1 95 41/46 100 CID 
 
Total phosphoproteins 188 
Spectral count 490 
Number of different phosphopeptides 220 
Number of multiply phosphorylated peptides 72 
Number of singly phosphorylated peptides 418 
Number of each phosphorylated amino acid observed 521(pS), 68(pT), 9(pY) 
Number of unique phosphorylated amino acids 309 
 
a
 Peptides identified by MS were searched for serine, threonine, or tyrosine residues containing a 
+80 m/z modification, which is consistent with the presence of a phosphate group. 50% protein 
and 79% peptides cutoffs were used to generate the Scaffold coverage which scored above 1.3% 
FDR threshold.
 b
 SC=Spectral Count. 
c
 PP= Peptide probability (written as percentage). 
d
 IS= Ion 
Score. 
e
 IDS= Identity Score. 
f 
LP= Localization Probability (written as a percentage, multiple 
numbers corresponding to the value of each site). 
g 
IM= Ionization Method. CID=Collision 
Induced Dissociation, ETD= Electron Transfer Disscociation, both=CID and ETD. 
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Gel image for Avidin Purification with Casein Model Study 
 
 
 
 
 
 
 
 
 
Figure A 4.7: ATP-biotin reaction. Β-casein (lane 1) were biotinylated with CK2 and ATP-
biotin (lane 2), load onto an avidin column (lane 3), washed (lane 4 and 5) and eluted with acid 
(lane 6). All proteins were visualized with sypro ruby stain (top) and anti-biotin (bottom). Two 
trials are shown here.  
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Table A 4.7: Phosphopeptides identified by MS analysis after kinase-catylzed biotinylation of 
casein and subsequent purification of the full-length proteins using NeutrAvidin affinity 
chromatography and acidic elution
a
  
Accession  
number Proteins/peptides name MW (Da) 
 
SP
b
 
 
PP
c
 IS
d
/IDS
e
 LP
f
 
 
IM
g
 
   
  
  
 
gi|30794348 casein alpha s1  24,500      
 VPQLEIVPNsAEER  
 
8 
 
95 58/46 100 
 
CID 
 YKVPQLEIVPNsAEER  
 
11 
 
95 69/46 100 
 
CID 
   
  
  
 
gi|27806963 casein alpha-S2  26,000      
 NmAINPsKENLcSTFcK  
 
9 
 
95 67/46 100 
 
CID 
 TVDmEsTEVFTK  
 
5 
 
95 54/46 99 
 
CID 
   
  
  
 
gi|30794310 casein beta  25,000      
 FQsEEQQQTEDELQDK  
 
11 
 
95 88/46 100 
 
CID 
 FQsEEQQQtEDELQDK  
 
9 
 
95 53/46 100,100 
 
CID 
 IEKFQsEEQQQTEDELQDK  
 
8 
 
95 65/46 100 
 
CID 
 IEKFQsEEQQQtEDELQDK  
 
8 
 
95 55/46 100,100 
 
CID 
   
  
  
 
Total phosphoproteins  3  
Total phosphopeptides  69  
Number of different phosphopeptides  6  
Number of multiply phosphorylated peptides  17  
Number of singly phosphorylated peptides  52  
Number of each phosphorylated amino acid 
observed 
 
69(pS),17(pT) 
 
Number of unique phosphorylated amino acids  5  
 
a
 The full length proteins isolated after affinity chromatography were digested with trypsin prior 
to MS analysis.  Peptides identified by MS were searched for serine, threonine, or tyrosine 
residues containing a +80 m/z modification, which is consistent with the presence of a phosphate 
group. 99% protein and 90% peptides cutoffs were used to generate the Scaffold coverage which 
scored above 0.6% FDR threshold.  
b
 SC=Spectral Count. 
c 
PP= Peptide probability (written as 
percentage). 
d
 IS= Ion Score. 
e
 IDS= Identity Score.  
f
 LP= Localization Probability (written as a 
percentage). 
g
 IM= Ionization Method. 
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Gel image for Avidin Purification with HeLa Cell Lysates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A 4.8: ATP-biotin reaction. HeLa cell lysates (lane 1) were biotinylated with ATP-biotin 
(lane 2), load onto an avidin column (lane 3), washed (lane 4 and 5) and eluted with acid (lane 
6). All proteins were visualized with sypro ruby stain (top) and anti-biotin (bottom). All the three 
trials are shown here.  
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Table A 4.8: Phosphopeptides identified by MS analysis after kinase-cataylzed biotinylation of 
HeLa cell lysates and subsequent purification of the full length proteins using NeutrAvidin 
affinity chromatography and acidic elution
a
  
Accession 
numbers Proteins/peptides name 
MW 
 (Da) SCb PPc ISd/IDSe LPf IMg 
RS3_HUMAN 40S ribosomal protein S3 26,671      
 ELAEDGYSGVEVRVtPtR  1 93 39/43 100,99 CID 
        
RL12_HUMAN 60S ribosomal protein L12  17,801      
 VVyLRcTGGEVGATSALAPK  11 95 52/43 100 CID 
        
RL14_HUMAN 60S ribosomal protein L14  23,414      
 APGtKGtAAAAAAAAAAK  1 82 34/43 100,100 CID 
        
RL18_HUMAN 60S ribosomal protein L18  21,617      
 tNRPPLsLSRMIR  1 82 34/43 98,14 CID 
        
F263_HUMAN 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3  59,592      
 IGGDSGLSsR  1 95 44/43 100 CID 
        
6PGD_HUMAN 
6-phosphogluconate dehydrogenase, 
decarboxylating  53,124      
 ALYAsKIISYAQGFmLLR  4 95 46/43 59 CID 
        
ACACB_HUMAN Acetyl-CoA carboxylase 2  276,526      
 GSGmIAGESSLAyEEIVTIsLVtcR  1 65 30/43 92,100,100 CID 
        
ARPC5_HUMAN Actin-related protein 2/3 complex subunit 5  16,303      
 ALAAGGVGSIVRVLtAR  1 82 36/43 96 CID 
        
ENOA_HUMAN Alpha-enolase  47,152      
 AGytDKVVIGMDVAASEFFR  56 95 43/43 100,100 CID 
        
ALMS1_HUMAN Alstrom syndrome protein 1  460,940      
 
SSLDFQVVQPSLPDSNTITQDL 
KTIPSQNSQIVtsR 1 93 38/42 18,18 CID 
        
AN13A_HUMAN 
Ankyrin repeat domain-containing protein 
13A 67,602      
 QGWTVLHEAVstGDPEMVYtVLQHR  1 87 36/43 51,51,51 CID 
        
AP1B1_HUMAN AP-1 complex subunit beta-1  104,621      
 AAMIWIVGEyAER  1 54 17/43 100 CID 
        
APOC3_HUMAN Apolipoprotein C-III  10,834      
 AsEAEDAsLLsFmQGYMK  1 71 31/43 98,79,86 CID 
        
ARRD1_HUMAN Arrestin domain-containing protein 1  45,963      
 VtcIGScGVSNK  1 90 37/43 100 CID 
        
BIRC6_HUMAN Baculoviral IAP repeat-containing protein 6  530,237      
 VALGAsRK  1 95 41/42 100 CID 
        
E41L1_HUMAN Band 4.1-like protein 1  98,487      
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 mTtETGPDSEVKK  1 93 40/43 25 CID 
        
E41L3_HUMAN Band 4.1-like protein 3  120,662      
 yTMSRSLDGEVGTGQyATTK  1 94 40/43 21,58 CID 
        
ACTBL_HUMAN Beta-actin-like protein 2  41,986      
 TTGIVmDSGDGVtHIVPIyEGYALPHAILR  10 95 42/43 92,99 CID 
        
KCMA1_HUMAN 
Calcium-activated potassium channel 
subunit alpha-1  137,546      
 mANGGGGGGGSsGGGGGGGGSSLR  2 92 38/43 90 CID 
        
CNN1_HUMAN Calponin-1 33,153      
 GAsQAGmTAPGtK  1 92 40/43 100,85 CID 
        
CPSM_HUMAN 
Carbamoyl-phosphate synthase 
[ammonia], mitochondrial  164,925      
 EyGVKVLGtsVESImATEDR  4 95 41/43 99,100,100 CID 
        
CBX3_HUMAN Chromobox protein homolog 3  20,794      
 GLDPERIIGATDSsGELMFLmK  1 55 28/43 33 CID 
        
COF2_HUMAN Cofilin-2 18,719      
 StLGEKLGGNVVVSLEGKPL  7 95 46/43 36 CID 
        
COCA1_HUMAN Collagen alpha-1(XII) chain  333,127      
 GmTsSEPISImEK  1 95 41/43 29 CID 
        
KCRB_HUMAN Creatine kinase B-type  42,627      
 LAVEALSSLDGDLAGRyyALK  1 95 40/43 100,100 CID 
        
CLC5A_HUMAN C-type lectin domain family 5 member A  21,504      
 GKGstLAIVNtPEK  1 85 36/43 100,100,100 CID 
        
CCDB1_HUMAN Cyclin-D1-binding protein 1  40,244      
 LNEAAVTVSREATtLTIVFSQLPLPSPQETQK  1 93 38/43 47 CID 
        
DYHC1_HUMAN Cytoplasmic dynein 1 heavy chain 1  532,388      
 LVEAISRDLSsQLLK  2 90 38/43 45 CID 
        
SERA_HUMAN D-3-phosphoglycerate dehydrogenase 56,633      
 ILQDGGLQVVEKQNLsK  2 55 28/43 100 CID 
        
RPA2_HUMAN 
DNA-directed RNA polymerase I subunit 
RPA2  128,215      
 ISFtILDAVISPPtVPK  1 95 45/43 11,98 CID 
        
ALG6_HUMAN 
Dolichyl pyrophosphate Man9GlcNAc2 
alpha-1,3-glucosyltransferase  58,166      
 IIQYLFLIsVItmVLLTLmtVtLDPPQK  1 86 35/43 67,67,67,67 CID 
        
DYDC2_HUMAN DPY30 domain-containing protein 2  20,569      
 EMEmtEMLK  2 95 45/43 100 CID 
        
MARH7_HUMAN E3 ubiquitin-protein ligase MARCH7  78,035      
 sNFSSRESEssR  1 58 17/43 97,51,51 CID 
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EF2_HUMAN Elongation factor 2  95,322      
 cLyAsVLTAQPR  1 71 31/43 100,100 CID 
        
IF4A1_HUMAN Eukaryotic initiation factor 4A-I 46,137      
 SGSsRVLITTDLLAR  3 88 37/43 24 CID 
        
MCA3_HUMAN 
Eukaryotic translation elongation factor 1 
epsilon-1  19,793      
 aAAAELSLLEKsLGLSK  6 90 40/43 65 CID 
        
EIF3A_HUMAN 
Eukaryotic translation initiation factor 3 
subunit A 166,557      
 mstRVLLAtLsIPITPER  1 89 36/43 71,71,71,97 CID 
        
IF4B_HUMAN Eukaryotic translation initiation factor 4B  69,136      
 GFGyAEFEDLDSLLsALsLNEEsLGNR  1 
   
55 28/43 80,80,80,80 CID 
        
XPO7_HUMAN Exportin-7  123,895      
 AtEPHmLETytPEVTK  1 55 28/43 99,61,61 CID 
        
FLNA_HUMAN Filamin-A 280,711      
 sQGDAsKVtAQGPGLEPSGNIANK  1 72 31/43 100,100,100 CID 
        
ALDOC_HUMAN Fructose-bisphosphate aldolase C  39,438      
 VLAAVYKALSDHHVYLEGTLLKPNmVtPGHAcPIK 1 62 31/43 21 CID 
        
SYUG_HUMAN Gamma-synuclein  13,312      
 EQANAVSEAVVsSVNTVATK  1 60 30/43 52 CID 
        
GNPI1_HUMAN Glucosamine-6-phosphate isomerase 1  32,651      
 VPtMALTVGVGTVmDAR  1 58 29/43 30 CID 
        
G6PI_HUMAN Glucose-6-phosphate isomerase  63,130      
 TITDVINIGIGGSDLGPLMVTEALKPySSGGPR 1 58 29/43 13 CID 
        
G3P_HUMAN 
Glyceraldehyde-3-phosphate 
dehydrogenase  36,035      
 LtGMAFRVPTANVSVVDLTcR  5 95 44/43 98 CID 
        
CLCN7_HUMAN H(+)/Cl(-) exchange transporter 7  88,663      
 FDSEKMAYTIHEIPVFIAmGVVGGVLGAVFNALNyWLtMFR 1 88 35/42 86,86 CID 
        
HSP7C_HUMAN Heat shock cognate 71 kDa protein  70,882      
 VssKNsLESYAFNmK  4 95 42/43 100,100,100 CID 
        
HMGB3_HUMAN High mobility group protein B3  22,963      
 IKsTNPGISIGDVAK  5 78 33/42 49 CID 
        
HSDL2_HUMAN 
Hydroxysteroid dehydrogenase-like protein 
2  45,379      
 tAQPHPKLLGtIYTAAEEIEAVGGK  1 82 34/43 63,86 CID 
        
INT9_HUMAN Integrator complex subunit 9 73,798      
 FGDVVHFmELWGKSSLNTVIFTEPDFsyLEALAPYQPLAMK 1 90 38/42 29,29 CID 
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K1C16_HUMAN Keratin, type I cytoskeletal 16  51,251      
 ISSVLAGGscR  1 55 29/43 100 CID 
        
K2C1_HUMAN Keratin, type II cytoskeletal 1  66,022      
 GGSGGGGGGssGGR  1 61 29/43 100,100 CID 
        
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal  65,416      
 yGSGGGSKGGSISGGGyGsGGGK  2 62 30/43 80,93,100 CID 
        
K2C7_HUMAN Keratin, type II cytoskeletal 7  51,369      
 TLNETELtELQsQISDTSVVLSmDNSR  2 95 44/43 22,74 CID 
        
K2C8_HUMAN Keratin, type II cytoskeletal 8  53,688      
 sLDmDSIIAEVK  4 81 33/43 100 CID 
        
BAG6_HUMAN Large proline-rich protein BAG6  119,389      
 LINLVGEsLR  1 91 36/43 100 CID 
        
LRC59_HUMAN Leucine-rich repeat-containing protein 59  34,913      
 AGsKGGNLR  1 95 39/42 100 CID 
        
LIPM_HUMAN Lipase member M  48,216      
 EFLyQTR  4 95 41/42 100 CID 
        
MUC16_HUMAN Mucin-16  2,353,421      
 SQSSVLADSsPMcttsTmGDTSVLTSTPAFLETR 2 91 37/43 23,23 CID 
        
NPM_HUMAN Nucleophosmin  32,557      
 VTLATLKmsVQPtVsLGGFEITPPVVLR  6 95 45/43 100,100,100 CID 
        
NDKB_HUMAN Nucleoside diphosphate kinase B  17,280      
 YmNsGPVVAmVWEGLNVVK  12 95 52/43 82 CID 
        
OR2A5_HUMAN Olfactory receptor 2A5  35,191      
 AFSTcSsHLcmVGLFFGSAIVMymAPKSR  1 93 41/43 29,29 CID 
        
PACRL_HUMAN PACRG-like protein  27,135      
 MQKsEGsGGtQLK  1 95 54/43 100,100,100 CID 
        
PDZD2_HUMAN PDZ domain-containing protein 2  301,623      
 AEYsQGKsSLMSDsR  1 87 36/43 93,98,18 CID 
        
PAL4G_HUMAN 
Peptidylprolyl cis-trans isomerase A-like 
4G  18,148      
 HTGSGILsMANAGPNTNGSQFFIcTAK  2 95 48/43 78 CID 
        
PRDX2_HUMAN Peroxiredoxin-2  21,874      
 LsEDyGVLKTDEGIAYR  4 89 38/43 100,100 CID 
        
PRDX5_HUMAN Peroxiredoxin-5, mitochondrial  22,068      
 ETDLLLDDsLVSIFGNR  1 92 38/43 94 CID 
        
PHLP_HUMAN Phosducin-like protein  34,264      
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 ttLDDKLLGEK  1 95 38/43 100,100 CID 
        
P3C2G_HUMAN 
Phosphatidylinositol-4-phosphate 3-kinase 
C2 domain-containing subunit gamma 165,701      
 SKtVFVGAINIR  1 93 39/43 54 CID 
        
PKHO2_HUMAN 
Pleckstrin homology domain-containing 
family O member 2  53,332      
 EVAsAAsDGLLR  1 95 41/43 100,100 CID 
        
PARP1_HUMAN Poly [ADP-ribose] polymerase 1  113,070      
 AESSDKLyR  1 62 29/43 100,100 CID 
 LTVNPGtK  1 61 33/43 100 CID 
        
PK1L2_HUMAN Polycystic kidney disease protein 1-like 2  272,556      
 WLIsmAVsFVESmFVtQPLK  1 87 37/43 100,98,85 CID 
        
PFD2_HUMAN Prefoldin subunit 2  16,630      
 SsGSGAGKGAVSAEQVIAGFNR  13 95 47/43 54 CID 
        
PR40A_HUMAN Pre-mRNA-processing factor 40 homolog A  108,789      
 YsALAKLSEK  1 90 37/43 46 CID 
        
PRP16_HUMAN 
Pre-mRNA-splicing factor ATP-dependent 
RNA helicase PRP16  140,488      
 ymtDGILLR  2 95 38/43 100,100 CID 
        
SAP_HUMAN Proactivator polypeptide  58,094      
 NStKQEILAALEK  2 75 33/43 51 CID 
 HEVPAKsDVycEVcEFLVK  1 95 42/43 100,100 CID 
        
NSD2_HUMAN 
Probable histone-lysine N-
methyltransferase NSD2  152,241      
 TTVsMPR  1 95 42/42 20 CID 
        
AT8B2_HUMAN 
Probable phospholipid-transporting 
ATPase ID  137,426      
 LNLKPDLsDtVR  1 95 39/43 100,100 CID 
        
PDC6I_HUMAN 
Programmed cell death 6-interacting 
protein  96,007      
 LALAsLGYEK  1 95 46/43 100 CID 
        
PDCD5_HUMAN Programmed cell death protein 5  14,267      
 EAEmRNsILAQVLDQSAR  5 95 50/43 100 CID 
        
PSB1_HUMAN Proteasome subunit beta type-1 26,473      
 AMtTGAIAAmLSTILYSR  1 62 30/43 57 CID 
        
AF17_HUMAN Protein AF-17  112,059      
 HSSGGGGGGAGGGGGSmGGGGSGFIsGRR 4 76 32/43 55 CID 
 TSRHssGGGGGGAGGGGGsmGGGGsGFISGR 3 87 36/43 87,87,95,41 CID 
        
PSYR_HUMAN Psychosine receptor 39,317      
 yLAVVYPLK  1 95 56/43 100 CID 
        
MGAL1_HUMAN Putative maltase-glucoamylase-like protein 73,914      
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FLJ16351  
 NMNNTGmFAHDEPPAyK  1 91 39/43 74 CID 
        
GDIB_HUMAN Rab GDP dissociation inhibitor beta 50,648      
 mLLYTEVtR  1 71 32/43 100 CID 
        
RADI_HUMAN Radixin 68,548      
 mPKPINVRVTtMDAELEFAIQPNTTGK  5 95 51/43 54 CID 
        
RANB3_HUMAN Ran-binding protein 3  60,192      
 LNDMAstDDGTLQsR  1 66 31/43 91,92,59 CID 
        
ABCA4_HUMAN 
Retinal-specific ATP-binding cassette 
transporter  255,933      
 tHPERIAGR  1 95 48/43 100 CID 
        
RGAG1_HUMAN 
Retrotransposon gag domain-containing 
protein 1 144,263      
 APIsGAmsmPLtR  2 74 17/43 100,100,100 CID 
        
PRPS2_HUMAN Ribose-phosphate pyrophosphokinase 2  34,752      
 LLsAGAtKVYAILTHGIFSGPAISR  1 95 53/43 94,83 CID 
        
SRSF2_HUMAN Serine/arginine-rich splicing factor 2  25,459      
 yGRVGDVYIPR  3 92 39/43 100 CID 
        
SPA9_HUMAN Serpin A9  46,540      
 STPAsQVySLNTDFAFR  1 85 35/43 32,93 CID 
        
SH2B3_HUMAN SH2B adapter protein 3  63,208      
 mNGPALQPSSPsSAPSASPAAAPR  1 95 44/43 65 CID 
        
UTP20_HUMAN 
Small subunit processome component 20 
homolog  318,378      
 DmSSIYsmYSTLLAHK  1 84 34/43 17 CID 
        
SPEE_HUMAN Spermidine synthase  33,807      
 QNQDAFDVIITDSSDPMGPAESLFKEsYYQLmK 1 79 32/43 14 CID 
        
GRP75_HUMAN Stress-70 protein, mitochondrial  73,663      
 EGSGSSGtGEQKEDQK  1 63 29/43 49 CID 
        
SODM_HUMAN Superoxide dismutase [Mn], mitochondrial  24,705      
 yQEALAKGDVTAQIALQPALK  1 51 28/43 84 CID 
        
TLN1_HUMAN Talin-1  269,747      
 GISmSSsKLLLAAK  1 73 17/43 25 CID 
        
TCPA_HUMAN T-complex protein 1 subunit alpha  60,327      
 sQmESmLISGYALNcVVGSQGmPKR  1 95 40/43 44 CID 
        
TCPB_HUMAN T-complex protein 1 subunit beta  57,472      
 ILLSsGRDAsLMVTNDGATILK  1 85 35/43 94,15 CID 
        
THIO_HUMAN Thioredoxin 11,719      
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 QIEsKTAFQEALDAAGDK  7 95 61/43 73 CID 
 QIESKtAFQEALDAAGDK  8 95 56/43 77 CID 
        
ELOC_HUMAN 
Transcription elongation factor B 
polypeptide 1 12,455      
 EHALtSGTIKAmLSGPGQFAENETNEVNFR  1 95 41/43 23 CID 
        
TAF4B_HUMAN 
Transcription initiation factor TFIID subunit 
4B  91,072      
 DNLLASGTssLtAtK  6 95 44/43 92,90,90,70 CID 
        
TIF1A_HUMAN Transcription intermediary factor 1-alpha 116,813      
 QLEHVMHFSKWAVSSGSSTALLysK  1 88 37/43 26,26 CID 
        
TIF1B_HUMAN Transcription intermediary factor 1-beta  88,531      
 HQEHILRFAsWALESDNNTALLLSK  1 95 40/43 100 CID 
        
TFR1_HUMAN Transferrin receptor protein 1  84,856      
 mmDQARsAFSNLFGGEPLSYTR  3 95 44/43 58 CID 
        
TKT_HUMAN Transketolase  67,861      
 QAFtDVATGSLGQGLGAAcGmAYtGK  1 75 31/43 42,48 CID 
        
TM14C_HUMAN Transmembrane protein 14C  11,547      
 NVWVFLATSGTLAGImGmRFYHsGK  1 89 36/43 21 CID 
        
TPD54_HUMAN Tumor protein D54  22,220      
 LGLstLGELKQNLSR  2 67 30/43 100,100 CID 
        
UBN2_HUMAN Ubinuclein-2 146,074      
 LTNSSsTGtVGK  1 95 42/43 21,100 CID 
        
UBP36_HUMAN Ubiquitin carboxyl-terminal hydrolase 36  122,635      
 tGSSSLPGRPSVIPDHSKK  5 95 43/43 82 CID 
        
UBP42_HUMAN Ubiquitin carboxyl-terminal hydrolase 42  145,211      
 ssNVLTLSLKR  1 88 36/43 100,100 CID 
        
CF062_HUMAN Uncharacterized protein C6orf62  27,066      
 DSsYSLESSLELLQK  1 93 38/43 25 CID 
        
CI066_HUMAN Uncharacterized protein C9orf66  31,167      
 sALETSAFPPSKPK  2 91 37/43 100 CID 
        
URB2_HUMAN 
Unhealthy ribosome biogenesis protein 2 
homolog  170,531      
 SLDsstPLPIVR  1 91 37/43 100,100,100 CID 
        
CA227_HUMAN UPF0732 protein C1orf227  11,338      
 mAsINRTIEImK  28 95 57/43 100 CID 
        
WBP11_HUMAN WW domain-binding protein 11  69,982      
 tsAyGPPTRAVsILPLLGHGVPR  1 50 27/43 87,87,89,69 CID 
        
ZNF90_HUMAN Zinc finger protein 90  69,041      
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 AFISSsLLYKHK  1 90 36/43 27 CID 
 
Total phosphoproteins 118 
Total phosphopeptides 341 
Number of different phosphopeptides 126 
Number of multiply phosphorylated peptides 131 
Number of singly phosphorylated peptides 182 
Number of each phosphorylated amino acid observed 223(S), 185(T), 109(Y) 
Number of unique phosphorylated amino acids 237 
 
a
 The full length proteins isolated after affinity chromatography were digested with trypsin prior 
to MS analysis.  Peptides identified by MS were searched for serine, threonine, or tyrosine 
residues containing a +80 m/z modification, which is consistent with the presence of a phosphate 
group. 90% protein and 55% peptides cutoffs were used to generate the Scaffold coverage which 
scored above 0.8% FDR threshold. 
b
 SC=Spectral Count. 
c
 PP= Peptide probability(written as 
percentage). 
d
 IS= Ion Score. 
e
 IDS= Identity Score. 
f 
LP= Localization Probability (written as a 
percentage, multiple numbers corresponding to the value of each site). 
g 
IM= Ionization Method. 
CID=Collision Induced Dissociation, ETD= Electron Transfer Disscociation, both=CID and 
ETD. 
Gel image for ATP control reaction 
 
 
 
 
 
 
 
 
Figure A 4.9: (A) Control experiment with ATP. Hela cell lysates (lane 1) were phosphorylated 
with ATP, load onto an avidin column (lane 2), washed (lane 3, 4 and 5) and eluted with acid 
(lane 6). All proteins were visualized with sypro ruby stain. (B) Quantification of elution lanes 
(lane 6) of ATP reactions and ATP-biotin (images shown in Figure A 4.8, lane 6), showing that 
13% protein signal was observed in the ATP control reaction compared to the ATP-biotin 
reaction (Figure A 4.8, lane 6 set to 100%).   
A B 
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Kinase-catalyzed protein phosphorylation is involved in a wide variety of cellular events. 
Development of methods to identify phosphoproteins in normal and diseased states is critical to 
fully characterize cell biology. Our lab recently discovered kinase-catalyzed biotinylation, where 
ATP-biotin is utilized by kinases to label phosphopeptides or phosphoproteins with a biotin tag. 
To explore kinase-catalyzed biotinylation, kinetic measurements were obtained with various 
kinases and the data indicated that kinase-catalyzed biotinylation occurs with catalytic efficiency 
appropriate for phosphoproteomics application. Next, the susceptibility of the biotin tag to 
phosphatases was characterized and found that the phosphorylbiotin group was relatively 
insensitive to protein phosphatases. Importantly, robust kinase-catalyzed biotinylation occurs 
without the need for phosphatase inhibitor treatment. The results suggest that kinase-catalyzed 
biotinylation is well suited for phosphoproteomics studies, with particular utility towards 
monitoring low abundance phosphoproteins. Finally, we report application of kinase-catalyzed 
biotinylation to the enrichment of the phosphopeptides in cell lysates for mass spectrometry-
based phosphoproteomics analysis. Significantly, the biotinylation strategy was used to enrich 
full-length phosphoprotein, which is challenging using metal ion purification. With the utility of 
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ATP-biotin labeling for phosphoproteomics analysis established, kinase-catalyzed biotinylation 
can be applied to characterizing and understanding of the role of phosphorylation in various 
biological events. 
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